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There is a resurgence of interest in G protein-coupled receptor (GPCR) structure-
guided drug design due to the rapid increase in high-resolution structures of these 
biologically important proteins. The µ opioid receptor (MOPr) is an important GPCR, 
both therapeutically for analgesia and in drug abuse. There are opportunities to 
develop new opioids which exhibit distinct efficacies for different signalling pathways, 
a phenomenon known as agonist bias. This could represent a strategy to fine-tune 
MOPr activation, directing signalling towards analgesia whilst avoiding adverse 
effects. However, the mechanisms underlying ligand efficacy and agonist bias at the 
MOPr remain poorly understood. With this in mind, we employed molecular dynamics 
(MD) simulations of ligand-MOPr complexes to identify potential structural signatures 
of MOPr activation and biased agonism. Small molecules and peptides were selected 
for their differing efficacies and bias profiles, docked to the inactive MOPr and 1 μs 
MD simulations performed. On a residue-level, these MD simulations predicted that 
opioids adopt distinct binding poses and therefore interact with different subsets of 
residues. Specifically, high efficacy agonists induced conformational changes in the 
W2936.48 microswitch. Mutagenesis of this residue resulted in a receptor which did not 
respond to agonists, indicating that W2936.48 is essential for MOPr activation. 
Comparison of the arrestin-biased peptide, endomorphin-2, with the novel G protein-
biased peptide, bilorphin, revealed that interaction with the MOPr extracellular loops 
may indicate bias towards arrestin recruitment. On the level of the transmembrane 
domains, the MOPr adopted distinct conformations which differentiated high efficacy 
ligands from those of lower efficacy, as well as agonists of opposing bias. 
Conformational changes in the MOPr helices were prevented by an allosteric sodium 
ion or the W2936.48A mutation. This work builds on evidence that GPCRs occupy 
multiple conformations dependent on the bound ligand. Moreover, this thesis 
identifies key residues which may be important in conferring ligand efficacy and 
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1.1 The µ opioid receptor 
Opioid drugs, such as morphine, are widely considered the gold standard for treating 
all types of severe pain, from acute, post-operative pain to on-going, chronic cancer 
pain. However, although opioids are frequently used in the clinic (a recent report in 
The Lancet showed a 34 % increase in opioid prescriptions in England between 1998 
and 2016 (1)), they are not without drawbacks. Adverse effects such as constipation, 
nausea, respiratory depression, addiction and the development of tolerance limit their 
use (2). Furthermore, the rise of the opioid addiction and overdose epidemic in the 
United States (3) has increased the drive to develop better analgesics and understand 
the molecular nature of opioid agonist efficacy. As such, the task of discriminating the 
desirable therapeutic effects of opioid ligands from their undesirable adverse effects 
has long been the goal of opioid pharmacologists and the pharmaceutical industry (4, 
5). Morphine, and other opioids, exert their biological effects through activation of the 
µ opioid receptor (MOPr) (6). 
1.1.1 The opioid receptor family 
The MOPr belongs to the opioid receptor family, which also includes the delta (DOPr), 
kappa (KOPr) and nociceptin (NOPr) receptors (7). All four opioid receptors exhibit 
high sequence homology, but the NOPr displays distinct pharmacology from the other 
three opioid receptors and is therefore often referred to as “opioid-like” (8). Opioid 
receptors are members of the G protein-coupled receptor (GPCR) superfamily of 
membrane proteins (see Section 1.2).  
Opioid receptors are widely expressed pre- and postsynaptically in both the central 
and peripheral nervous system, as well as in some non-neuronal tissues. The MOPr 
shows the highest levels of expression in the thalamus, periaqueductal gray (PAG), 
locus coeruleus (LC), rostral ventromedial medulla (RVM), and dorsal horn of the 
spinal cord (9). In general, opioid receptors function as inhibitors of neuronal 
excitability, though the ultimate effect of opioid receptor activation may be excitation 




of the MOPr results in a range of physiological effects including analgesia, euphoria, 
respiratory depression and inhibition of the gastrointestinal tract. Although the MOPr 
is thought to generally signal from the plasma membrane, a recent study by Stoeber 
et al., has suggested that MOPr signalling can also occur within endosomes and the 
Golgi, potentially leading to different signalling outcomes (11). The existence of 
heterodimers within the opioid receptor family adds further complexity to opioid 
signalling, with studies of the DOPr-MOPr dimer in particular reporting novel signalling 
and modulation of ligand binding affinities (12-14).    
1.1.2 Pharmacology 
Studies of MOPr knockout mice showed that the MOPr mediates all the analgesic and 
euphoric actions of morphine (15), indicating that the MOPr is the primary target of 
the opioid analgesics.  
Morphine, the prototypical opioid agonist derived from the opium poppy, is an alkaloid 
possessing a rigid ring structure with a protonatable amine. The majority of opioid 
ligands are also based on this “morphinan” structure, although there are notable 
exceptions such as methadone and fentanyl, both synthetically derived opioid 
agonists. Structure-activity relationship studies have demonstrated that most opioid 
ligands bind to the MOPr via an interaction between the protonated amine and an 
aspartate residue in the receptor orthosteric site (see Section 1.2.3.2).  
The first endogenous opioid peptides to be described were the enkephalins (16), later 
followed by the endorphins and dynorphins (17, 18), none of which are selective for 
the MOPr over other opioid receptors. Putative endogenous agonists of the MOPr 
include the endomorphins, endomorphin-1 and endomorphin-2, both tetrapeptides 
highly selective for the MOPr (19). The most commonly used peptide agonist in in 
vitro studies of the MOPr is the pentapeptide, DAMGO, a full agonist for both G 
protein-mediated signalling and phosphorylation, arrestin recruitment and 




comprise an N terminal protonated tyrosine residue, or similar, which fulfils the 
equivalent function of the protonated amine in small molecule opioids (7). 
1.1.3 Intracellular signalling from the MOPr  
Activation of the MOPr by an opioid agonist results in conformational changes in the 
receptor (see Section 1.2.3) allowing the intracellular portion of the protein to adopt 
an open conformation able to couple to a G protein (22, 23), the predominant subtype 
coupling to the MOPr being the Gi/o family (24-26). As depicted in Figure 1.1, through 
this G protein-dependent signalling, opioids decrease neuronal excitability by 
promoting the opening of G protein-coupled inwardly rectifying potassium (GIRK) 
channels (27-31) and inhibiting voltage gated calcium channels (32, 33), resulting in 
hyperpolarisation of the cell to inhibit action potential firing, and the suppression of 
neurotransmitter release. Activation of the Gi/o G protein also causes inhibition of 
adenylyl cyclase and thus a reduction in cyclic AMP levels (26, 34, 35). The MOPr 
can also initiate signalling through the ERK pathway, as well as other kinases 
including PKC and JNK (36-39). 
To produce analgesia, this inhibitory effect of MOPr activation results in reduced 
neuronal firing in the ascending pain pathway from the dorsal horn of the spinal cord 
to the thalamus, and disinhibition of the descending pain pathway from the PAG and 
RVM to the spinal cord (10). Also inhibition of rhythm-generating neurons in the pre-
Bötzinger complex, or related nuclei, is thought to result in respiratory depression (40). 
The euphoric actions of MOPr agonists are produced in the mesolimbic reward 
pathway, where disinhibition of neurones in the ventral tegmental area (VTA) causes 







Figure 1.1 Intracellular signalling from the MOPr 
a) Upon activation by an extracellular agonist (green), the MOPr activates Gi/o G proteins (orange), 
resulting in dissociation of the Gα unit from the Gβγ subunits. Gα inhibits adenylyl cyclase (AC), whilst 
the Gβγ subunits open GIRK channels and close calcium channels. b) Following agonist activation, 
MOPr is phosphorylated on the intracellular loops and C tail by GRK (violet). c) Phosphorylation leads to 
the recruitment of arrestin (purple), termination of G protein signalling and initiation of arrestin-dependent 





1.1.4 Regulation   
Residues in the MOPr intracellular loops and C tail are subject to phosphorylation by 
kinases, both in the basal state and in response to agonist application (42, 43). 
Phosphorylation of the MOPr promotes recruitment of arrestin and subsequent 
receptor desensitisation and internalisation; there is a strong correlation between the 
ability of an agonist to induce phosphorylation and endocytosis of the MOPr (21).  
The primary site of MOPr phosphorylation is the unstructured intracellular C terminal 
tail where a cluster of serine and threonine residues, the “370TREHPSTANT379” motif, 
undergo agonist-mediated phosphorylation (42). Another serine residue, S363, is 
constitutively phosphorylated in the absence of opioid agonist (44-46). Within the 
“370TREHPSTANT379” motif phosphorylation appears to be hierarchical, where all 
opioid agonists induce phosphorylation of S375, but ligands differ in their ability to 
induce multi-site phosphorylation (44, 47). In general, high efficacy agonists such as 
DAMGO induce phosphorylation of all sites in the “370TREHPSTANT379” motif, 
whereas lower efficacy agonists such as morphine can only induce significant 
phosphorylation of S375 (44, 48). Moreover, S375 appears to act as the initiator of 
MOPr C tail phosphorylation, as a S375A mutation resulted in decreased 
phosphorylation of other residues within the 370TREHPSTANT379 motif (49). In the 
same study, the authors showed that phosphorylation of the 370TREHPSTANT379 motif 
is necessary for sustained interaction with arrestin and consequent MOPr 
internalisation (49). 
The MOPr, like other GPCRs, is primarily phosphorylated by G protein-coupled 
receptor kinases (GRKs), of which there are seven isoforms (50). Studies in HEK 293 
cells and LC neurons have shown that for high efficacy agonists, MOPr 
phosphorylation and desensitisation is GRK2/3-dependent, whereas morphine 
desensitisation has a  PKC component (39, 46, 47, 51-54). There is also evidence of 
opioid receptor phosphorylation and desensitisation mediated by other kinases, 




Tolerance to opioids is defined as a reduction in responsiveness after prolonged 
treatment with an agonist (6). The molecular mechanisms of opioid tolerance are 
contentious and still under investigation (6). However, receptor desensitisation, along 
with longer term adaptive changes in the cell, are believed to play a role. Parallel to 
studies of MOPr desensitisation in vitro, in vivo tolerance to high efficacy opioids 
appears to be GRK-dependent (61, 62), whereas tolerance to low efficacy opioids 
(morphine and oxycodone) can be reversed by PKC inhibition (63, 64). Although there 
are clear parallels between the kinases involved in MOPr desensitisation and in vivo 
opioid tolerance, it is not yet clear how far desensitisation of the receptor contributes 
to tolerance (6). In a seminal paper, tolerance to morphine was reported to be 
abolished in unconditional arrestin-3 knock out mice, suggesting that arrestin-
mediated receptor desensitisation is required for opioid tolerance (65). Interestingly, 
a more recent report by Kliewer et al., showed that in knock-in mice expressing a 
phosphorylation-deficient MOPr, analgesic tolerance was attenuated, though not 
completely abolished, suggesting that phosphorylation of the receptor along with 
other components are involved in opioid tolerance (66). Moreover, morphine tolerance 
did not develop in LC neurons from animals expressing phosphorylation-deficient 
MOPr (67).  
In summary, the MOPr is an important drug target, both therapeutically in analgesia 
and in drug abuse, with complex pharmacology and regulation. A better 
understanding of how the receptor structure relates to the function of this clinically 




1.2 Structure and function of G protein-coupled receptors 
1.2.1 GPCR signalling  
G protein-coupled receptors (GPCRs) serve as cell sensors to external stimuli, 
translating extracellular inputs to intracellular signalling events. GPCRs are the largest 
superfamily of membrane proteins, comprising over 800 different receptors (68), with 
important roles in all tissue types, from the cardiovascular system to the central 
nervous system, regulating a vast array of physiological processes. These diverse 
roles of GPCRs necessitate that they can respond to a wide range of stimuli, from 
small molecules and peptides, to ions (69), photons and even mechanical force (70).  
Upon activation by an agonist, GPCRs undergo conformational changes to facilitate 
coupling to intracellular heterotrimeric G proteins. G proteins are composed of Gα, 
Gβ and Gγ subunits, with the type of Gα subunit dictating the G protein subtype (Gs, 
Gi/o, Gq/11 or G12/13). Binding of the G protein to the activated GPCR induces the 
exchange of GDP for GTP within the Gα subunit, and dissociation of the complex into 
separate Gα subunits and Gβγ dimers. The dissociated subunits regulate second 
messenger proteins and modulate ion channels to initiate cellular signalling.  
After activation, residues on the GPCR intracellular loops and C tail are 
phosphorylated, primarily by GRKs but also other kinases as discussed for the MOPr 
in Section 1.1.4, which promotes the recruitment of arrestins. Arrestin, as the name 
suggests, terminates G protein signalling causing desensitisation of the receptor. 
Arrestins can also act as scaffolds to recruit the cellular machinery required for 
receptor internalisation, and initiate arrestin-dependent, G protein-independent 
signalling (71). There are four arrestin isoforms, subdivided into two families; the 
visual arrestins (arrestin-1 and arrestin-4) and the non-visual arrestins (arrestin-2 and 
arrestin-3). The predominant arrestin isoform involved in the regulation of the MOPr 
is probably arrestin-3 (72). Note that arrestin-2 and arrestin-3 are also termed β-
arrestin1 and β-arrestin2, respectively. However, the systematic names arrestin-2 and 




1.2.2 GPCR structure 
Due to their wide role in physiology and disease and intrinsically high druggability, 
GPCRs represent the largest family of protein targets for FDA (USA Food and Drug 
Administration) approved drugs, with approximately 35 % of medicines acting on this 
superfamily (73). Revolutionary technological developments in structural biology over 
the last few decades have made possible the determination of high resolution 
structures of these dynamic membrane proteins (74), and have thus led to the 
increasing use of structure-based drug discovery to rationally design new 
therapeutics.  
Figure 1.2 shows the dramatic rise in the number of available GPCR structures since 
the first structure of bovine rhodopsin was resolved in the year 2000 (75). The inactive, 
antagonist-bound x-ray crystal structure of the MOPr was resolved in 2012 (76), 
followed by the agonist and G protein-mimetic nanobody-bound structure in 2015 
(22). Most recently, developments in the field of cryo-electron microscopy (cryoEM) 
(77) have led to many reported structures of GPCRs in complex with intracellular 








Figure 1.2 Exponential increase in GPCR structures 
The cumulative number of GPCR structures available on the Protein Data Bank since the year 2000. 




This plethora of new GPCR structures has provided unprecedented insight into how 
receptor structure relates to function, and yet the precise molecular determinants of 
drug specificity and efficacy have not been fully elucidated. A better understanding of 
how ligand-receptor interactions translate to activation of a GPCR will aid future drug 
design for these important biological targets.  
GPCRs can be classified by sequence homology into the following subfamilies; Class 
A (Rhodopsin-like), Class B1 (secretin receptor-like), Class B2 (adhesion receptors), 
Class C (metabotropic glutamate receptor-like) and Class F (frizzled-like) (79). Class 
A is by far the most populated class, both in receptor number (around 80 % of the 
GPCRome are Class A receptors (80)) and as drug targets, with the vast majority of 
GPCR-targeting compounds acting on this class (68). The MOPr is a Class A GPCR.  
The general architecture of GPCRs encompasses an extracellular N terminus, seven 
hydrophobic α-helical transmembrane domains (TMs) connected by three 
extracellular and three intracellular loops, and an intracellular C tail important for 
receptor trafficking and regulation. Within the Class A GPCR subfamily (and to a large 
extent, Class B1 and B2) there is significant conservation of the structural motifs which 
appear to underlie receptor activation, the key components of which are discussed 
below.   
In order to make comparisons between different receptors, residues in Class A 
GPCRs can be numbered according to the system developed by Ballesteros and 
Weinstein (81). In this system, residues in the GPCR transmembrane domains are 
given the notation “X.Y”, where “X” is the helix number (1 to 7), and “Y” is the position 
along the helix; the most conserved residue in each helix is numbered “50” and all 
others are numbered by their position relative to this residue. Ballesteros-Weinstein 




1.2.3 Key motifs for Class A GPCR activation 
Although this large superfamily of GPCRs vary in sequence and the type of ligand 
they respond to, incredibly the activation-related conformational changes converge 
around the intracellular region (82) so that over 800 different receptors couple to only 
four G protein families and four subtypes of arrestin.  
Key motifs throughout the GPCR architecture are conserved within GPCR subfamilies 
and are responsible for transmitting the binding of an agonist ligand to the orthosteric 
pocket in the extracellular portion of the helix bundle, to large conformational changes 
on the intracellular side of the protein. Comparison of the available x-ray crystal 
structures, cryoEM structures and other biophysical data, has identified conformations 
of groups of residues and whole helices which hallmark the active state.  
Activation of the MOPr, and all currently resolved active-state Class A GPCRs, is 
associated with large conformational changes in the receptor transmembrane 
domains on the intracellular side of the protein (Figure 1.3). TM5 and TM7 move in 
towards the helix bundle, whilst a large outswing of TM6 results in an “open” receptor 
conformation to accommodate interaction with a G protein (22, 83-87). For the 
receptor to adopt the fully active state, characterised by this large outward movement 
of TM6, agonist binding is insufficient and the interaction with a G protein or mimetic 
nanobody is also required (88-91). An NMR study of the MOPr revealed that although 
the conformational changes in TMs 5 and 6 required the presence of a G protein, 
smaller conformational changes in intracellular loop (ICL) 1 and helix 8 were observed 
in the presence of an agonist alone, suggesting that these more subtle movements 
may precede G protein coupling (92).  
On the residue level, Figure 1.4 depicts the important signal transduction motifs in 
Class A GPCRs, comparing the positions of these groups of residues in the inactive 




protein bound-MOPr cryoEM structure. The following sections will describe these 






Figure 1.3 Transmembrane domain movements associated with MOPr activation 
Activation of the MOPr is characterised by large scale movements of the intracellular ends of TMs 5, 6 
and 7. Arrows depict the helix movements between the β-FNA bound inactive MOPr crystal structure 
(PDB: 4DKL, (76)) (grey), and the DAMGO and Gi bound active MOPr cryoEM structure (PDB: 6DDE 






Figure 1.4 Important motifs in Class A GPCRs 
Residues considered to be important in signal transduction from the orthosteric ligand binding site to the 
intracellular domain are shown for the β-FNA bound inactive MOPr crystal structure (PDB: 4DKL, (76)) 





1.2.3.1 DRY motif and the ionic lock 
The E/DRY motif is a conserved group of residues on the third transmembrane 
domain (TM3) which have been shown to play important roles in GPCR signal 
transduction, as mutations of this site can enhance GPCR constitutive activity (93-
96), abolish G protein coupling (97, 98), whilst naturally occurring mutations in this 
region cause disease (99). In the inactive state, E/D3.49 forms a salt bridge with 
R3.50 (100).  
Importantly, the DRY motif also interacts with TM6, for which the most striking 
difference between the inactive and active MOPr is the large outward swing of this 
helix (Figures 1.3 and 1.4), opening a crevice on the intracellular side of the receptor 
allowing coupling to a G protein or arrestin (22). This large domain movement of TM6 
is common across GPCRs, serving as a hallmark of the active state (101, 102). This 
TM6 outswing was first characterised in a study of rhodopsin which used spin labelling 
to show that a large movement of TM6 was coupled to receptor activation, well before 
any crystal structures were available (103). In the inactive state, an interaction termed 
the “ionic lock” between R3.50 of the DRY motif on TM3 and an acidic residue in 
position 6.30 on TM6 stabilises the receptor in the closed inactive conformation. The 
MOPr, and other opioid receptors, lack an acidic residue in position 6.30, but instead 
a threonine in position 6.34 participates in the inactive state interaction with R3.50, so 
that in opioid receptors this “ionic lock” is in fact a hydrogen bond. However, the 
interaction appears to serve the same purpose (76). Disruption of the ionic lock by 
mutation of either residue to alanine resulted in increased constitutive activity of the 
β2 adrenoceptor (93, 100). Furthermore, mutation of T6.34 in the MOPr resulted in a 
constitutively active receptor in the case of a T6.34K mutation, whilst the T6.34D 
receptor was inactive (104). These studies suggest that this TM3 – TM6 interaction, 
whether through a salt bridge or hydrogen bond, is indeed important in maintaining 




Recently, cryoEM structures of a series of Class A and Class B GPCRs have revealed 
that the size of this TM6 outswing varies between receptors (23, 105-108). It has been 
suggested that this discrepancy relates to the G protein coupling specificity of the 
GPCR, with receptors primarily coupled to the Gs subtype of G protein favouring a 
greater movement of TM6 than Gi/o coupled receptors (23, 109, 110). In the cryoEM 
structure of the MOPr-Gi complex, TM6 is displaced by 10 Å compared to the inactive 
structure, whereas in the β2 adrenoceptor, TM6 is displaced by a further 9 Å (23).  
1.2.3.2 Orthosteric ligand binding site 
For Class A GPCRs the orthosteric ligand binding site is located towards the 
extracellular side of the receptor, comprising a solvent-accessible pocket surrounded 
by TMs 3, 5, 6 and 7. Compared to other crystallised Class A GPCRs, perhaps 
because it is fundamentally a peptide-sensing receptor, the MOPr has a remarkably 
deep orthosteric binding pocket extending into the helix bundle (76). Mutagenesis 
studies, later corroborated by crystallographic data, have shown that D3.32 and H6.52 
in particular are essential residues for opioid ligand binding, recognising the 
protonated amine and the phenol groups of the opioid, respectively (22, 76, 95, 111-
114).   
Due to the wide diversity in the type of ligands recognised by the GPCR family, the 
precise movements and ligand-residue interactions within the orthosteric ligand 
binding site vary between receptors. However, these agonist-related changes quickly 
converge to stabilise common side chain movements in key motifs at the base of the 
orthosteric pocket (101). Indeed, this region of the GPCR helix bundle below the 
orthosteric site serves as a hub of signal transduction activity and is discussed in 
sections 1.2.3.3 to 1.2.3.5 below. 
For the MOPr, which has so far been crystallised with a covalently bound antagonist 




relevant opioids and endogenous agonists interact with the MOPr orthosteric pocket 
is incomplete.  
1.2.3.3 Allosteric sodium ion binding site 
Immediately below the orthosteric site sits a highly conserved allosteric binding pocket 
for a sodium ion (Figure 1.4). The term “allosteric” refers to any modulatory binding 
site on a protein outside of the “orthosteric” site to which the endogenous ligand binds.  
For over 40 years, sodium has been known to modulate agonist binding and GPCR 
signalling within a physiological range of concentrations in many Class A GPCRs, 
including the MOPr (115-121). More recently, high resolution x-ray crystal structures 
were able to detect the binding of sodium in the helix bundle (122-125). Notably, a 
sodium ion was resolved in the inactive state structure of the DOPr (124). In this site, 
the sodium ion is directly coordinated by the conserved residues D2.50, N3.35 and 
S3.39, as well as water molecules. A second coordination shell includes the 
conserved tryptophan microswitch in position 6.48 (see Section 1.2.3.4). As these 
residues are conserved in the MOPr, it is generally assumed that the configuration of 
the allosteric sodium site is similar in the MOPr, however the available crystal 
structures of the MOPr are not at high enough resolution to detect a bound sodium 
ion.  
Mutations of this allosteric sodium ion binding site have striking effects on both ligand 
binding affinity and signal transduction (126-131). Sodium generally functions as a 
negative allosteric modulator of GPCR function, reducing the binding affinities of 
agonists, whilst enhancing that of antagonists, and inhibiting downstream signalling 
(115, 116, 120, 121, 132). Compellingly, 19F-NMR experiments reported sodium 
stabilising the inactive state ensemble of the adenosine A2A receptor, providing 
biophysical evidence of the negative modulatory effect of sodium on this GPCR (133). 
Interestingly, there are also reports of biased modulation by the allosteric sodium site, 




the balance between G protein and arrestin signalling (134). Together, these data 
clearly identify sodium and the allosteric pocket in which it resides, as important 
regulators of GPCR function.  
The positive allosteric modulator of the MOPr, BMS-986122, may exert its modulatory 
effect via the allosteric sodium ion binding pocket, as BMS-986122 inhibited the ability 
of sodium to reduce agonist binding (135). Positive allosteric modulators of the MOPr 
have therapeutic merit if they can be developed to specifically enhance the activity of 
endogenous opioid peptides to alleviate pain, whilst avoiding adverse effects in non-
analgesic pathways (136). Probe dependence here would be key, as compounds 
capable of enhancing the euphoric effects of abused opioids would have considerable 
abuse liability. The allosteric sodium pocket therefore provides an interesting novel 
target for MOPr allosteric modulators. 
Moreover, White et al., obtained crystal structures of D2.50N and S3.39A mutant 
adenosine A2A receptors, showing that mutations in the allosteric sodium site did not 
affect the conformation of residues in the orthosteric binding site, but did modulate 
the conformation of the distant NPxxY motif (see Section 1.2.3.6), highlighting the role 
of the allosteric sodium site in transmitting conformational changes between the 
extracellular and intracellular domains of the GPCR (137). 
Importantly, GPCR activation involves structural rearrangements which collapse the 
allosteric sodium pocket and presumably disrupt sodium binding (138, 139). These 
dramatic changes in the sodium pocket have been used as evidence that sodium is 
an important regulator of receptor activation (138). One hypothesis proposes that the 
sodium ion occupies the allosteric pocket in the inactive state until, upon agonist 
binding, structural changes in the extracellular region around the orthosteric site lead 
to relocation of the sodium ion from the allosteric pocket to the cytoplasm, and this 




mechanism and physiological role of sodium modulation of GPCR function is still 
unknown.  
Finally, it has been suggested (140) that translocation of sodium ions through the 
receptor from the extracellular to intracellular side may provide a mechanism for the 
observed voltage sensitivity of some GPCRs, such as the α2A adrenoceptor (141), M1, 
M2, M3 and M5 muscarinic receptors (142-144) and the P2Y receptor family (145). 
This may indeed be important for opioid receptors, which are expressed in excitable 
tissue, and deserves further exploration.  
1.2.3.4 W6.48 rotamer toggle switch 
A highly conserved tryptophan in position 6.48 resides in the second coordination 
shell of the allosteric sodium ion binding pocket (Figure 1.4) at the base of the 
orthosteric ligand binding site. Spectroscopic and computational studies identified 
conformational changes in this residue which corresponded to agonist stimulation of 
the receptor, leading to the hypothesis that W6.48 may act as an important 
microswitch for GPCR activation (146-152). Indeed, subsequent crystal and cryoEM 
structures, including that of the MOPr, revealed rotameric changes in the W6.48 
indole ring between inactive and active state structures (22, 23, 76, 153, 154). As 
depicted in Figure 1.4, rotation around the Cβ-Cγ axis allows the indole ring to adopt 
different conformations; orientated perpendicular to the lipid bilayer (the inactive 
antagonist-bound MOPr), parallel to the bilayer (the fully active agonist- and G protein-
bound MOPr), or a position in between. Mutagenesis of this residue drastically alters 
ligand-induced signalling in a range of GPCRs, in some cases reducing ligand binding 
affinity (155-157), abolishing downstream signalling (158-160), or even altering the 
bias profile for some receptors (158, 161). However, functional assays with a W6.48 
mutant have not been reported for the MOPr. 
Together, these data suggest that W6.48 functions as an important link between the 




1.2.3.5 PIF motif 
Also close to the allosteric sodium site resides the PIF motif (alternatively termed the 
“core triad” (22)) comprising P5.50 of TM5, I3.40 of TM3 and F6.44 of TM6. 
Comparison of the available inactive and active state structures of the MOPr (22, 76), 
and other Class A GPCRs (86, 162-164), revealed concerted movements of these 
residue side chains such that P5.50 moves inwards, whilst the side chain of I3.40 
undergoes a rotameric change and the phenyl ring of F6.44 swings towards TM5 
(Figure 1.4). It has been suggested that these movements serve to alter the hydrogen 
bonding network between side chains within the helix bundle to connect changes in 
the orthosteric site to the intracellular domain of the GPCR (22). Indeed, mutations of 
the PIF motif in the 5HT2C receptor abolished the inverse agonist profile of ritanserin 
for Gq activation (165).  
1.2.3.6 NPxxY motif 
On the intracellular side, the NPxxY motif has also been identified as undergoing 
conformational changes during receptor activation (166, 167). Similar to the DRY 
motif stabilising the inactive state, the GPCR active state appears to be stabilised by 
a water-mediated interaction between Y7.53 of the NPxxY motif and Y5.58 in TM5; 
sometimes termed the “tyrosine cluster”. This is supported by numerous studies 
across many GPCRs showing that single or double mutations of Y5.58 and Y7.53 
result in disruption to receptor signalling and destabilisation of the active state (168-
172). Moreover, conformational changes around the NPxxY motif have been used in 
computational studies to reliably assign the activation state of the GPCR (173). 
Finally, disease-causing mutations at this site have been identified in humans, again 
highlighting the critical role of this motif in normal GPCR function (174-176).  
1.2.3.7 Intracellular loops 
The three intracellular loops, particularly ICL3, are highly dynamic and therefore often 
replaced with a T4 lysozyme, or other stabilising protein, in GPCR crystal structures. 




conformational change on receptor activation due to the outward movement of TM6 
(see Section 1.2.3.1). Both ICL2 and ICL3 also have important roles in coupling to 
intracellular G proteins and arrestin, as residues in these loops are found at the 
interface between the GPCR and its binding partner in crystal structures of GPCR-G 
protein and GPCR-arrestin complexes (177). Interestingly, in the only current 
structure of a GPCR-arrestin complex, that of rhodopsin and visual arrestin (178), 
ICL1 is also found at this interface, whereas it does not appear to be involved in G 
protein coupling in structures of GPCR-G protein complexes (23, 105).   
1.2.3.8 Extracellular loops 
It is becoming increasingly appreciated that the extracellular loops play an important 
role in GPCR function. ECL2 is the longest extracellular loop in Class A GPCRs and 
has been implicated in ligand recognition (179-183), GPCR activation (181, 184, 185), 
agonist bias (186, 187) and as the binding site for allosteric modulators (87, 188, 189). 
Studies of the muscarinic and endothelin receptors, along with rhodopsin, have 
suggested that ECL2 forms a “lid” over the orthosteric binding site, effectively trapping 
the ligand in the binding pocket and possibly controlling ligand dissociation rate (75, 
190, 191). Similarly, ECL2 forms an intermediate binding site during ligand 
association and dissociation from β-adrenoceptors (192, 193).  
For the MOPr, studies using chimeric receptors have implicated the ECLs in 
determining ligand selectivity between different opioid receptor subtypes and other 
Class A GPCRs (194-197). Furthermore, the cryoEM structure of the DAMGO-MOPr-
Gi complex (23), as well as computational studies docking fentanyl (198) and 
herkinorin (199) to the MOPr, all revealed interactions between the ligands and the 




1.3 Biased agonism 
1.3.1 Definition 
The previously held simplistic view of GPCR pharmacology was that GPCRs function 
as binary switches, residing in either an inactive state or an agonist-bound active 
state. However, it is now appreciated that GPCRs can occupy a variety of functional 
states, stabilised by different ligands, with different affinities for coupling to 
intracellular signalling partners. This idea that an agonist can stabilise a distinct 
conformational state of the receptor with higher affinity for one intracellular signalling 
protein over another leads to the concept of biased agonism (also known as ligand 
bias, functional selectivity and ligand directed signalling) (200).  
Biased agonism is defined as a ligand inducing preferential signalling through one 
pathway over another, via stabilisation of different active conformations of the GPCR 
(Figure 1.5). Ligand bias is always described relative to a reference agonist, usually 
the endogenous ligand, taken to be “unbiased” or “balanced”. In Figure 1.5a, the 
reference agonist (green) stabilises a conformation of the GPCR capable of engaging 
a G protein or an arrestin, whereas, the G protein-biased agonist (blue) stabilises a 
conformation which favours G protein activation over arrestin recruitment. This 
preferentially directs signalling through the G protein pathway. Conversely, the 
arrestin-biased agonist (red) has the opposite bias profile; promoting a receptor 
conformation which preferentially recruits arrestin over G protein activation.  
Agonist bias can be measured and quantified by comparison of concentration-
response curves in the relevant cell signalling assays. In the example in Figure 1.5b, 
the G protein-biased ligand (blue curve) is left-shifted compared to the reference 
agonist (green) in the G protein assay, but in the arrestin assay the G protein-biased 
agonist has a reduced maximum response and right-shifted curve, relative to the 
reference agonist. Vice versa, the arrestin-biased ligand has lower potency in the G 
protein assay (red curve), but a left-shifted curve in the arrestin assay, compared to 




necessitating the use of bias calculations and statistics to determine relative bias 
between compounds (201).   
Classically, the term ligand bias is often used to describe bias between G protein or 
arrestin-mediated signalling. However, bias can also occur between different G 
protein subtypes (202-204), different arrestin isoforms (205), and other signalling 







Figure 1.5 Biased agonism 
a) An unbiased ligand (green) stabilises an active receptor conformation capable of engaging all the 
downstream signalling pathways, G protein (orange) and arrestin (purple). A G protein-biased ligand 
(blue) will stabilise an active conformation which preferentially activates G protein signalling, whereas an 
arrestin-biased ligand (red) will preferentially recruit arrestin. b) In cell signalling assays, compared to the 
reference agonist (green), the G protein-biased agonist (blue) has a left-shifted curve in the G protein 
assay, but a reduced response in the arrestin assay. In contrast, the arrestin-biased agonist (red) 
switches from being less potent than the reference agonist in the G protein assay, to more potent in the 





1.3.2 Biased compounds in the clinic 
The possibility of a ligand being able to bias downstream signalling towards one 
particular intracellular outcome potentially has huge implications for drug design. 
Clinically, a biased ligand could avoid adverse effects by directing signalling away 
from a pathway known to cause side effects, whilst simultaneously enhancing the 
beneficial effect by displaying increased efficacy for the therapeutic signalling 
pathway.  
Although the rational design of biased compounds is still in the early stages, some 
clinically used compounds have retrospectively been identified as biased agonists. 
For instance, the β2 adrenoceptor antagonist, carvedilol, used to treat heart failure, 
has been since shown to be arrestin-biased, as it stimulates recruitment of arrestin to 
the β2 adrenoceptor whilst acting as an antagonist for G protein activation (207). This 
arrestin-biased nature of carvedilol may contribute to improved survival statistics in 
heart failure patients treated with carvedilol over other β-blockers (208), as arrestin 
signalling from the β2 adrenoceptor appears to be cardio-protective (209).  
In the opioid field, although various G protein-biased MOPr compounds are under 
development (see Section 1.3.4), none have yet reached the clinic. Biased agonism 
is also under investigation as a therapeutic strategy for other opioid receptor subtypes 
(210, 211). For example, the KOPr agonist, nalfurafine, which is currently licenced in 
Japan as an anti-pruritic, was recently reported to be G protein-biased (212). This 
finding may provide an explanation for its reduced dysphoric effects compared to 
other KOPr agonists (213, 214).  
As yet, no newly developed biased agonist for any GPCR has reached the clinic. For 
instance, TRV-027, an arrestin-biased ligand at the angiotensin II type 1 receptor, was 
efficacious in in vivo models of congestive heart failure, reducing blood pressure but 




that TRV-027 failed to perform better than placebo, and development of this 
compound has since halted (218).  
The reason for this attrition is unclear, though it remains challenging to translate 
biased signalling observed at the cellular level to efficacy in whole animal systems 
(219, 220).  
1.3.3 Molecular mechanisms of ligand bias 
The molecular mechanism of biased agonism at the MOPr, and indeed any GPCR, is 
yet to be fully elucidated. The current favoured hypothesis is that the underlying 
conformational heterogeneity of a GPCR allows the receptor to occupy multiple 
distinct active conformations, dependent on the bound ligand (221). If agonists are 
capable of stabilising unique active conformations of a receptor, it follows that these 
distinct active states would have different affinities for intracellular effector proteins, 
and therefore drive signalling through one coupling partner over another. 
There is a body of evidence from spectroscopic studies supporting the presence of 
multiple GPCR functional states. For instance, using a quantitative mass 
spectrometry technique labelling residues at multiple sites along the protein, Kahsai 
et al., showed that the β2 adrenoceptor adopts different conformations in the presence 
of 9 functionally distinct ligands (222). Indeed, an NMR study of the same receptor 
showed the β2 adrenoceptor existing in multiple inactive, active and intermediate 
conformations (91). A similar approach also reported the presence of at least two 
inactive and two active states of the adenosine A2A receptor, with the relative 
population of each state determined by the bound ligand (223). More recently, study 
by Wingler et al., used DEER spectroscopy to probe the conformational state of the 
angiotensin II type I receptor in the presence of a panel of differently biased ligands 
(224). They showed not only that in the apo state the receptor exists in a 
conformationally heterogenous population, but that agonist binding caused large 




presence of G protein-biased agonists the receptor favoured an “open” state, whereas 
arrestin-biased agonists shifted the ensemble to an “occluded” conformation, which 
was less capable of interacting with a G protein.  
The lack of a cell membrane and unusual detergent environment in the above studies 
may impact the conformations favoured by the GPCR. The development of 
biosensors using FlAsH-BRET constructs may allow monitoring of receptor 
conformations in an intact cell. FlAsH-BRET utilises a tetracysteine motif incorporated 
into the intracellular domain of the GPCR to bind a fluorescent biarsenical hairpin 
(FlAsH) tag, which acts as an acceptor for bioluminescence resonance energy 
transfer (BRET) from a luciferase enzyme fused to the GPCR C tail. Conformational 
changes in the GPCR intracellular domains are detected as a change in the BRET 
signal. Such sensors have already been reported for the β2 adrenoceptor, angiotensin 
II type I receptor, and prostaglandin F2α receptor (225, 226). 
The last year has seen the rapid appearance of many cryoEM-resolved structures of 
GPCR-G protein complexes (23, 105, 106, 108, 227-230). The speed at which this 
field is moving suggests that we shall surely see many more complexes resolved in 
the near future, including that of GPCR-arrestin complexes and GPCRs bound to 
biased agonists, allowing comparison of the activated receptor conformations. At the 
time of writing, the only GPCR-arrestin structures available are that of the rhodopsin-
visual arrestin complex (178, 231, 232). Comparison of the rhodopsin-arrestin 
interface with that of GPCR-G protein complexes suggests that in general, a shared 
interface involving TMs 3, 5 and 6 exists for G proteins and arrestins, however the 
extent of the outswing of TM6 is greater for the G protein-bound receptor than arrestin 
(177, 233), in agreement with the “occluded” state described by Wingler et al., (224). 
Moreover, coupling to arrestin may involve more extensive interactions at the TM7 / 
helix 8 interface (177). This is supported by a study of the angiotensin II type 1 
receptor which used molecular dynamics simulations (see Section 1.4) to investigate 




mutants (234). Simulations of the G protein-biased mutant were associated with a 
change in the conformation of TM7, whereas the arrestin-biased mutant exhibited 
increased stability of the same helix. The authors therefore suggest that in the 
angiotensin II type I receptor, destabilisation of TM7 is involved in G protein activation, 
whilst stabilisation facilitates arrestin signalling.  
A cryoEM resolved structure of the Class B GLP-1 receptor in complex with the Gs G 
protein and the G protein-biased agonist ExP5, revealed a possible structural 
mechanism for biased agonism at this peptide-sensing receptor (108). Unlike the 
GLP-1 bound receptor (235), ExP5 engaged in interactions with the extracellular end 
of TM1, causing this helix to rotate towards TM2, whereas with GLP-1 bound TM1 
was positioned closer to TM7. Alanine mutagenesis of residues in TM1 confirmed 
their importance in ExP5 G protein-mediated signalling, but not for GLP-1. In addition, 
the conformation of ECL3 was different between the two agonist-bound structures, 
with mutation of ECL3 residues hindering the binding affinity of GLP-1, but not ExP5. 
This suggests that at the GLP-1 receptor, biased ligands stabilise different 
conformations on the extracellular side of the protein which translates to an allosteric 
effect on effector coupling of the intracellular domain.  
In order to facilitate the rational structure-guided design of biased ligands, work is also 
underway to identify specific residues and motifs important for encoding agonist bias. 
For example, comparison of the crystal structures of ergotamine bound to the 5HT2B 
(162) and 5HT1B (236) receptors, at which it is an arrestin-biased and unbiased ligand 
respectively, revealed structural differences in the PIF and NPxxY motifs (see 
Sections 1.2.3.5 and 1.2.3.6). In these structures, the PIF motif was stabilised in an 
active conformation in the 5HT1B receptor, but not in the 5HT2B receptor, whereas 
NPxxY was in an active conformation in the 5HT2B receptor, suggesting that these 
residues may be important in specifying the bias profile of ergotamine (162). Residues 
in the allosteric sodium ion binding site (Section 1.2.3.3) have also been implicated in 




constitutive arrestin recruitment, but not G protein signalling (124). A series of studies 
of aminergic receptors have also identified a conserved hydrophobic residue in 
position 45.52 of ECL2 (numbering for loops follows the nomenclature described in 
(237)), along with position 7.35 in TM7 and residues in TM5, as predictors for biased 
agonism at this receptor family (186, 187, 238, 239). 
Together, these studies point to a mechanism whereby biased ligands stabilise 
distinct receptor conformations via their interactions with residues in the binding 
pocket and stabilisation of specific conformations of key activation motifs. However, 
the precise nature of these interactions and whether there is a general mechanism for 
bias across the Class A GPCR family is unknown.  
1.3.4 Biased agonism at the MOPr 
There is abundant evidence that agonist bias exists at the MOPr. A thorough study of 
a variety of opioid ligands by McPherson et al., correlated the agonist intrinsic efficacy 
for GTPγS binding with arrestin-3 recruitment, showing that the endomorphins, along 
with etorphine and alfentanil, were notable outliers (21). A subsequent analysis 
revealed endomorphin-2 to be biased towards arrestin recruitment (240). Similarly, 
Thompson et al., characterised a series of opioid peptides across a range of signalling 
pathways, revealing that endomorphin-1, loperamide and α-neoendorphin displayed 
unique bias profiles compared to the other ligands (241). Bioluminescence or 
fluorescence resonance energy transfer (BRET or FRET) assays are widely used to 
interrogate ligand-induced G protein activation and arrestin recruitment, and both 
techniques have been utilised to demonstrate the differential bias of morphinan small 
molecule MOPr agonists (242, 243). 
There are increasing efforts to develop G protein-biased agonists at the MOPr, based 
on the observation by Bohn et al., that arrestin-3 knockout mice displayed enhanced 
analgesia in response to morphine, but with a reduction in side effects such as 




accepted conclusion from these genetic studies is that arrestin recruitment to the 
MOPr mediates most (if not all) of the adverse effects seen with MOPr agonists. 
Moreover, a study by Schmid et al., correlated increasing bias towards G protein 
activation with a greater therapeutic window between efficacy in inducing anti-
nociception and the dose limiting adverse effect of respiratory depression, adding 
weight to the G protein bias hypothesis (246). 
This is contradicted however, by the recent paper by Kliewer et al., reporting that mice 
expressing a phosphorylation-deficient MOPr exhibited a similar, or in some cases 
enhanced, side effect profile in response to morphine compared to wildtype-
expressing mice (66).  Furthermore, Montandon et al., used genetically modified mice 
to show that when GIRK channel subunits are knocked out, opioid agonists induce 
very little respiratory depression, providing evidence that GIRK channels mediate, at 
least in part, the inhibition of respiration by opioids (29). As GIRK channel activation 
is mediated by G proteins, this suggests that respiratory depression may not be 
avoided by a G protein-biased agonist, and the complete deconvolution of analgesic 
properties over all adverse side effects by opioids may not be possible.  
Although the clinical usefulness of biased opioid ligands is still under debate, the 
development of G protein-biased MOPr agonists has nevertheless continued. 
Oliceridine (or TRV-130) (247), is currently in Phase 3 clinical trials for use in acute 
pain, with the latest published results of the Phase 2b trial showing modest 
improvement over morphine; oliceridine produced similar levels of analgesia, but with 
rapid onset and reduced gastrointestinal side effects compared to morphine (248). 
However, oliceridine appears to still retain abuse potential (249, 250), suggesting that 
G protein-biased opioids will not overcome the problem of opioid addiction (251). 
A computational screen for new MOPr ligands with novel scaffolds fortuitously hit 
upon a G protein-biased agonist, PZM21, structurally distinct from other small 




nociception in mice in the hot plate test, but minimal respiratory depression, 
constipation and reinforcement in conditioned place preference. However, a study 
carried out in our laboratory failed to replicate these findings, showing instead that 
PZM21 caused respiratory depression at a similar level to morphine, casting doubt 
onto the findings of the original paper (253).  
Although oliceridine and PZM21 receive the most attention, several groups have 
reported the discovery of biased agonists at the MOPr. For instance, mitragynine 
pseudoindoxyl was identified as a mixed DOPr antagonist, MOPr G protein-biased 
agonist with efficacy in anti-nociception assays but reduced onset of tolerance and 
other opioid side effects (254). The salvinorin A derivative, herkinorin, is a MOPr 
agonist which does not recruit arrestin nor induce receptor internalisation (255) 
(although conversely, Manglik et al., reported that herkinorin does robustly recruit 
arrestin, with a maximum response comparable to DAMGO (252)). In in vivo studies, 
whilst herkinorin dose-dependently induced anti-nociception, it produced minimal 
tolerance under chronic administration (256).  More recently, a cyclic MOPr peptide 
was reported as the first G protein-biased MOPr agonist with a “peptide-like” structure 
(257). 
However, it is often the case, particularly for G protein-biased MOPr agonists, that 
these compounds are partial agonists for G protein activation, making the quantitative 
assessment of ligand bias difficult (258, 259). Indeed, oliceridine and PZM21 have 
been shown to act as low efficacy partial agonists for G protein signalling, both in 
BRET assays directly measuring G protein activation (253), and on downstream ion 
channel targets (260).  Moreover, deconvoluting the relative contributions of bias 
versus efficacy in mediating the different in vitro and in vivo profiles of these agonists 
is problematic. For instance, in a recent study of agonist bias in native neurons, 
buprenorphine was identified as a G protein-biased agonist, which may in part explain 
its clinical usefulness as an effective analgesic and opioid-abuse treatment with low 




partial agonist at the MOPr, so some of its therapeutic effects may also be attributable 
to its lower efficacy.  
1.3.5 Structural basis of MOPr biased agonism 
There is limited structural data on the molecular mechanism of biased agonism at the 
MOPr, partly due to the lack of strongly biased MOPr agonists (see Section 1.3.4, 
above).  
Insights from NMR spectroscopy suggest that, like other GPCRs, the MOPr can exist 
in multiple ligand-bound conformations, with unbiased or oppositely biased agonists 
stabilising distinct states (262). The authors proposed a model whereby in the 
antagonist-bound state the MOPr favours a closed conformation, but the agonist-
bound receptor exists in an equilibrium between the closed state and multiple “open” 
active states, with biased ligands favouring one active state over another (262). This 
model has been recently supported by a similar study of the angiotensin II type I 
receptor showing again that the receptor existed in a heterogenous population of 
closed and open states, stabilised by different biased ligands (224). Furthermore, both 
independent studies agree that the arrestin-biased conformation is likely to have a 
more occluded intracellular cavity than the G protein-coupled state (224, 262).  
Molecular dynamics simulations by Schneider et al., modelling the binding and 
subsequent ligand-MOPr interactions of the G protein-biased ligand oliceridine versus 
morphine, showed different subsets of residues participated in information transfer 
between the orthosteric ligand binding site and the intracellular domain of the MOPr 
(263). Specifically, residues in TMs 1, 3 and 7 and helix 8 contributed to the allosteric 
networks only in the oliceridine-MOPr complex, whereas residues in TMs 2, 4 and 6 
were unique to the morphine-MOPr complex (263). Interestingly, one of these 
residues highlighted in the molecular dynamics study, W7.35, when mutated to 
alanine altered the bias profiles of the MOPr peptide agonists, DAMGO and 




Together, these studies suggest that bias at the MOPr has a molecular basis in that 
the distinct pattern of ligand-residue interactions influences the overall conformation 
of the receptor, which then drives differential effector coupling. However, specific 
pharmacophores and ligand-residue interactions responsible for dictating G protein 
or arrestin bias, or even overall agonist intrinsic efficacy, are yet to be discovered.  
The DAMGO-MOPr-Gi complex has recently been resolved by cryoEM (23). With the 
current rate of technological development in the field of high-resolution cryoEM (77), 
along with the increasing number of reported MOPr biased agonists, it is surely only 
a matter of time before further unbiased and biased ligand-MOPr structures are 
resolved in complex with other intracellular proteins, such as arrestins or GRKs. 
Ultimately, comparison of multiple MOPr-effector and MOPr-ligand complexes may 
well reveal the molecular mechanism of how different ligands direct receptor coupling 
to distinct effector proteins.  
Until such structures are available, however, computational techniques such as 
molecular dynamics simulations, are invaluable as a tool to predict the behaviour of 
yet unsolved ligand-receptor complexes, based on the currently available 
crystallographic data. Molecular dynamics, and its application to the study of GPCRs, 




1.4 Molecular dynamics simulations 
1.4.1 Definition 
Molecular dynamics (MD) simulations are a computational approach to capture the 
dynamic behaviour of biological molecules. Using a crystal structure or homology 
model as a starting point, an MD “trajectory” is generated to simulate the thermally 
induced movement of the structure. Trajectories are calculated using Newtonian 
mechanics to determine the atomic positions and velocities at each time step, 
governed by the temperature, pressure and energetics of the system.  
MD simulations can be “atomistic”, whereby each atom in the system is represented 
explicitly and individually, or “coarse-grained”, where atoms are grouped together into 
beads with an overall property to reduce the degrees of freedom and therefore reduce 
the computational effort required so that long timescale simulations can be performed. 
However, in coarse-grained MD what you gain in simulation time you lose in 
resolution, so detailed side chain movements and ligand-residue interactions cannot 
be explored. In atomistic MD, although the achievable simulation timescales are much 
shorter, the behaviour of individual atoms is modelled, allowing much more detailed 
interpretation of the results. To investigate the detailed ligand-residue interactions and 
behaviour of key signalling motifs in the MOPr, this thesis will therefore use atomistic 
MD simulations.  
1.4.2 Advantages and limitations 
There are a number of advantages in using MD simulations to explore the behaviour 
of protein-ligand complexes. Firstly, as mentioned in Section 1.3.5, currently available 
protein structures can be utilised to model how other, yet unsolved, ligand-protein 
complexes may interact and behave. In the case of the MOPr, neither of the high 
resolution x-ray crystal structures currently available show the receptor bound to a 




Secondly, whilst x-ray and cryoEM structures of GPCRs have given much insight into 
ligand binding poses and structural differences between inactive and active states, 
they are static snapshots in time of highly dynamic proteins, and under non-
physiological conditions. In order to obtain highly purified and stable samples, GPCRs 
are usually modified with thermo-stabilising mutations (265), engineered to contain 
fusion partners such as a T4 lysozyme or BRIL (266), stabilised by the addition of an 
antibody or nanobody (267, 268), and truncated at the N and C termini, so that the 
resulting receptor may be quite different from that found in vivo. Furthermore, 
structures of ligand-GPCR complexes are often determined using ligands with 
unusual properties, such as very slow dissociation rates, picomolar affinity (22, 269), 
or covalent binding (76) in order to further stabilise the GPCR in a single conformation. 
In preparing a GPCR structure to model using MD simulations, fusion proteins, 
antibodies and mutations are removed in order to model the receptor in a more native-
like state. In addition, any number of biologically interesting or clinically important 
ligands can be docked to the receptor and subsequently simulated. 
MD simulations also capture the dynamic behaviour of a protein; information which is 
lost in a static structure, and is particularly important when studying GPCRs which are 
known to exist in a heterogeneous ensemble of different conformational states (270).  
Finally, compared to traditional in vitro experiments, molecular docking and MD 
simulations are a relatively high-throughput method to study different receptors, 
variants, and compounds. In silico screening is now routinely performed in drug 
discovery to narrow down the number of lead compounds subsequently used in in 
vitro studies (271-273).  
Of course, it must be remembered that in silico approaches are only models of 
biological systems. MD simulations are inherently limited by the accuracy of the 
available forcefields (the algorithms and equations providing the parameters for 




Although advances in computing power have vastly increased the possible simulation 
time from picoseconds to microseconds, except on the most highly specialised 
machines (274), the timescales for membrane-embedded GPCR MD simulations are 
still limited to between nanoseconds and microseconds. This is in contrast to 
physiological GPCR signalling which occurs over milliseconds to hours. Even where 
longer timescale simulations are achievable, there may still be incomplete sampling 
of the conformational landscape due to energy minima (275). Both of these issues 
can (in part) be overcome by the use of enhanced sampling methods, such as 
accelerated MD and meta-dynamics (275).  
Finally, it is not possible to model all aspects of the environment of the native cell, for 
example the exact membrane composition around the receptor, interactions with 
other proteins (other than G proteins and arrestins) and interactions with the 
cytoskeleton. All of these factors may have important impacts on GPCR function (140, 
144, 276-278).  
1.4.3 Application to the study of GPCRs 
In spite of the limitations described above, the application of MD simulations to the 
study of GPCRs, and indeed the MOPr, have yielded some important findings. 
Using the specially designed supercomputer, Anton in the D. E. Shaw laboratory 
(274), Dror et al., were able to model the binding pathway of small molecule ligands 
to the β1 and β2 adrenoceptor, showing that the ligands all interacted with a common 
extracellular vestibule before transitioning to the orthosteric binding pocket (192). 
Similarly, MD simulations of the M3 muscarinic receptor showed the inverse agonist, 
tiotropium, also interacted transiently with an extracellular vestibule on dissociation 
from the receptor (279). Combined with previously reported mutagenesis data (280), 
the authors proposed this extracellular vestibule may represent an allosteric site on 
muscarinic receptors. This allosteric site has since been successfully exploited in the 




In the opioid receptor family, a putative binding site for allosteric modulators of the 
DOPr has been discovered using MD simulations (282). The in silico experiments 
resolved a binding site between TMs 1, 2 and 7 above the orthosteric binding pocket, 
which was validated by in vitro mutagenesis in the same study. Similarly, docking and 
MD simulations of the methadone-bound MOPr in the presence of the positive 
allosteric modulator, BMS-986122, revealed a similar allosteric pocket in an 
extracellular vestibule composed of TMs 2 and 7. This revealed a possible molecular 
mechanism for the modulatory effect of this compound, whereby binding of BMS-
986122 disrupted sodium binding (283), which is in line with the experimental data on 
these compounds, discussed in Section 1.2.3.3.  
MD simulations have also been utilised to predict unusual binding modes of some 
GPCR ligands. Notably, in both the cannabinoid CB2 and PAR1 receptors, MD 
simulations have revealed that lipophilic ligands for these receptors can enter the 
orthosteric site via a pathway through the phospholipid bilayer (284, 285). Chan et al., 
recently reported a hitherto unknown binding site for the endogenous muscarinic 
agonist acetylcholine, much deeper in the receptor pore than the orthosteric site (286). 
Moreover, insight from crystallographic and MD data was successfully used by 
McCorvy et al., to rationally design biased compounds at the dopamine D2 receptor 
(187), providing proof of concept that agonist bias can be reliably predicted using key 
ligand-residue interactions highlighted in MD simulations.   
The mechanism of GPCR activation and deactivation has also been explored using 
very long timescale simulations of the β2 adrenoceptor. Starting from the active-state 
crystal structure, after removal of the agonist and G protein mimetic nanobody, the 
receptor was observed to relax back to an inactive conformation, revealing several 
intermediate conformations along this deactivation pathway (287).  
Molecular modelling is perhaps most powerful when used in parallel with experimental 




validated by mutagenesis and signalling assays in cell lines. As discussed above in 
Section 1.3.3, DEER spectroscopy of the angiotensin II type I receptor was used to 
identify unique receptor conformations stabilised by biased agonists (224). In the 
same paper, MD simulations of the angiotensin II type I receptor were also performed 
showing that the positions of the transmembrane domains in the MD simulations 
overlapped with the spin densities from the DEER measurements, showing that the 
receptor indeed sampled a range of conformations different to that observed in the 
static crystal structure. In addition, Landin et al., combined MD simulations with NMR 
studies of the adenosine A2A receptor to show a unique conformation of TM5 stabilised 
by the antagonist, compound 1, again highlighting the use of in silico techniques to 
corroborate experimental data (288).  
To summarise, MD simulations of GPCRs have revealed unique ligand binding sites 
and receptor conformations which are not captured in x-ray or cryoEM structures. 
Along with experimental data, these studies have provided important insights into the 
structure and function of these important drug targets and allowed the rational design 






1.5 Outstanding questions 
There are a number of outstanding questions relating to the molecular mechanisms 
of opioid ligand efficacy and bias; 
1. How do the interactions of an opioid with the MOPr binding pocket dictate 
efficacy?  
Much of our understanding of the nature of agonist efficacy is based on the “canonical” 
Class A GPCR, the β2 adrenoceptor (166). However, the molecular mechanisms 
governing ligand efficacy at the MOPr may be very different.  
Firstly, the MOPr is primarily Gi/o coupled, whereas the β2 adrenoceptor couples to Gs. 
The recently reported cryoEM structures of GPCR-G protein complexes have 
revealed important differences in the conformation of the intracellular domain between 
Gs and Gi/o coupled receptors (23).  
Secondly, although the clinically used opioid drugs are small molecules, the MOPr is 
a peptide receptor. It therefore has a much deeper binding pocket than the β2 
adrenoceptor (76) and has evolved to respond to large peptide molecules. The 
adrenoceptors, on the other hand, recognise small molecule catecholamines. The 
important interactions between the respective ligands and the orthosteric pocket are 
therefore likely to be very different. Although it is generally appreciated that Class A 
GPCR activation mechanisms converge around the intracellular, G protein-coupling 
domain, the conformational changes around the orthosteric site are divergent across 
different receptors and receptor families (82, 101). It cannot be assumed that the 
ligand-residue interactions identified in one receptor are conserved in another.  
Finally, at the time of writing, the only available high resolution x-ray crystal structures 
of the MOPr are in complex with either a covalently bound antagonist (β-FNA) or a 
very high affinity, slowly dissociating, experimental agonist (BU72) (22, 76). Neither 




ligands compare with medically important opioids, such as morphine, buprenorphine 
and methadone. Data on the interactions between the MOPr and its endogenous 
peptide ligands are also lacking; in the cryoEM-resolved structure of the MOPr-Gi 
complex, DAMGO is not the endogenous agonist and there is low resolution in the 
binding pocket (23). 
2. Do different MOPr ligands stabilise distinct receptor conformations? 
Spectroscopic data suggest the presence of multiple active conformations for other 
GPCRs (222, 224). However, there is limited literature on this phenomenon for the 
MOPr, although Okude et al., reported the existence of an equilibrium between open 
and closed conformations of the intracellular domain of the MOPr (262).   
3. How do the ligand-receptor interactions and MOPr conformations differ for biased 
agonists? 
There are currently no structures of the MOPr bound to biased ligands. Therefore, as 
discussed in Section 1.3.5, there is limited data on the structural basis of opioid ligand 
bias. Computational studies have so far largely focussed on oliceridine (173, 263, 
289), which may not be strongly biased (260), and there are few studies which 





1.6 Thesis aims 
Given the therapeutic potential of developing MOPr ligands with distinct signalling 
profiles (Section 1.3.4), along with the gap in current scientific knowledge around the 
molecular mechanisms governing ligand efficacy and bias at this clinically important 
receptor (Section 1.5), this thesis will aim to use a combination of in silico and in vitro 
approaches to identify possible molecular mechanisms for opioid ligand efficacy and 
bias.  
The aims are: - 
i) Using in silico MD simulations: 
- Characterise the interactions of biased and unbiased opioid ligands with the 
MOPr orthosteric binding pocket 
- Determine how the binding of a sodium ion modulates opioid ligand binding 
and receptor conformation 
- Explore receptor conformational changes induced by biased and unbiased 
ligands 
- Identify key residues in conveying efficacy and/or bias at the MOPr 
ii) Using in vitro cell signalling assays: 
- Characterise the signalling profiles of biased and unbiased MOPr ligands 
- Validate hypotheses based on MD simulation data by expressing the relevant 






















2.1 Molecular modelling studies  
2.1.1 Molecular mechanics  
Molecular dynamics (MD) simulations model the dynamic behaviour of a biological 
system, using a molecular mechanics forcefield to define the energy of each atom 
and hence the potential energy of the whole system.  
In a molecular mechanics forcefield, the system energy is broken down into bonded 
and non-bonded interactions between the atoms (Equation 1). 
[Equation 1]     ∆𝐸 =  ∆𝐸𝑏𝑜𝑛𝑑𝑒𝑑 +  ∆𝐸𝑛𝑜𝑛−𝑏𝑜𝑛𝑑𝑒𝑑 
Bonded (or covalent) interactions are described by energy terms for bond length and 
stretching, bond angle bending, and torsion angle rotation (Equation 2). 
 [Equation 2]  ∆𝐸𝑏𝑜𝑛𝑑𝑒𝑑 =  ∆𝐸𝑏𝑜𝑛𝑑𝑠 + ∆𝐸𝑎𝑛𝑔𝑙𝑒𝑠 +  ∆𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠 
All molecular mechanics have this general form but may differ in some of the details 
of the functions used. Next, I will outline the functions used in the Amber-ff14SB 
forcefield (290), which are typical of most modern forcefields.  
The energy term for bond length equates two covalently bonded atoms to balls 
connected by a spring, with the energy required to stretch or compress the bond 
described by Hooke’s Law (Equation 3). 





Where 𝑘𝑏 is the force constant, specific to the pair of bonded atoms, 𝑙 is the bond 
length and 𝑙0 is the equilibrium bond length. This function follows a harmonic potential, 
whereby stretching or compressing the bond requires increasing energy.  










Where 𝑘𝑎 is the force constant (smaller than the force constant for bond length 𝑘𝑏), 𝜃 
is the angle between 3 bonded atoms, and 𝜃0 is the equilibrium angle. The smaller 
force constant for angle bending ensures that the energy required to distort a bond 
angle is lower than to distort bond length.  
Torsion angle rotation (the angle made between the 2 planes of 4 sequentially bonded 
atoms) is described by trigonometric functions to model the favoured, low energy 
torsional states such as trans, gauche+ and gauche- conformations for tetrahedral 
atoms (𝑛=3), and E and Z (cis and trans) for trigonal atoms (𝑛=2) (Equation 5). 
[Equation 5]  ∆𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠 =  
𝑉𝑛
2
[1 + 𝑐𝑜𝑠(𝑛𝜔 −  𝛾)] 
Where 𝑉𝑛 is the force constant for torsion rotation, 𝜔 is the torsion angle and 𝛾 is the 
phase shift.  
Non-bonded interactions are described by energy terms for van der Waals 
interactions and electrostatic (Coulombic) interactions (Equation 6).  
[Equation 6]  ∆𝐸𝑛𝑜𝑛−𝑏𝑜𝑛𝑑𝑒𝑑 =  ∆𝐸𝑉𝐷𝑊 +  ∆𝐸𝐶𝑜𝑢𝑙𝑜𝑚𝑏𝑖𝑐 
Van der Waals interactions between 2 atoms are described by the Lennard-Jones 
equation (Equation 7), whereby very short range contacts are repulsive (modelling 
orbital overlap), the optimal interaction distance is weakly attractive, and longer 
distances give energy values towards zero.  
















Electrostatic interactions between 2 atoms are described by Coulomb’s Law 
(Equation 8). When the 2 atoms have the same sign (e.g. both positive) the force will 
be increasingly repulsive with decreasing distance. When the 2 atoms have the 
opposite charge, the force will be attractive.  




Where 𝑘𝑒 is Coulomb’s constant, 𝑞1 and 𝑞2 are the partial charges of atoms 1 and 2, 
and 𝑟 is the distance between atoms 1 and 2. 
The total potential energy of the modelled system is therefore equal to the sum of all 
the energy terms described above, plus any “improper” terms for bonds not 
adequately described by the bond length and bond angle functions, such as out-of-
plane bending of planar arrangements of atoms like carbonyl and amide groups. 
Hence: 
[Equation 9] 
 ∆𝐸𝑡𝑜𝑡𝑎𝑙 =  ∆𝐸𝑏𝑜𝑛𝑑𝑠 +  ∆𝐸𝑎𝑛𝑔𝑙𝑒𝑠 +  ∆𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠 +  ∆𝐸𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟 +  ∆𝐸𝑉𝐷𝑊 +  ∆𝐸𝐶𝑜𝑢𝑙𝑜𝑚𝑏𝑖𝑐 
In an MD simulation, the time-dependent movement of all the atoms in the system are 
resolved using the above equations. Firstly, energy minimisation is performed to allow 
the system to “relax” to the nearest local energy minimum. For the MD simulations 
presented in this thesis, the steepest descent method of energy minimisation was 
employed. Following minimisation, the system is slowly heated to the desired 
production temperature and then an equilibration simulation performed to equilibrate 
the system’s density and dimensions. Finally, production MD can be performed; each 
atom is assigned an initial velocity, according to the system temperature (usually 300 
or 310 K), and then moved for one time step (usually 2 fs). The forces acting on each 
atom are then recalculated, and the process repeated until the desired simulation time 




The production simulations in this thesis were all performed under constant 
temperature and pressure (NPT ensembles), using the Langevin thermostat and the 
anisotropic Berendsen barostat. These methods control the average temperature and 
pressure of the system, whilst allowing small fluctuations so that the kinetic energy of 
the system is not fixed.  
The MD simulations were conducted under periodic boundary conditions. This 
approach eliminates edge effects in a simulation and long-range Coulombic 
interactions can be efficiently calculated using the Particle Mesh Ewalds method. 
Briefly,  the system is modelled in a box, but the atoms are free to diffuse around and 
out of the box. The system is surrounded by an infinite number of identical replicate 
boxes in all directions to form a lattice, with all the replicate molecules in each of the 
boxes moving in the same way. This means that any atom that leaves the system box 
will immediately re-enter from the opposite side and atoms can interact with other 
atoms in the replicate boxes, thus removing any surface effect.  
Water was simulated using the TIP3P water model (291). This models water as a rigid 
molecule of fixed geometry, which can participate in non-bonded interactions.  
2.1.2 Making the MOPr models from crystal structures 
The initial starting structures and the final structures used in MD simulations are 
shown in Figure 2.1. X-ray crystal structures of the inactive β-FNA bound MOPr 
(PDB:4DKL) (76) (Figure 2.1a) and the active BU72 bound MOPr (PDB:5C1M) (22) 
(Figure 2.1b) were obtained from the Protein Data Bank. The co-crystallised bound 
ligands were removed so that both receptors were in their unliganded, apo form. The 
inactive structure contains a T4 lysozyme (Figure 2.1a, orange) in place of intracellular 
loop 3 (ICL3). Using Insight II the lysozyme was removed, and a loop search 
performed to find a homologous loop which aligned well with the intracellular ends of 
TMs 5 and 6. A loop was selected by visual inspection and the residues changed to 




inspected for clashes and bonds rotated where necessary. For the active MOPr 
model, the G protein-mimetic nanobody, Nb39, was removed from the active structure 
(Figure 2.1b, green). In order to compare the inactive and active structures during the 
MD simulation, both proteins were adjusted to be the same length. The inactive 
structure retained a longer portion of the C terminal helix 8, so this was spliced onto 
the active structure (Figure 2.1b, grey), assuming that the active state MOPr retains 
this α helix. The N terminus of the active structure (Figure 2.1b, purple) has been 
shown to fold over the ligand binding pocket during activation (22, 92) and so deemed 
inappropriate to splice onto the inactive structure. The active protein was therefore 





Figure 2.1 Modification of the MOPr crystal structures 
a) Crystal structure of the antagonist-bound MOPr-T4 lysozyme chimera (PDB: 4DKL (76)), with the 
MOPr shown in grey and the lysozyme in orange. To make the inactive MOPr model, the lysozyme was 
removed and intracellular loop 3 (ICL3, blue-green) was modelled as described in Section 2.1.2. b) 
Crystal structure of the agonist and G protein-mimetic nanobody bound MOPr (PDB: 5C1M (22)), with 
the MOPr shown in teal, the nanobody in green and the N and C termini in purple. To make the active 
MOPr model, the nanobody and the N and C termini of the MOPr were removed, and helix 8 from the 





2.1.3 Ligand docking  
The full molecular docking and molecular dynamics protocol is outlined in Figure 2.2.  
The co-crystallised ligand β-FNA in the inactive MOPr crystal structure shares a 
morphinan scaffold with all the morphinan ligands used in this study (morphine, 
norbuprenorphine, buprenorphine and diprenorphine). Therefore, the binding pose of 
β-FNA in the crystal structure was used as a template to determine the initial 
orientation of the morphinan ligands for MD simulation (76, 152). Ligands were 
protonated at the amine and parameterised with the Antechamber package and the 
general Amber force field (GAFF) (292). The GAFF is a molecular mechanics 
forcefield (see Section 2.1.1), specialised for pharmaceutical molecules, and is used 
by the Antechamber software to generate parameter files for drug molecules by 
assigning atom types and charges. Amber parameter topology and coordinate files 
were then prepared using the LEaP software.   
For the non-morphinan ligands (methadone, DAMGO, endomorphin-2 and bilorphin), 
the conformer generation and subsequent docking protocol described below and 
summarised in Figure 2.2, was used to find a binding pose before simulation of the 
full ligand-MOPr complex. 
2.1.3.1 Generation of ligand conformations 
The 3D conformers of methadone and endomorphin-2 were downloaded from 
PubChem (CID: 22267 and 5311081), and the structures of DAMGO and the novel 
peptide bilorphin were built in the molecular modelling program, Chimera (293). 
Peptide bonds are generally in the trans conformation (Figure 2.3a), however, the 
Tyr1-Pro2 peptide bond of endomorphin-2 can adopt either a cis or trans conformation, 
with conflicting evidence in the literature as to which is the bioactive conformation of 
endomorphin-2 (294-299). The two different 3D conformers of endomorphin-2 were 
therefore built in Chimera and treated as separate ligands for MD simulation and 




hence peptides were protonated at the backbone N terminus, methadone at the 
tertiary amine, and parameterised with Antechamber and the GAFF (292). Amber 
parameter topology and coordinate files were prepared in LEaP such that each ligand 
was solvated with TIP3P water and 0.15 M NaCl, in a simulation box with initial 
dimensions 45, 50, 45 Å. The system was minimised in two steps; initially the water 
and ions were minimised over 1000 steps with the ligand restrained, then the whole 
system was minimised over a further 2500 steps. The system was heated under 
constant volume and pressure from 0 K to 310 K over 20 ps, and then equilibrated 
under constant pressure for 100 ps. Simulations were run for 1 μs per ligand under 
the Amber ff14SB force field (290). Temperature and pressure were controlled with 
the Langevin thermostat and the anisotropic Berendsen barostat, with a 2 fs time step 
and trajectories written every 100 ps. Trajectory data were analysed with the Amber 
analysis software, cpptraj (300), to extract 10,000 conformations for each ligand to 
use in molecular docking. 
2.1.3.2 Molecular docking 
Molecular docking was performed with the Bristol University Docking Engine (BUDE) 
(301). Ligands were docked to the inactive MOPr model (Section 2.1.2) 
independently. The following describes the docking procedure for one ligand. Multi-
conformer docking was run such that the 10,000 conformations of the ligand were 
treated as independent molecules. A box of size 15, 15, 15 Å centred on the 
orthosteric binding site was designated as the search space. BUDE’s genetic 
algorithm was used to search the available pose space for the best energy poses. A 
total of 105,000 poses were sampled for each of the 10,000 ligand conformers. The 
total possible number of poses was 1.57 x 108 for each conformer, corresponding to 
x,y,z translation within the box and 360˚ rotation in all axes in 10˚ increments. The 50 
lowest energy binding poses were inspected visually and subjected to a distance 
constraint between the protonated amine of the ligand and D1473.32 of less than 3 Å. 




2.1.4 System set-up  
Each unliganded receptor or ligand-MOPr complex were modelled as separate 
systems. The receptors were embedded in phospholipid bilayers using the 
replacement method, and the simulation box (initial dimensions: 90, 110, 90 Å) 
solvated with TIP3P water and 0.15 M NaCl, using the CHARMM-GUI software for 
generating membrane models (302). The box size was chosen to ensure the receptor 
was always at least 90 Å away from its images and therefore outside of interaction 
distance. The N terminus and C terminus of each receptor were acetylated or 
amidated, respectively, and a disulphide bond formed between C1403.25 and C217ECL2. 
Hydrogen atoms were added to the receptor consistent with pH 7. The lipid 
composition of the bilayer contained palmitoyl-oleoyl-phosphatidyl-choline (POPC) 
and palmitoyl-oleoyl-phosphatidyl-ethanolamine (POPE), as well as cholesterol at a 
level comparable to that in mammalian cells (303-305). The ratio of 
POPC:POPE:cholesterol was approximately 5:5:1, with the final membrane-
embedded MOPr systems each containing 103 POPC lipids, 100 POPE lipids and 20 
cholesterol molecules. The total number of atoms was approximately 85,000 in each 
system. Amber parameter topology and coordinate files were prepared in LEaP.  
2.1.5 Molecular dynamics simulations 
Structures were minimised over 10,000 steps, then the system was heated under 
constant volume and pressure with lipids restrained, from 0 K to 100 K over 5 ps, and 
then from 100 K to 310 K over 100 ps. 10 rounds of 500 ps equilibration was 
performed under constant pressure to equilibrate the periodic box dimensions. Each 
production simulation was run for 125 ns under the Amber ff14SB and Lipid14 force 
fields (290, 306). Temperature and pressure were controlled using the Langevin 
thermostat and the anisotropic Berendsen barostat, with a 2 fs time step and 
trajectories written every 100 ps.  
To increase sampling, after the initial 125 ns production simulation 7 structures from 




equilibrated and 125 ns production simulations were run as described above. This 
resulted in a total of 1 μs MD data for each receptor model in a series of 8 x 125 ns 
parallel steps, with newly minimised structures and new random velocities for each 
simulation.  
Accelerated MD (aMD) uses an external boost potential to accelerate conformational 
changes, with the aim of increasing sampling over the same amount of computation 
time as conventional MD. The aim is for protein conformational changes to be 
investigated which would otherwise not be accessible over the short computing time 
available. Parameters for the aMD were calculated as described in Kappel et al., 
(307), using the Equations 10 - 13 below. Values for the average total potential energy 
(Vaverage total) and average dihedral energy (Vaverage dihedral) were obtained from the 
conventional MD simulations. Natoms is the total number of atoms in the system. 
[Equation 10]    𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 = 𝑉𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 + 0.3 × 𝑉𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙   
[Equation 11]    𝛼𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 = 0.3 ×  𝑉𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙  × 0.2 × 𝑁𝑎𝑡𝑜𝑚𝑠 
[Equation 12]    𝐸𝑡𝑜𝑡𝑎𝑙 =  𝑉𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑜𝑡𝑎𝑙 +  0.2 ×  𝑁𝑎𝑡𝑜𝑚𝑠 
[Equation 13]    𝛼𝑡𝑜𝑡𝑎𝑙 = 0.2 ×  𝑁𝑎𝑡𝑜𝑚𝑠 
2.1.6 Computational resources 
All simulations were performed on either BlueCrystal phase 3 (Advanced Computing 
Research Centre, University of Bristol), or on a local workstation with Nvidia GTX 
1080. 125 ns of production MD takes approximately 7 days using BlueCrystal, or 4 






Figure 2.2 Molecular docking and molecular dynamics protocol 
Starting with either a morphinan ligand, non-morphinan ligand, or unliganded simulation (grey boxes), 
docking poses are decided, receptors are embedded in a bilayer, and MD simulations performed to 






Figure 2.3 Trans and cis peptide bonds 
a) Rotation around the peptide bond allows the formation of trans or cis isomers. For non-proline 
residues, trans isomers are the predominant form due to steric hinderance in the cis conformation. For 
peptide bonds involving proline, cis isomers can also form as the proline side chain offers less steric 
hinderance. b) Endomorphin-2 contains a proline residue and can exist in either trans (orange) or cis 





2.1.7 Analysis  
Trajectories were visualised in the molecular visualisation program, VMD (308) and 
analyses were performed using cpptraj (300). All images relating to molecular 
modelling were made in Chimera (293). Before any further processing, trajectories 
were fitted to the inactive MOPr model to remove translation and rotation of the 
receptor. For all figures illustrating trajectories, the parallel simulations were 
concatenated to a trajectory totalling 1 µs, and the individual simulations indicated on 
the plots by light grey vertical lines at 125 ns intervals. 
Root mean square deviation (RMSD) measurements were taken to determine the 
stability of both the receptor and the docked ligands. For RMSD calculations on the 
receptor, calculations were performed on just the alpha carbons of the 
transmembrane domains (Figure 2.4a) to avoid including the highly flexible loops and 
residue side chains in the analysis, which would mask more subtle movements of the 
receptor helices. Atomic coordinates were compared to the first frame of the 
production simulation. For RMSD calculations on the ligands, calculations were 
performed using the heavy (non-hydrogen) atoms of the ligand and comparing the 
atomic positions to the initial docked pose of the ligand, and to the final binding pose 
after 1 µs MD simulation. 
Principal component analyses on the alpha carbons of the receptor transmembrane 
domains (Figure 2.4a) was performed to extract the first two principal components 
(PC) of motion. Trajectories were aligned by the alpha carbon atoms of a set of “core 
residues” (Figure 2.4b) which showed the least amount of movement through the 
simulation (determined by per residue RMS fluctuations). This avoided translation and 
rotation of the receptor and anchored the protein around a core area so movement of 
the rest of the structure could be determined. The covariance matrix was calculated 
and diagonalised using cpptraj, and the PCs obtained by mapping the alpha carbons 
of all structures’ trajectories. Each frame of the simulated trajectories was mapped 




by the receptor at each time point. Pseudo-trajectories for each PC were generated 
in cpptraj to visualise the helix movements contributing to the PC.   
Interactions between the bound ligand and receptor residues were determined using 
a 4.5 Å distance cut-off, and calculated as the percentage of simulation time the 
contact was present.  
The angle of the W2936.48 “rotamer toggle switch” was determined by measuring the 







Figure 2.4 Snake plots of the murine MOPr used in the molecular modelling 
a) The MOPr transmembrane region is shown in blue. The coordinates of these residues were used for 
the RMSD calculations and the PCA. b) The core residues to which trajectories were aligned prior to 




Figure 2.5 Torsion angles in tryptophan  
χ1 and χ2 torsion angles in the tryptophan side chain. χ1 is angle of the Cα – Cβ axis. χ2 is the angle of 




2.2 In vitro cell signalling studies 
2.2.1 Compounds 
The novel peptide, bilorphin, was synthesised in the laboratories of Prof. Rob Capon 
and Prof. Paul Alewood, University of Queensland, and provided to us as a gift. 
DAMGO (Sigma-Aldrich), endomorphin-2 (Sigma-Aldrich), morphine (MacFarlan 
Smith) and methadone (Sigma-Aldrich) were dissolved in sterile, de-ionised water. 
Diprenorphine (Sigma-Aldrich), norbuprenorphine (NIDA Drug Supply Program), 
buprenorphine (Tocris) and bilorphin were dissolved in dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich). High concentration drug stocks (10 - 30 mM) were stored as frozen, 
small volume aliquots (10 - 20 µl). Prior to use, all drug stocks were diluted in clear, 
serum-free media (ThermoFisher) to the desired concentration prior to assay. Unless 
otherwise stated, the vehicle control in all experiments was 0.01 % DMSO in serum-
free media.  
2.2.2 Plasmid preparation 
The pQCXIN-hMOPR-RLucII and pQCXIH-Arr3-GFP10 constructs were a gift from Dr 
Tomasso Costa, Istituto Superiore di Sanita. The pcDNA3.1-Gαi-RLucII and 
pcDNA3.1-Gγ-GFP plasmids were a gift from Dr Michel Bouvier, University of 
Montreal. The pcDNA3-Arr3-RLuc construct was a gift from Dr Nick Holliday, 
University of Nottingham. The pcDNA3-HA-rMOPR and pcDNA3-rMOPR-YFP 
constructs were from Dr Helen Sanderson, University of Bristol. The plasmids 
containing the W293A and L219A MOPr point mutations were generated by myself 
using the QuikChange site directed mutagenesis kit as detailed in Section 2.2.6. For 
all the plasmids used in this thesis, the methods for obtaining purified DNA from 
bacteria were as follows; 
20 μl aliquots of DH5α competent cells (Invitrogen), stored at -80 ˚C, were thawed on 
ice. 2 – 4 μl of plasmid DNA was added to the competent cells and the mixture 
incubated on ice for 30 minutes. Plasmids were transformed into the bacteria by heat 




2 minutes. 200 μl of pre-warmed SOC media (Invitrogen) was added to each tube of 
competent cells / DNA and incubated at 37 ˚C for 1 hour with shaking, to improve 
recovery of the competent cells. Following incubation, bacteria were streaked onto 
Luria-Bertani (LB) agar plates containing 100 μg/mL ampicillin (ThermoFisher) for 
selection of only bacteria containing the transformed plasmid, and incubated 
overnight at 37 ˚C.  
The following day (at least 16 hours post-transformation) single, well-separated 
colonies were picked from the agar plates and added to separate tubes of 3 ml LB 
broth containing 100 μg/mL ampicillin. Selection of a single colony with no 
surrounding satellite colonies is important to ensure selection of a single clone. The 
tubes of LB broth were incubated at 37 ˚C overnight with shaking. The following day, 
the bacterial cultures were expanded in 200 ml flasks of LB broth and 100 μg/mL 
ampicillin. Flasks were incubated for 24 hours at 37 ˚C with shaking.  
Plasmid DNA was purified from the bacterial culture using the HighSpeed Plasmid 
Preparation Kit (Qiagen), based on alkaline lysis. Unless specified, all buffers and 
reagents were provided in the kit. Bacteria were pelleted by centrifugation at 4500 x 
g for 20 minutes at 4 ˚C, and the supernatant discarded. Pellets were resuspended in 
resuspension buffer containing 100 μg/mL RNase A. Cells were then lysed by addition 
of lysis buffer and incubated at room temperature for 5 minutes, before termination of 
the lysis reaction by addition of the neutralisation buffer. The lysate was cleared by 
filtration through the QIAfilter cartridge. The cleared lysate was added to the 
HighSpeed Tip containing an anion exchange resin which binds the negatively 
charged phosphates on the plasmid DNA. The column was washed with wash buffer, 
and then the DNA eluted using a high salt buffer. DNA was precipitated by incubation 
with isopropanol (Sigma-Aldrich) for 5 minutes. The precipitated DNA was collected 
by filtration through the QIAprecipitator, washed with 70 % ethanol (Sigma-Aldrich) 




The obtained DNA was quantified by UV spectrophotometry at 260 nm (Nanodrop 
2000, Thermo Scientific), and purity determined by the 260 / 280 nm absorbance ratio. 
DNA was sequenced by Source Bioscience to confirm the correct DNA sequence of 
each insert.  
2.2.3 Cell culture and transfection 
Human embryonic kidney (HEK) 293 cells were maintained at 37 ˚C in high glucose 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing L-Glutamine 
(ThermoFisher) and supplemented with 10 % foetal bovine serum (FBS) (Life 
Technologies) and 100 U /ml penicillin and 0.1 mg/ml streptomycin (Invitrogen). Cells 
were seeded onto 10 cm dishes and grown to 80 % confluence before sub-culture or 
transfection. 
HEK 293 cells were transfected with the required plasmids by lipofectamine 2000 
transfection (Invitrogen). 48 hours prior to assay, cells were washed with phosphate-
buffered saline (PBS) and the DMEM growth media replaced with OptiMEM media 
(ThermoFisher). The required DNA were diluted in OptiMEM media to a total volume 
of 500 µl. Separately, the lipofectamine reagent (at a DNA (µg) to lipofectamine (µl) 
ratio of 1:2.7) was diluted in OptiMEM to a total volume of 500 µl. After a 5 minute 
incubation, the lipofectamine dilution was added dropwise to the DNA dilution and 
incubated at room temperature for 20 minutes. The DNA-lipofectamine complex was 
then added dropwise to the dish of HEK 293 cells. The cells were incubated with the 
DNA-lipofectamine overnight, and then the OptiMEM media was replaced with DMEM 
+ 10 % FBS the following morning. Cells were allowed to grow for a further 24 - 36 
hours before assay.  
2.2.4 Bioluminescence Resonance Energy Transfer (BRET) assay 
Bioluminescence resonance energy transfer (BRET) assays were used to measure 
the recruitment of arrestin-3 to the MOPr, and the dissociation of the Gαi and Gγ 




in our laboratory by Dr Gerda Gasiunaite, showing the optimal ratio of donor:acceptor 
DNA and the absence of a BRET signal from cells transfected with pcDNA alone 
(309).  
The principle of the BRET assay is shown diagrammatically in Figure 2.6a. BRET 
relies on the energy transfer between a bioluminescent donor, renilla luciferase (Rluc) 
and a fluorescent acceptor, such as yellow fluorescent protein (YFP) or green 
fluorescent protein (GFP). Rluc catalyses the oxidation of the substrate 
coelenterazine to coelenteramide, emitting light with a peak at wavelength 475 nm 
(coelenterazine h) or 410 nm (coelenterazine 400a), depending on the coelenterazine 
analogue used. The light is captured by the YFP or GFP, which then emits at a longer 
wavelength, with peaks at approximately 535 nm for YFP or 515 nm for GFP. As the 
efficiency of this energy transfer is highly dependent on distance, it will only occur 
when the donor and acceptor come into close range, approximately 10 - 100 Å. 
Conjugating the Rluc and the YFP or GFP onto different proteins therefore allows 
detection of when the two cellular proteins come into close proximity or move further 
apart. 
This energy transfer can be quantified by calculation of the BRET ratio; the ratio 
between the acceptor and donor peak emissions (Equation 14).  
[Equation 14]        𝐵𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 =  
𝑌𝐹𝑃 𝑜𝑟 𝐺𝐹𝑃 𝑒𝑚𝑖𝑠𝑠𝑜𝑛
𝑅𝐿𝑢𝑐 𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛
 𝑥 1000 
An increase in the BRET ratio indicates that the proteins are in closer proximity, whilst 
a decrease indicates that the distance between donor and acceptor has increased.  
For the Gi activation assay, HEK 293 cells were transfected with 3 μg HA-rat MOPr, 
3 μg Gαi1-RlucII and 3 μg Gγ2-GFP, to measure BRET between the RlucII and GFP 
(BRET2). Two different BRET configurations were used to measure arrestin-3 
recruitment to the MOPr. Initially the BRET1 configuration was used; HEK 293 cells 




configuration results in a high background and low signal due to the poor spectral 
resolution as the donor and acceptor emission peaks differ by only ~50 nm (Figure 
2.6b). To improve the signal the constructs were switched to the BRET2 configuration; 
cells were transfected with 5 μg MOPr-RlucII and 5 μg arrestin-3-GFP10. This gives 
a larger wavelength shift between the donor and acceptor emission peaks, a lower 
background, and a higher signal to noise ratio (Figure 2.6b).  
For all BRET configurations, immediately prior to assay the transfected HEK 293 cells 
were resuspended in clear, serum-free DMEM (ThermoFisher) and then transferred 
to a flat-bottom 96 well Corning plate at 90 μl per well. Drugs were dissolved in water 
or DMSO and then diluted in DMEM media to the required concentration. The final 
DMSO concentration never exceeded 0.01 %. The BRET assay was performed on 
the FLUOstar Omega microplate reader (BMG Labtech) at 37 ˚C. Coelenterazine h 
(Insight Biotechnology) was used as the substrate for the BRET1 configuration. 
Coelenterazine 400a (Insight Biotechnology) was used as the substrate for the BRET2 
configuration. Both substrates were dissolved in methanol and DMEM and added to 
the plate at a final concentration of 5 μM and 1 % methanol. Each substrate was 
injected 5 seconds prior to reading the plate. For G protein activation, BRET 
measurements were taken 2 minutes after drug application. For arrestin-3 
recruitment, BRET measurements were taken after a 10 minute incubation with the 
drugs. The ratio of the light emitted by the BRET acceptor (YFP or GFP) to the light 
emitted by the BRET donor (Rluc) was used to calculate the BRET ratio (Equation 
14). For assays using the BRET1 configuration, signals were recorded via 475-30 nm 
(RLuc) and 535-30 nm (YFP) emission filters (Figure 2.6b). For assays in the BRET2 
configuration, signals were recorded via 410-80 nm (RLuc) and 515-30 nm (GFP) 
emission filters (Figure 2.6b). All treatments were performed in duplicate and the 
average response taken. Each assay condition was repeated in 3 - 5 independent 
experiments. For the Gi activation assay, data were expressed as the percentage 




DMSO. A decrease in the BRET ratio is indicative of dissociation of the Gαi and Gβγ 
subunits upon activation (note that only the Gγ subunit contains the GFP tag, but it is 
assumed that the Gβ and Gγ subunits remain associated). For the arrestin-3 
recruitment assay, data were expressed as BRET ratio minus background from 
transfected cells treated with media or media + DMSO. An increase in the BRET ratio 
is indicative of arrestin-3 being recruited to the receptor. Analyses and curve fitting 
were performed in GraphPad Prism version 7. All ligands were compared to DAMGO, 
as the standard high efficacy agonist at the MOPr.  
Detection time points were chosen based on previously described G protein activation 
and arrestin translocation assays in the literature (243, 310-313), and the previous 
assay optimisation performed in our laboratory by Dr Gerda Gasiunaite (309). In 
addition, time course experiments were performed for each BRET configuration when 
cells were stimulated with 10 μM DAMGO.  
Figure 2.7a shows the time course for DAMGO-induced dissociation of the Gαi and 
Gβγ subunits, measured by BRET. Baseline recordings were taken for 1 minute and 
then the cells were stimulated with 10 μM DAMGO. DAMGO caused a decrease in 
the BRET ratio, consistent with the dissociation or rearrangement of the G protein 
subunits, which was maximal within 2 minutes of drug administration, and remained 
for the duration of the assay time. For all future experiments measuring Gi activation, 
2 minutes post-drug was taken as the detection time point for maximal signal. 
The time courses for DAMGO-induced arrestin-3 recruitment to the MOPr with the 
two different BRET configurations are plotted in Figures 2.7b and 2.7c. The overall 
kinetics with the two pairs of BRET constructs are very similar, with a steep rising 
phase over the first 2 minutes, and a plateau between 6 and 12 minutes. The signal 
from the BRET2 constructs (Figure 2.7c) is ~100 fold higher than for the BRET1 




these time courses the time point chosen for maximal recruitment was 10 minutes 





Figure 2.6 The principle of the BRET assay 
a) The breakdown of coelenterazine is catalysed by renilla luciferase (RLuc), emitting light. When 
proteins A and B are in close proximity, YFP or GFP is excited by the light emitted by the breakdown of 
coelenterazine and emits light of a longer wavelength. When protein A and B are not in close range, YFP 
or GFP is not excited. b) Diagram of the approximate excitation and emission spectra for different BRET 
configurations. BRET2 gives a greater separation between donor and acceptor peaks than BRET1. The 





Figure 2.7 Time courses for different BRET configurations 
a) Time course for dissociation of Gαi and βγ subunits induced by 10 μM DAMGO applied after 60 
seconds, in cells transfected with HA-tagged rat MOPr, Gαi-RlucII and Gγ-GFP; n=1. Time courses for 
arrestin-3 recruitment to the MOPr induced by 10 μM DAMGO applied at time 0, using b) the MOPr-
YFP/arr3-RLuc BRET1 constructs or c) the MOPr-RLucII/arr3-GFP BRET2 constructs. Data plotted as 





2.2.5 Quantification of ligand bias  
Ligand bias between Gi protein activation and arrestin-3 recruitment was quantified 
using the Black and Leff operational model of agonism (201, 314) employing the 
method described in van der Westhuizen et al., (315). 
The operational model (Equation 15) describes the response of an experimental 
system to a given concentration of agonist. 





Where E is the agonist-induced response, basal is the response in the absence of 
agonist, Emax is the maximal possible tissue response, [A] is the agonist 
concentration, KA is the functional equilibrium dissociation constant, τ is the 
operational efficacy (a composite of intrinsic agonist efficacy, receptor density and 
effector coupling), and n  is the slope of transducer function. 
The transduction ratio (
τ
KA 
) was taken as a parameter of agonist activity at a particular 
signalling pathway. To allow curve fitting, the transduction ratio was expressed as a 
single parameter, R. To obtain the transduction ratio (R) for each ligand at each 
pathway, baseline-subtracted concentration – response data for each ligand was fit 
to the operational model in Equation 16, which was derived from Equation 15 by 
dividing through by KA and R
𝑛[𝐴]𝑛 and expressing KA and R as logarithms. 











Emax was constrained to the maximum response of the reference full agonist, 
DAMGO, in each assay. The slope, n, was constrained to 1, and the basal response 
to 0. The value of logKA was constrained to zero for full agonists and derived from the 




To remove any influence of system and observational bias, all agonists were 
compared to the reference ligand DAMGO (Equation 17).  
[Equation 17]  Δlog (
τ
KA











Ligand bias between G protein activation and arrestin-3 recruitment for each agonist 
was calculated from Equation 18, expressed as ΔΔ log (
τ
KA
) or the “Bias Factor”. 
[Equation 18]  ΔΔ log (
τ
KA











The standard error for each ligand’s Δlog (
τ
KA
) was calculated from Equation 19. The 
standard error for the Bias Factor was calculated using Equation 20. 
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The resulting Bias Factors were compared by one-way ANOVA with Tukey’s post-test 
to determine statistical significance.   
2.2.6 Site-directed mutagenesis  
The desired point mutations were introduced to the pcDNA3-HA-rMOPR and 
pQCXIN-Myc-hMOPR-RlucII plasmids using the QuikChange-XL site-directed 
mutagenesis kit according to the manufacturer’s instructions (Agilent). The protocol 
relies on mutagenesis by polymerase chain reaction (PCR) and is summarised in 
Figure 2.8. Forward and reverse primers containing the desired mutation (Table 2.1) 
were designed using the Agilent QuikChange Primer Design tool (available at: 




HPLC purified by ThermoFisher. In each primer the mismatched bases containing the 
mutation are flanked by at least 11 base pairs of complementary sequence, to allow 
annealing of the primer to the template DNA. 
All buffers and reagents were provided with the kit, unless otherwise specified. The 
PCR reactions were set up in thin-walled PCR tubes as follows; 5 µl reaction buffer, 
50 ng of template pcDNA3-HA-rMOPR or 100 ng of template pQCXIN-Myc-hMOPR-
RlucII plasmid, 125 ng mutagenic primer #1, 125 ng mutagenic primer #2, 1 µl dNTP 
mix, 3 μl QuikSolution (containing DMSO to improve product amplification and reduce 
secondary structure formation) and double-distilled water added to a final reaction 
volume of 50 µl. 1 µl of PfuTurbo DNA polymerase was added last. Reactions were 
kept on ice until the tubes were transferred to the thermocycler (Biometra TRobot). 
The reactions were cycled according to the times and temperatures in Table 2.2. 
Samples were heated to 95 °C to denature the double-stranded template DNA. The 
reaction was then cooled to 60 °C to allow the primers to anneal, before heating to 68 
°C; the optimum temperature for DNA polymerase activity to synthesise the new DNA 
strand. This was repeated 18 times to amplify the product. An extra 7 minute 
extension time was added to the end of the PCR protocol to ensure full amplification 







Table 2.1 Primers for site-directed mutagenesis 











After PCR, the reaction tubes were cooled on ice for 2 minutes to terminate the DNA 
polymerase activity. Samples were then incubated with Dpn I restriction enzyme to 
digest the non-mutated template plasmid. The Dpn I enzyme recognises methylated 
DNA, which is only present on the template plasmid isolated from E.coli as there are 
no methylases present in the PCR reaction to methylate the PCR product. This 
digestion step ensures that only the mutated plasmid is left over in the PCR product 
mix to be transformed into the bacteria. 
4 µl of each PCR product was transformed into separate aliquots of XL10-Gold 
Ultracompetent cells, pre-treated with β-mercaptoethanol, by heat shock, and the rest 
of the reaction used to check for the presence of a band at ~7 kb (pcDNA3) or ~10 kb 
(pQCXIN), by electrophoresis on a 1 % agarose gel. After transformation and 
incubation for 1 hour in SOC media, the bacteria were plated on LB agar plates 
containing 100 µg/mL ampicillin. Agar plates were incubated at 37 °C overnight and 
colonies picked the following day. Colonies were grown in LB broth and plasmid 
preparation carried out as detailed in Section 2.2.2. The obtained plasmid DNA was 
sequenced by Source Bioscience to determine if the desired mutations had been 
incorporated (see Appendix I and II for sequencing results).  
Both mutagenic and transformation controls were included in the experiment. The 
mutagenic control was a pWhitescript template plasmid, which after successful 
mutation by PCR with the control mutagenic primers, will cause transformed bacterial 
colonies to appear blue on LB agar plates containing isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) and X-gal (Invitrogen). Bacterial 
colonies expressing the unmutated plasmid will appear white. To check for 
transformation efficiency, a separate aliquot of XL10-Gold Ultracompetent cells were 
transformed with pUC18 plasmid, which will also cause the bacterial colonies to 






Figure 2.8 Site-directed mutagenesis by PCR 
Schematic representation of the PCR protocol and subsequent transformation of E.coli. The single point 
mutations were generated by annealing of primers (dark green) to the template strand (light green) 
containing the region to be mutated (wildtype region in grey, mutated region in red). After primer 
annealing, DNA strands were extended by DNA polymerase. Reactions were cycled multiple times to 
amplify the DNA product. PCR product was then digested with Dpn I restriction enzyme to leave just the 
mutagenized DNA. This was transformed into bacteria, which were then plated on agar containing 





2.2.7 Surface receptor enzyme-linked immunosorbent assay (ELISA) 
The surface expression of the HA-rMOPR construct and the W293A and L219A point 
mutants was confirmed using surface receptor enzyme-linked immunosorbent assay 
(ELISA), based on the methods described by Daunt et al., (316). HEK 293 cells were 
transfected by lipofectamine transfection (see Section 2.2.3). The following day, cells 
were counted and plated equally at 250,000 cells per well in a 24-well plate coated 
with poly-L-lysine (Sigma-Aldrich) and grown overnight in DMEM media 
supplemented with 10 % FBS and penicillin/streptomycin. Untransfected HEK 293 
cells were also plated as background controls.  
The following morning, approximately 36 hours post-transfection, the cell media was 
replaced with serum-free DMEM and incubated at 37 ˚C for 10 minutes. Cells were 
then fixed with 4% paraformaldehyde (PFA) (VWR International) for 5 minutes. This 
time was chosen as sufficient time for fixation but short enough to prevent membrane 
permeabilisation (316). Cells were washed three times in Tris-buffered saline (TBS) 
to remove the PFA, and then incubated with 1% bovine serum albumin (BSA) (Sigma-
Aldrich) for 45 minutes to block non-specific binding sites. After blocking, cells were 
incubated with the primary antibody, mouse anti-HA monoclonal (#MMS-101R, 
BioLegend), for 1 hour at 1 in 1000 dilution. Cells were washed three times with TBS 
to remove any unbound antibody, and then blocked with 1% BSA for 15 minutes. After 
blocking, cells were incubated with the secondary antibody, goat anti-mouse IgG 
alkaline phosphatase conjugate (#A5153, Sigma), at 1 in 1000 dilution for 1 hour. 
Cells were then washed three times with TBS to remove any unbound antibody and 
incubated at 37 ˚C for 40 minutes with alkaline phosphatase substrate (Bio-Rad 
Laboratories) to detect the signal. Once colour change had occurred, the reaction was 
stopped by transferring the substrate to wells containing 0.4 M NaOH, at a 1:1 ratio. 
Absorbance at 405 nm was read on a Tecan Infinite plate reader (Tecan), and values 




were performed in triplicate wells and an average taken. Data were analysed in 
GraphPad Prism version 7.   
2.2.8 Receptor internalisation assay (ELISA) 
Agonist-induced receptor internalisation was also measured by ELISA, as described 
by Cooke et al., (317). In order to measure receptor internalisation without the 
confounding factor of subsequent recycling of receptors to the surface, receptor 
internalisation in response to opioid agonists was measured by pre-labelling surface 
receptors prior to incubation with drugs. As described in Section 2.2.7, HEK 293 cells 
were transiently transfected with HA-rMOPR or the W293A or L219A point mutants 
and the following day plated in poly-L-lysine coated 24-well plates. 
The following day, 36 hours post-transfection, media was replaced with serum-free 
DMEM and the plates incubated at 37 ˚C for 10 minutes. Cell surface receptors were 
labelled by incubation with the anti-HA primary antibody ((#MMS-101R, BioLegend) 
for 1 hour at 4 ˚C. This lower temperature reduced any constitutive receptor 
internalisation. Cells were washed three times with TBS to remove unbound antibody, 
and then incubated with opioid agonists diluted in 0.5 % BSA at 37 ˚C for 30 minutes. 
This time point was chosen as sufficient time for maximum receptor internalisation to 
have occurred (21, 47, 318). Cells were fixed with 4 % PFA for 5 minutes and then 
washed three times with TBS, before blocking in 1 % BSA for 15 minutes. After 
blocking, cells were incubated with the secondary antibody for 1 hour and detection 
performed as described in Section 2.2.7, using alkaline phosphatase substrate 
(Thermo Fisher).  
All experiments were performed in triplicate and an average taken. Data were 
analysed in GraphPad Prism version 7. After subtraction of the background 
absorbance from untransfected cells, receptor internalisation was expressed as the 







Chapter 3: MD simulations of the unliganded MOPr capture 
















With the technological advances in structural biology over the last two decades, 
determination of membrane protein structures at high resolution has become possible 
(167, 319-322). To date, there are two x-ray crystal structures of the MOPr (22, 76). 
The first, resolved by Manglik et al., comprises the antagonist-bound receptor with 
intracellular loop 3 (ICL3) replaced with a T4 lysozyme (76), thus representing an 
inactive conformation of the MOPr. More recently, an active state MOPr structure was 
resolved with the receptor bound to an agonist and a G protein mimetic nanobody 
(22). Whilst these structures provide important insight into the receptor conformation 
at the beginning and end of the activation process, these static snapshots cannot 
explain the dynamic nature of the MOPr and how this is modulated by the cellular 
environment.  
Radioligand binding studies conducted over 40 years ago identified sodium as a 
negative allosteric modulator of the MOPr, as binding of antagonists was enhanced 
in the presence of sodium whilst the affinity of agonists was diminished (115). A similar 
negative modulatory effect of sodium was also reported for other GPCRs (116-119). 
It was not until a very high resolution crystal structure of the adenosine A2A receptor 
was reported that a molecular mechanism for this sodium modulation was identified 
(122). In this high resolution structure, a sodium ion was found bound within the 
transmembrane helix bundle below the orthosteric ligand binding site. A sodium ion 
was later resolved in structures of the DOPr, β1 adrenoceptor and PAR1 receptor 
(123-125), suggesting that this conserved sodium binding site is a mechanism for 
sodium-dependent modulation of agonist activity across a range of Class A GPCRs. 
However, although the earliest in vitro studies described the effect of sodium at the 
MOPr (115, 120, 121), neither of the available crystal structures of the MOPr are at a 




Molecular dynamics (MD) simulations allow exploration of the conformational 
landscape of the MOPr in a native-like membrane, capturing some of the innate 
conformational heterogeneity of the receptor which is lost in static crystal structures. 
Importantly, MD simulations can also model how water and ions interact with the 
MOPr, information which is often beyond the resolution routinely achievable by 
crystallographic and spectroscopic techniques.  
Therefore, in this chapter I use the inactive- (76) and active-state (22) MOPr crystal 
structures to develop models of the membrane-embedded unliganded (apo) MOPr. I 
perform all-atom MD simulations of each MOPr model, sampling 1 µs of MD data, in 





3.2 Materials & Methods 
Two models of the unliganded (apo) MOPr were generated from the available x-ray 
crystal structures. The model made from the agonist- and nanobody-bound crystal 
structure (22) (PDB: 5C1M), and the model made from the antagonist-bound crystal 
structure (76) (PDB: 4DKL), were termed the active MOPr model and the inactive 
MOPr model, respectively. The crystal structures were downloaded from the Protein 
Data Bank and modified as described in Chapter 2 Section 2.1.2. In brief, all ligands 
and interacting proteins were removed and the missing ICL3 was modelled in to the 
inactive MOPr structure using Insight II. The two models were each embedded in 
phospholipid and cholesterol bilayers and solvated in water and NaCl.  
Molecular dynamics (MD) simulations of the membrane-embedded apo MOPr 
structures were performed as described in Chapter 2 Section 2.1.5, to produce 1 µs 
of MD data for each MOPr model. Additionally, 1 µs of accelerated MD was performed 
as described in Chapter 2 Section 2.1.5. All analyses were performed using cpptraj 






Separate systems of the membrane-embedded MOPr using either the inactive or 
active model, were each subjected to up to 1 µs of MD simulation. The interactions 
between the receptor and sodium ions in the solvent were monitored to determine if 
our computational model could capture the binding of a sodium ion to the allosteric 
site.  
During the MD simulations, sodium moved from the bulk solvent on the extracellular 
side of the membrane to bind within the transmembrane domains of both apo MOPr 
models. The position of an individual sodium ion during each frame of the trajectories 
is mapped in Figure 3.1. The clusters of these positions of the sodium ion at each 
time point indicate that for the inactive MOPr model, sodium interacted with the 
receptor at three distinct sites, whereas for the active MOPr model, sodium only 
accessed two of these sites. In both cases, only one sodium ion was observed to 
enter the MOPr helix bundle at any given time.  
For both the inactive and active MOPr models, a sodium ion entered from the 
extracellular side of the receptor, first interacting with polar and acidic residues at the 
extracellular end of TM2 and ECL2 (“Site 1”); N1272.63, S214ECL2 and D216ECL2. The 
next cluster was found around the orthosteric ligand binding site, “Site 2”, where a 
sodium ion interacted with D1473.32 in both the inactive and active MOPr models. The 
final cluster, “Site 3”, was only populated in the inactive MOPr model, and was 
identified as the conserved allosteric sodium ion binding site by comparison with the 
position of the sodium ion in the related crystal structures (the DOPr and adenosine 
A2A receptor (122, 124)). Here, the sodium ion was coordinated by residues in TM2 
and 3; D1142.50, N1503.35 and S1543.39. 
To measure the movement of the sodium ion along this pathway visualised in Figure 
3.1, the distance between the interacting sodium ion and D1142.50 in the allosteric site 




simulations of the inactive MOPr model, a sodium ion interacted with Site 1 on the 
extracellular side of the receptor at multiple points during the simulation (Figure 3.2a). 
On all but one occasion, the sodium ion then moved further into the receptor helix 
bundle to interact with D1473.32 in Site 2. From here, the sodium ion then bound to the 
allosteric binding site, Site 3. In conventional MD simulations of the active MOPr 
model, whilst sodium did interact with Site 1 at the extracellular side of the receptor 





Figure 3.1 Entry of sodium into the allosteric site from the bulk solvent 
The route taken of sodium from the bulk solvent into the receptor pore during 1 μs conventional MD 
simulations of the unliganded MOPr models, revealing 3 distinct sites. Sodium ions at each frame of the 
trajectory are depicted as light blue beads, with interacting residues as sticks. Sodium ions from the final 
10 ns of each 125 ns simulation are coloured purple. In the inactive MOPr model (left) the sodium ion 






Figure 3.2 Movement of sodium through the 3 sites  
Data plotted as the distance between the sodium ion and D1142.50 of the allosteric sodium binding site 
(Site 3) during conventional MD simulations of a) the inactive MOPr model and b) the active MOPr model 




Figure 3.3 The allosteric sodium ion binding site (“Site 3”) 
a) A sodium ion (purple) occupies the allosteric sodium site during MD simulations of the unliganded 
inactive MOPr model. The sodium ion is coordinated by D1142.50, N1503.35, S1543.39 and two water 
molecules. b) In the active MOPr model this binding pocket is collapsed, with a hydrogen bond formed 




Accelerated MD simulations were employed to enhance the sampling of the receptor 
conformational space (see Chapter 2 Section 2.1.5). During the accelerated MD 
simulations of the inactive MOPr model, a sodium ion very rapidly moved from the 
bulk solution to bind in the allosteric site (Site 3) and remained bound for the entire 
simulation (Figure 3.2c). In contrast, in accelerated MD simulations of the active MOPr 
model, although a sodium ion entered the helix bundle more readily than in the 
conventional MD simulations, the ion oscillated between Sites 2 and 3, and did not 
bind stably to the allosteric sodium site (Figure 3.2d).  
Closer inspection of the conformation of the residues comprising the allosteric sodium 
site suggests that the lack of interaction of sodium with this site in the active MOPr 
model is probably due to the alternative conformation of these residues (Figure 3.3). 
In the inactive MOPr model (Figure 3.3a), the sodium ion was coordinated by two 
water molecules, D1142.50, N1503.35 and S1543.39, in agreement with the crystal 
structure of the DOPr (124). However, in the active MOPr model the binding pocket 
collapsed due to an inward movement of TM7 above the NPxxY motif, the inward 
movement of TM3 such that S1543.39 formed a hydrogen bond with D1142.50, and the 
side chain of N1503.35 rotated to point away from the helix bundle (Figure 3.3b). This 
binding pocket collapse thus prevented the binding of a sodium ion.  
These data suggest that sodium will readily bind to the conserved allosteric site in the 
inactive MOPr model, and transitions between two other binding sites on route; first 
interacting with a cluster of polar and acidic residues on the extracellular surface of 
the MOPr, then the orthosteric binding site and finally reaching the allosteric pocket. 
However, for the active MOPr model, although sodium can interact with the other two 
sites in the receptor, a sodium ion will only interact with residues in the allosteric site 







In this chapter, MD simulations of the unliganded (apo) MOPr successfully modelled 
the binding of a sodium ion to the receptor. The resolution of the currently available 
MOPr crystal structures was not able to detect a sodium ion bound to the allosteric 
site, therefore the observations described here demonstrate the power of using MD 
simulations to visualise the dynamic nature of important interactions between the 
protein and ions which are not captured in crystal structures.  
Moreover, the position of the sodium ion when occupying “Site 3” in the inactive MOPr 
model agreed with that resolved in the x-ray crystal structure of the inactive DOPr 
(124). In this allosteric site, the sodium was coordinated by residues highly conserved 
in Class A GPCRs (D1142.50 and S1543.39), as well as the N1503.35 residue specifically 
conserved in opioid receptors (78, 138). In Chapter 4, I will use these coordinates of 
the sodium ion in the allosteric site to investigate the effect of sodium on the ligand-
MOPr complex.  
In addition, we were able to model the binding pathway of sodium to the inactive 
MOPr, showing that the sodium ion was first captured by a site on the extracellular 
surface of the MOPr, before transitioning into the helix bundle; first binding to D1473.32 
of the orthosteric ligand binding site, and finally binding in the allosteric pocket. These 
MD data are similar to that reported in other computational studies modelling sodium 
binding to opioid receptors, where sodium first interacts with extracellular residues 
and the orthosteric site (323-325).  
Interestingly, although sodium could readily bind to the inactive MOPr model under 
either conventional or accelerated MD conditions, the same was not true for the active 
MOPr model. Under conventional MD we did not observe sodium binding to the 
allosteric site in the active state receptor, and even using accelerated MD the sodium 
ion was unable to bind stably to the allosteric pocket due to a collapsed conformation 




inactive state MOPr; agreeing with the experimentally observed negative modulatory 
effect of sodium (115, 121). Similarly, a recent study by Hu et al., reported that sodium 
binding to the inactive MOPr is more energetically favourable than active-state binding 
(326). Furthermore, in MD simulations of the DOPr, the presence of an allosteric 
sodium ion stabilised the inactive conformation of the W6.48 rotamer toggle switch 
(see Chapter 1 Section 1.2.3.4), and constrained the movement of TM6; both 
hallmarks of the GPCR inactive state (161, 166).   
Finally, the lack of sodium interaction with the allosteric site in these MD simulations 
of the active MOPr model indicates that the active MOPr model remained in the active 
state even in the absence of the co-crystallised agonist BU72 and the G protein-
mimetic nanobody, and under accelerated MD conditions. This suggests that the 
active conformation captured in the crystal structure is in a very low energy 
conformation and/or would require very long timescale MD simulations to revert to an 
inactive conformation, beyond what is achievable with our available computational 
resources. Therefore, I will use the inactive MOPr model for further ligand-bound MD 
experiments in order to capture the changes in the MOPr conformation induced by 
the ligand of interest, rather than that already stabilised by BU72 and the Nb39 





Using MD simulations of the unliganded MOPr, in this chapter I have shown that a 
sodium ion can spontaneously bind to the conserved allosteric sodium binding site in 
the inactive state receptor. However, the collapse of this site in the active state 
prevents sodium binding. These data agree with radioligand binding, crystallographic 
and computational data showing that sodium is a negative allosteric modulator of the 
MOPr, stabilising the inactive state, and provides confidence that our MD simulation 







Chapter 4: The binding poses of small molecule opioids 












Crystal structures of the MOPr bound to both an antagonist and an agonist have been 
resolved at high resolution (22, 76). The co-crystallised antagonist β-FNA is unusual 
in that it forms a covalent bond with the receptor, whilst the co-crystallised agonist 
BU72 is an experimental compound, not used in the clinic, and may have super-
agonist properties (92, 327). There is therefore little structural information on how 
more typical and clinically important small molecule opioid ligands bind to the MOPr. 
In this chapter, I perform molecular docking and molecular dynamics simulations with 
5 such small molecule opioids, in order to identify how they bind to the MOPr, and 
how ligand binding translates to receptor activation. I show that small molecules 
sharing the same chemical scaffold adopt distinct binding poses in the MOPr 
orthosteric site, correlating with ligand intrinsic efficacy.   
The majority of small molecule opioids are morphinan derivatives with a common ring 
scaffold, but different substituents on the amine and carbons 3, 6 and 7 (Figure 4.1a). 
The aim of this study was to utilise ligands sharing the same core morphinan scaffold, 
but with different efficacies at the MOPr, to understand the nature of drug efficacy at 
this clinically important GPCR. The chosen ligands were; norbuprenorphine, a high 
efficacy agonist, buprenorphine, a low efficacy agonist, and diprenorphine, an 
antagonist. I first confirmed the expected signalling characteristics of these 
compounds in bioluminescence resonance energy transfer (BRET) assays measuring 
G protein activation and arrestin-3 recruitment. Molecular dynamics (MD) simulations 
of the membrane-embedded MOPr bound to each ligand were performed and ligand 
binding poses, residue interactions, and induced receptor protein conformations 
compared for these compounds of widely varying efficacy. In addition, through further 
MD simulations I investigated the role of an allosteric sodium ion in determining the 
binding positions of these drugs. Sodium is a negative allosteric modulator of Class A 
GPCRs, binding to a conserved site in the receptor transmembrane domains (122-




has yet to be fully elucidated. The work in this chapter was published in the Journal 
of Molecular Biology (DOI: 10.1016/j.jmb.2017.05.009).  
In order to widen the conclusions of this morphinan study (152) to a greater test set 
of small molecule ligands and to include important clinically used opioids, I also 
performed MD simulations with the MOPr bound to methadone and morphine.  
Buprenorphine (Figure 4.1e) is an opioid ligand derived from oripavine. It has mixed 
activity at opioid receptors; behaving as a partial agonist at the MOPr and KOPr, and 
as an antagonist at the DOPr (21, 328, 329). Buprenorphine is a clinically important 
opioid, used both as an analgesic and as a maintenance therapy in heroin addiction. 
Norbuprenorphine (Figure 4.1d) is a major metabolite of buprenorphine and a potent 
agonist at the MOPr, KOPr and DOPr (21, 329, 330). As a metabolite, 
norbuprenorphine shares the same chemical scaffold as buprenorphine but lacks the 
cyclopropylmethyl ring group on the amine. Although norbuprenorphine is 
pharmacologically active at opioid receptors, it has limited in vivo effects due to poor 
brain exposure because it is a substrate for the efflux transporter P-glycoprotein (331). 
Diprenorphine (Figure 4.1f) is a MOPr antagonist (328), with a similar chemical 
structure to buprenorphine, including the cyclopropylmethyl ring on the amine, but 
with a smaller substituent group on carbon 7.  Morphine (Figure 4.1b), the prototypical 
opioid, is also based on the morphinan scaffold. It is a partial agonist at the MOPr and 
the gold standard of pain relief. Methadone is the only small molecule used in this 
chapter which is not based on the morphinan scaffold (Figure 4.1c), though it retains 







Figure 4.1 Structures of the small molecules 
a) Many opioid ligands are based on a morphinan scaffold. 2D structures of the small molecules used in 






4.2 Materials and Methods 
4.2.1 BRET assays 
Ligand-induced Gi activation and arrestin-3 recruitment were measured by BRET 
assay, as described in Chapter 2 Section 2.2.4. DAMGO was included in all 
experiments as the reference full agonist.  
For norbuprenorphine, buprenorphine and diprenorphine, the BRET1 configuration 
was used to measure arrestin-3 recruitment in HEK 293 cells expressing rat MOPr-
YFP and arrestin-3-RLuc. Diprenorphine antagonism was determined by incubation 
of the HEK 293 cells with 1 μM diprenorphine for 10 minutes, prior to addition of 10 
μM DAMGO and measurement of the BRET signal. 
After experiments with the buprenorphine-series had been completed, the arrestin 
BRET assay was switched to the BRET2 configuration as it produced a higher signal 
than BRET1 (see Chapter 2 Figure 2.7). Therefore, for morphine and methadone the 
BRET2 configuration was used to measure arrestin-3 recruitment in HEK 293 cells 
expressing human MOPr-RlucII and arrestin-3-GFP. For this reason, drugs cannot be 
compared across the two arrestin-recruitment assays, but can instead be compared 
to the reference agonist DAMGO included in all experiments.  
Data analysis and curve fitting was performed in GraphPad Prism v7. For the Gi 
activation assay, BRET ratios were expressed as the percentage decrease from 
vehicle-treated control wells. For the arrestin-3 recruitment assays, data were 
expressed as the BRET ratio minus background from vehicle-treated control wells.  
Data were then fitted to log concentration – response curves with a Hill Slope of 1.0, 
and the minimum constrained to zero. The EC50 and maximum response (EMax) values 





4.2.2 Molecular modelling 
Molecular docking was performed as described in Chapter 2 Section 2.1.3. The 
position of β-FNA in the crystal structure of the MOPr (76) was used to determine the 
initial binding pose of the morphinan ligands (morphine, norbuprenorphine, 
buprenorphine and diprenorphine). For the non-morphinan ligand, methadone, 
conformer generation and molecular docking with BUDE was carried out as detailed 
in Section 2.1.3. The initial docked poses for all 5 ligands are shown in Figure 4.2. 1 
µs MD simulations of all 5 membrane-embedded ligand-MOPr complexes were 
performed as described in Chapter 2 Section 2.1.5. In addition, 1 µs of accelerated 
MD was performed on the norbuprenorphine-, buprenorphine- and diprenorphine-
bound MOPr, as described in Chapter 2 Section 2.1.5.  
4.2.3 MD simulations with an allosteric sodium ion 
For the MD experiments in the presence of an allosteric sodium ion, the ion was 
placed in the allosteric site in the position it occupied spontaneously in MD simulations 
of the unliganded inactive MOPr model (Chapter 3). A total of 250 ns of MD simulation 
was performed with norbuprenorphine or buprenorphine in the same initial binding 
poses as in Figure 4.2, and with the sodium ion occupying the allosteric site. In 






Figure 4.2 Initial docked poses of the small molecules 
a-d) The co-crystallised morphinan antagonist β-FNA (grey sticks) was used to determine the initial 
starting poses for morphinan small molecules: a) norbuprenorphine, b) buprenorphine, c) diprenorphine, 
and d) morphine. e) For methadone, 10,000 conformers were docked using BUDE as outlined in Chapter 
2 Section 2.1.3. The pose selected for MD simulations is shown above. The essential opioid binding 
residues, D1473.32 and H2976.52, were used to choose the best docked poses and are depicted as dark 






4.3 Results  
4.3.1 Ligand-induced G protein activation and arrestin recruitment 
Dissociation of the Gαi and Gβγ subunits upon activation of the MOPr was measured 
in HEK 293 cells expressing HA-rat MOPr, Gαi-RlucII and Gγ-GFP. A ligand-induced 
decrease in the BRET ratio compared to untreated cells was indicative of this subunit 
rearrangement or dissociation. Recruitment of arrestin-3 to the MOPr was measured 
in HEK 293 cells expressing rat MOPr-YFP and arrestin-3-Rluc (BRET1), or in HEK 
293 cells expressing human MOPr-RlucII and arrestin-3-GFP (BRET2). In both cases, 
a ligand-induced increase in the BRET ratio compared to untreated cells was 
indicative of the arrestin and receptor coming into closer proximity. Concentration-
response curves for Gi activation and arrestin-3 recruitment are shown in Figure 4.3.  
DAMGO behaved as a potent full agonist for both Gi activation and arrestin-3 
recruitment, with an EC50 ranging between 0.05 – 0.5 µM for Gi activation, and 2.5 ± 
0.6 µM (Table 4.1) and 1.6 ± 0.5 µM (Table 4.2) for arrestin-3 recruitment in the BRET1 
and BRET2 assays, respectively. There is a slight discrepancy between the calculated 
EC50 values for DAMGO in the Gi activation assays performed months apart (Tables 
4.1 and 4.2), however the values are not significantly different (Welch’s t-test, p > 
0.05). Compared to DAMGO, norbuprenorphine was a full agonist for Gi activation 
(Figure 4.3a), with an EC50 of 0.18 ± 0.1 µM (Table 4.1). In the arrestin recruitment 
assay (Figure 4.3b), norbuprenorphine was a potent partial agonist, with an EC50 of 
0.2 ± 0.05 µM and an Emax approximately 68 % of the DAMGO response (Table 4.1). 
Buprenorphine was a partial agonist for Gi activation, producing a response 
approximately 48 % of that due to DAMGO (Figure 4.3a, Table 4.1). In the arrestin 
recruitment assay, buprenorphine produced a very weak response, barely above the 
levels of detection (Figure 4.3b). 1 μM diprenorphine failed to produce a response in 
either the Gi activation or arrestin-3 recruitment assays (yellow filled circles in Figures 
4.1a and 4.1b). Furthermore, incubation of cells with 1 μM diprenorphine prior to 




the G protein and arrestin assays (purple filled circles in Figures 4.1a and 4.1b), 
therefore confirming diprenorphine’s antagonist activity.  
Morphine behaved as a partial agonist for both Gi activation (Figure 4.3c) and arrestin-
3 recruitment (Figure 4.3d). The EC50 and Emax for morphine in the G protein assay 
was 0.96 ± 0.4 µM and 74 % that of DAMGO, respectively (Table 4.2). In the arrestin-
3 assay morphine had an EC50 of 1.2 ± 0.6 µM and an Emax of 32 % of the DAMGO 
response (Table 4.2).  
Methadone was a full agonist in both assays (Figures 4.3c and 4.3d), with an EC50 of 
0.39 ± 0.1 µM for Gi activation and 3.1 ± 1.2 µM for arrestin-3 recruitment (Table 4.2).  
These results are in agreement with the previously reported signalling characteristics 






Figure 4.3 Ligand-induced G protein activation and arrestin recruitment 
a) In HEK 293 cells expressing HA-MOPr, Gαi-RLucII and Gγ-GFP, DAMGO (black circles), 
norbuprenorphine (green squares) and buprenorphine (blue triangles) induced concentration-dependent 
activation of Gi, measured as a decrease in the BRET signal. b) 1 μM diprenorphine alone (yellow) did 
not activate Gi. In the presence of 1 μM diprenorphine, 10 μM DAMGO did not activate Gi (purple). c) In 
HEK 293 cells expressing HA-MOPr-YFP and arrestin-3-RLuc (BRET1), DAMGO (black circles) and 
norbuprenorphine (green squares) induced concentration-dependent recruitment of arrestin-3 to the 
MOPr, measured as an increase in the BRET signal. Buprenorphine (blue triangles) induced a much 
lower response. d) 1 μM diprenorphine alone (yellow) did not recruit arrestin-3. In the presence of 1 μM 




diprenorphine, 10 μM DAMGO did not recruit arrestin-3 (purple). e) In HEK 293 cells expressing HA-
MOPr, Gαi-RLucII and Gγ-GFP, DAMGO (black circles), methadone (grey squares) and morphine 
(magenta triangles) induced concentration-dependent activation of Gi, measured as a decrease in the 
 BRET signal. f) In HEK 293 cells expressing MOPr-RLucII and arrestin-3-GFP (BRET2), DAMGO (black 
circles), methadone (grey squares) and morphine (magenta triangles) induced concentration-dependent 
recruitment of arrestin-3 to the MOPr, measured as an increase in the BRET signal. All values are mean 







Table 4.1 EC50 and maximum response values for DAMGO, norbuprenorphine and buprenorphine 
in the Gi activation and arrestin-3 recruitment assays 
Data are expressed as mean ± SEM, of 5 independent experiments. * p < 0.05, significantly different 





Table 4.2 EC50 and maximum response values for DAMGO, methadone and morphine in the Gi 
activation and arrestin-3 recruitment assays 
Data are expressed as mean ± SEM, of 5 independent experiments. * p < 0.05, significantly different 





4.3.2 Ligand binding poses and residue interactions 
MD simulations were performed with the inactive MOPr model embedded in a lipid 
bilayer and bound to each of the 5 small molecule ligands; norbuprenorphine, 
buprenorphine, diprenorphine, morphine and methadone. A total of 1 µs MD data was 
collected for each ligand-MOPr complex. 
Root mean square deviation (RMSD) calculations were performed to determine how 
far the MOPr changed from the initial inactive conformation and the stability of the 
bound pose of the ligand (Figure 4.4). For the receptor, RMSD calculations were 
performed on the alpha carbons of the transmembrane domains to avoid the high 
fluctuations of the loop regions and residue side chains masking important helix 
movements (light grey in Figures 4.4a-e). For the ligands, the heavy atoms of each 
ligand were compared to the initial docked pose to determine how far the ligand 
moved from this position, and to the final frame of the simulation to provide a measure 
of the stability of the final binding pose.  
For all ligand-MOPr complexes, the RMSD calculations performed on the receptor 
transmembrane domains quickly reached a plateau. The norbuprenorphine-MOPr 
complex deviated the most from the initial helix positions, plateauing at approximately 
2 Å (light grey in Figure 4.4a). The methadone-MOPr complex deviated from the initial 
conformation by approximately 1.5 Å (light grey in Figure 4.4e), whilst the 
buprenorphine-, diprenorphine- and morphine-bound MOPr helices reached a plateau 
at approximately 1 Å RMSD (light grey in Figures 4.4b-d). The higher RMSD values 
for the norbuprenorphine- and methadone-bound MOPr complexes suggests that 
these higher efficacy ligands induced a greater conformational change in the MOPr 
helices compared to the inactive MOPr model, than did the lower efficacy ligands. 
For the ligands, norbuprenorphine deviated the most from its initial docked position, 
with an RMSD value of approximately 4 Å (green in Figure 4.4a). In contrast, 




deviated very little from the initial docked pose. For the majority of the simulation time 
diprenorphine (yellow in Figure 4.4c) remained close to the initial docked position, but 
it did occasionally sample an alternative binding position. Methadone (dark grey in 
Figure 4.4e) reached a plateau at 3 Å from the initial docked pose. Compared to the 
final binding pose, norbuprenorphine, buprenorphine and morphine were stable in 
their binding positions (light blue in Figures 4.4a, 4.4b and 4.4d). Again, diprenorphine 
remained in the same binding pose for the majority of the simulation but did sample 
the alternative pose (light blue in Figure 4.4c). Methadone had the least stable binding 







Figure 4.4 RMSD plots for the small molecule ligand-MOPr complexes 
a) RMSD calculations performed on the heavy atoms of norbuprenorphine compared to the initial docked 
position (green) or the final binding pose (light blue). b) RMSD calculations performed on the heavy 
atoms of buprenorphine compared to the initial docked position (dark blue) or the final binding pose (light 
blue). c) RMSD calculations performed on the heavy atoms of diprenorphine compared to the initial 
docked position (yellow) or the final binding pose (light blue). d) RMSD calculations performed on the 
heavy atoms of morphine compared to the initial docked position (magenta) or the final binding pose 
(light blue). e) RMSD calculations performed on the heavy atoms of methadone compared to the initial 
docked position (dark grey) or the final binding pose (light blue). RMSD calculations were also performed 
on the alpha carbons of the MOPr transmembrane domains, compared to the first frame of the MD 
simulation (light grey in each plot). Data expressed as raw values (faded line) and moving average over 





The final binding pose for each ligand is shown in Figure 4.5. In simulations with the 
morphinan ligands (Figures 4.5a-d), the ligand remained in the MOPr orthosteric site, 
maintaining interactions with the essential opioid ligand binding residues D1473.32 and 
H2976.52. The final pose for methadone differed from the initial docked position in that 
the amine group lost its interaction with D1473.32, and instead interacted with its own 
aromatic ring (Figure 4.5e). In fact, during the 1 μs simulation time, methadone 
alternated between the canonical ionic interaction between the amine and D1473.32, 
and the amine rotating to interact with the aromatic ring. This instability of the amine-
D1473.32 interaction may explain why methadone’s binding pose fluctuated more so 
than the other ligands.  
The lower efficacy morphinan ligands, morphine, buprenorphine and diprenorphine, 
remained stably bound in the initial docked pose overlapping with the pose of the co-
crystallised antagonist β-FNA (Figures 4.2b-d and 4.5b-d). Unexpectedly, the high 
efficacy morphinan norbuprenorphine shifted from the initial docked position, pivoting 
about the amine-D1473.32 interaction, to sit deeper in the receptor binding pocket 
(Figure 4.5a). The presence of the cyclopropylmethyl ring appeared to restrict the 
ability of buprenorphine and diprenorphine to pivot about this interaction, so despite 
sharing the same morphinan scaffold as norbuprenorphine, they adopted binding 
poses higher in the receptor pore. The alternative binding pose of diprenorphine 
sampled infrequently during the simulation (Figure 4.4c) was due to the ligand 
switching from a direct interaction between the amine and D1473.32, and one mediated 





Figure 4.5 Final binding poses for the small molecules 
Final binding poses of the small molecule ligands in the MOPr orthosteric site after 1 µs MD simulations 
(taking the final frame of the concatenated trajectory composed of the 8 individual 125 ns parallel 
simulations). The MOPr helices are shown in light grey, with residues forming the ligand binding site as 
sticks. a) norbuprenorphine is depicted in green and sits deeper in the binding pocket than the other 
morphinan ligands. b) buprenorphine depicted in blue, c) diprenorphine depicted in yellow, d) morphine 






As these small molecules adopted distinct binding poses in the orthosteric site, they 
therefore interacted with different subsets of residues. Ligand-residue interaction 
plots, with a cut-off distance of 4.5 Å, are shown in Figure 4.6. All the small molecules 
interacted with residues in TM3 and TM6; D1473.32, Y1483.33 and M1513.36 in TM3, and 
W2936.48, I2966.51, H2976.52 and V3006.55 in TM6. Norbuprenorphine alone engaged in 
interactions with TM2, specifically Q1242.60, N1272.63 and Y1282.64, but was the only 
ligand not to contact residues in TM5 (Figure 4.6a). Buprenorphine engaged in the 
most extensive interactions with the orthosteric pocket (Figure 4.6b). This may reflect 





Figure 4.6 Ligand-residue interactions for all small molecule ligand-MOPr complexes  
a) Norbuprenorphine, b) buprenorphine, c) diprenorphine, d) morphine, and e) methadone. Ligand-
residue interactions are expressed as the percentage of simulation time each residue is within 4.5 Å of 




4.3.3 The W2936.48 rotamer toggle switch  
The highly conserved aromatic residue, W2936.48, is positioned at the base of the 
orthosteric ligand binding pocket (Figure 4.5), and forms part of the second 
coordination shell of the allosteric sodium ion binding site (see Chapter 1 Sections 
1.2.3.3 and 1.2.3.4). Previous studies of other Class A GPCRs have suggested that 
W2936.48 acts as a toggle switch for receptor activation (22, 134, 150, 151, 156, 334). 
During our MD simulations of ligand-bound MOPr, W2936.48 underwent significant 
changes in the angle of its indole ring side chain. These rotamer changes were 
monitored by plotting the χ2 angle, shown in Figure 4.7. With the indole ring positioned 
perpendicular to the bilayer, viewed as a “vertical” position when looking through the 
plane of the membrane, the χ2 dihedral is approximately 120°. Rotation about this 
dihedral so that the indole ring is positioned parallel to the bilayer (“horizontal” when 
viewed in the plane of the membrane) results in a χ2 angle closer to 0°. In the 
antagonist-bound MOPr crystal structure, W2936.48 is in the “vertical” position (76). In 
the “horizontal” position, observed in the agonist- and G protein-bound fully active 
MOPr structure (23), the indole ring obstructs the allosteric sodium ion binding site.  
The initial conformation for all MD simulations was with W2936.48 in the “vertical” 
position, as seen in the inactive MOPr model. The low efficacy ligands did not 
significantly alter this initial conformation of the W2936.48 indole ring. As shown in the 
plots in Figure 4.7 with buprenorphine (Figure 4.7b), diprenorphine (Figure 4.7c) or 
morphine bound (Figure 4.7d), the sidechain of W2936.48 largely maintained a 
“vertical” conformation, with the indole ring of the tryptophan perpendicular to the 
bilayer, favouring a χ2 angle between 80 - 120˚ and pointing into the ligand binding 
pocket. Both buprenorphine- and diprenorphine-bound receptors occasionally 
sampled the “horizontal” conformation of W2936.48; buprenorphine more frequently 
than diprenorphine, whereas morphine maintained the “vertical” W2936.48 position for 




In contrast, in the MD simulations of the MOPr bound to the higher efficacy ligands, 
W2936.48 underwent significant conformational changes. With norbuprenorphine 
bound, the indole ring of W2936.48 favoured the “horizontal” conformation, parallel to 
the lipid bilayer, maintaining a χ2 angle of 0 - 60˚ and spanning the base of the ligand 
binding site (Figure 4.7a). This rotameric change in W2936.48 appeared to be due to 
the deeper binding pose of norbuprenorphine (Figure 4.5a). Steric hinderance 
between the ligand in its deeper binding pose and the indole ring of W2936.48 would 
prevent W2936.48 remaining in the “vertical” conformation. The rotameric change in the 
W2936.48 side chain to the “horizontal” conformation avoided this clash. 
The other high efficacy agonist, methadone, also caused W2936.48 to favour this 
“horizontal” conformation, although it also sampled the “vertical” conformation (Figure 
4.7e). This may be related to methadone’s less stable binding pose in that it did not 
fully maintain the amine – D1473.32 interaction for the entire simulation time, and 







Figure 4.7 W2936.48 rotamer toggle switch 
The behaviour of the W2936.48 rotamer toggle switch plotted as the χ2 dihedral angle during 1 μs MD 
simulations of the MOPr bound to a) norbuprenorphine, b) buprenorphine, c) diprenorphine, d) morphine, 
and e) methadone. Insets show how the dihedral angle relates to the conformation of the indole ring. 






4.3.4 Principal component analysis shows distinct helical arrangements 
Large, high-dimensional datasets, such as that obtained by MD, are difficult to analyse 
by eye or simple statistics. Principal component analysis (PCA) reduces highly 
dimensional data to the main or ‘principal’ components which account for the most 
variation in the data set (335). In the case of these GPCR MD data, these components 
refer to atomic positions of the receptor helices. PCA was employed to examine the 
subtle conformational changes in the receptor transmembrane domains, allowing 
mapping of clusters of conformations sampled by the different ligand-MOPr 
complexes to determine any differences between the conformations favoured by the 
MOPr in the presence of the different small molecule ligands.  
PCA was performed on the norbuprenorphine-, buprenorphine- and diprenorphine-
bound MD simulations to determine what effect small changes in the ligand chemical 
structure had on the conformation of the MOPr. After fitting to remove global rotation 
and translation of the system, the covariance matrix was generated from just the alpha 
carbons of the MOPr transmembrane domains, to avoid including the highly dynamic 
loops and residue side chains in the analysis. The receptor conformation at each time 
point was projected onto principal components (PC) 1 and 2 and plotted in Figure 
4.8a. This resulted in clusters of receptor conformations which converge if the helical 
structures are becoming more similar or diverge if the conformations are different.  
PC1 and PC2 accounted for 28.2 % and 11.3 % of the variance, respectively. All 3 
ligand-MOPr complexes sampled conformations across PC2, but clustered differently 
based on PC1, with the norbuprenorphine-bound MOPr occupying a distinct cluster 
(green, Figure 4.8a) to the buprenorphine- (blue, Figure 4.8a) and diprenorphine-
bound MOPr (yellow, Figure 4.8a). This indicated different helical arrangements 
depending on the bound ligand. The diprenorphine-bound MOPr cluster overlapped 
with the buprenorphine-bound cluster, suggesting that these receptor conformations 
were similar. Moreover, both the buprenorphine- and diprenorphine-bound clusters 




suggesting that with these low efficacy ligands bound, the MOPr favoured a more 
inactive conformation. The distinct conformational cluster sampled by the 
norbuprenorphine-bound MOPr did not overlap with the inactive MOPr model, and 
thus may represent the norbuprenorphine-bound MOPr occupying an intermediate 
state which may ultimately transition to an active conformation.  
By generating a pseudo-trajectory of PC1 and extracting structures from the actual 
simulations that represent extremes of PC1, we were able to visualise the helix 
movements contributing to the principal component. An overlay of structures 
extracted from the norbuprenorphine-bound cluster and the buprenorphine-bound 
cluster is shown in Figure 4.8b, with the helix movements described by PC1 depicted 
as white arrows. PC1 primarily described alternative conformations in the extracellular 
region of the receptor close to the orthosteric binding site, and to a lesser extent 
differences in the intracellular portions of the helices. Notably, the extracellular ends 
of TM1, 3 and 7 moved outwards from the helical bundle in the presence of 
norbuprenorphine, whilst the extracellular ends of TM2 and 6 moved inwards. On the 
intracellular side of the MOPr, TM5 moved in towards the helix bundle with 





Figure 4.8 Principal Component Analysis reveals distinct MOPr conformations 
a) Principal component analysis was performed on the alpha carbons of the receptor transmembrane 
domains, before projecting the receptor conformations at each simulation time point onto PC1 and PC2. 
The norbuprenorphine-MOPr complex is in green, the buprenorphine-MOPr complex in blue, the 
diprenorphine-MOPr complex in yellow, and the black point indicates the conformation of the inactive 
MOPr model.  
b) Extracted structures representing the extremes of PC1 demonstrate the conformational differences 
between the norbuprenorphine-MOPr complex (green) and the buprenorphine-MOPr complex (blue). 
Loops have been removed from the image to depict only the part of the receptor the principal component 
analysis was performed on. White arrows indicate conformational changes in the helices moving from 






4.3.5 The effect of an allosteric sodium ion on ligand binding pose, W2936.48 
conformation and helix positions 
During unliganded MOPr simulations a sodium ion was observed to move from the 
extracellular space into the receptor pore to occupy the allosteric sodium binding site 
(Chapter 3). Sodium is a negative allosteric modulator of Class A GPCRs, with the 
first studies showing sodium modulation of agonist binding conducted on opioid 
receptors (120, 121). This previous literature on receptor modulation by sodium, and 
our MD data showing divergent effects on the behaviour of the W2936.48 in the second 
coordination shell of the sodium site, led us to investigate the effect of an allosteric 
sodium ion in our MD simulations of ligand-MOPr complexes. 250 ns simulations of 
the MOPr bound to norbuprenorphine or buprenorphine, with a sodium ion placed in 
the allosteric site were performed, with the ligands in the same initial binding poses 
as before (Figures 4.2a and 4.2b). The sodium ion did not leave the allosteric site 
during the simulation time for either the norbuprenorphine- or buprenorphine-bound 
receptor.  
The ligand binding poses, the conformation of the W2936.48 rotamer, and the MOPr 
helix conformations in the presence and absence of an allosteric sodium ion are 
shown in Figure 4.9. In the presence of an allosteric sodium ion, both 
norbuprenorphine and buprenorphine maintained the shallower binding pose 
favoured by the low efficacy ligands in the previous simulations (Figure 4.9a). 
Compared to simulations in the absence of an allosteric sodium ion, 
norbuprenorphine was shifted upwards in the binding pocket (Figure 4.9b). However, 
the binding pose of buprenorphine was unchanged in the presence or absence of the 
sodium ion (Figure 4.9c). This suggests that sodium disrupts the binding pose of high 
efficacy agonists, more so than low efficacy ligands. 
The behaviour of the rotamer toggle switch W2936.48 was also different in the presence 
of an allosteric sodium ion (Figure 4.9e). For the buprenorphine-bound receptor, 




sodium, with a χ2 angle between 60-120°. In contrast, for the norbuprenorphine 
simulations the rotamer of W2936.48 switched from a “horizontal” conformation in the 
absence of sodium (~ 0°), to the “vertical” conformation with a sodium ion bound in 
the allosteric site. This “vertical” conformation in the presence of sodium, with a χ2 
angle between 80-120°, was comparable to the conformation favoured by the 
buprenorphine- and diprenorphine-bound receptor, pointing into the ligand binding 
pocket. These data suggest that the presence of an allosteric sodium ion prevented 
the high efficacy agonist norbuprenorphine inducing conformational changes in the 
rotamer toggle switch. 
PCA was performed as described in Section 4.3.4 on the norbuprenorphine and 
buprenorphine-bound simulations in the presence and absence of an allosteric 
sodium ion (Figure 4.9d). As shown in Section 4.3.4, the norbuprenorphine- (green, 
Figure 4.9d) and buprenorphine-bound (blue, Figure 4.9d) MOPr complexes occupied 
distinct clusters in the absence of an allosteric sodium ion. With the sodium ion 
occupying the allosteric site, the conformation of the buprenorphine-bound MOPr was 
unchanged in terms of PC1 and PC2 (yellow, Figure 4.9d), indicating that the 
presence of sodium did not significantly alter the conformation of the MOPr helices. 
In contrast, for the norbuprenorphine-bound receptor the presence of an allosteric 
sodium ion caused the conformational cluster (black, Figure 4.9d) to shift to overlap 
with both the sodium-bound and sodium-free buprenorphine-bound clusters. This 
suggests that the presence of sodium prevented the norbuprenorphine-bound MOPr 
transitioning to the alternative intermediate state observed in the absence of sodium.  
Taken together, the change in norbuprenorphine’s binding pose, the angle of 
W2936.48, and the conformations sampled by the MOPr helices, suggest that the 
presence of an allosteric sodium ion caused the norbuprenorphine-bound MOPr to 






Figure 4.9 Presence of a sodium ion in the allosteric site disrupts high efficacy agonist binding 
a) The final frames from 250 ns MD simulations of norbuprenorphine-bound MOPr (green) or 
buprenorphine-bound MOPr (blue) with a sodium ion in the allosteric site (purple). b) Comparison of 
norbuprenorphine’s binding pose in the absence of an allosteric sodium ion (grey), and in the presence 
of sodium (green). c) Comparison of buprenorphine’s binding pose in the absence of an allosteric sodium 
ion (grey) and in the presence of sodium (blue). d) Projection of the receptor conformation at each time 
point onto principal components 1 and 2. The norbuprenorphine-bound receptor in the absence of an 
allosteric sodium is in green and buprenorphine-bound receptor in the absence of sodium in blue. The 
norbuprenorphine-bound receptor in the presence of sodium is in black, and the buprenorphine-bound 
receptor in the presence of sodium is in yellow. e) Rotamer angle of W2936.48 over 250 ns MD with 
norbuprenorphine or buprenorphine bound, in the presence or absence of an allosteric sodium ion. Data 




4.3.6 Accelerated MD simulations corroborate the conventional MD findings 
Accelerated MD (aMD) is a method of increasing sampling over a short computational 
time by employing a boost potential to accelerate conformational changes (336). For 
the norbuprenorphine-, buprenorphine- and diprenorphine-bound MOPr, up to 1 µs of 
aMD simulation data was collected to determine if this enhanced sampling technique 
would reveal any further conformational changes in the MOPr in response to each 
ligand. Each simulation was started with the ligands in the same initial binding pose 
as in the conventional MD (Figures 4.2a-c).  
The aMD results are summarised in Figure 4.10, and broadly agreed with the data 
from the conventional MD simulations. The binding poses of norbuprenorphine, 
buprenorphine and diprenorphine were similar in the conventional MD and aMD 
simulations, with norbuprenorphine adopting a deeper binding position and engaging 
the W2936.48 rotamer (Figure 4.10a), whilst buprenorphine and diprenorphine 
maintained a shallower binding pose (Figures 4.10b and 4.10c).  
PCA was also conducted on the aMD simulations, using the same method as 
described in Section 4.3.4 for the conventional MD. For the aMD principal components 
1 and 2 accounted for 14.2 % and 9.7 % of the variance, respectively. Like in the 
conventional MD (Figure 4.8a), the norbuprenorphine-bound MOPr formed a distinct 
cluster of conformations to the buprenorphine or diprenorphine-bound MOPr (Figure 
4.10d). The greater spread of the aMD PCA plot, ranging from approximately -40 to 
40, showed the conformational space sampled by aMD was greater than that by the 
conventional MD simulations (ranging from approximately -20 to 20). This highlights 
the value of this technique in increasing sampling of the conformational landscape of 
the MOPr over a relatively short computational time. Nevertheless, both approaches 
gave the same overall result; norbuprenorphine induced the MOPr helices to adopt a 




Furthermore, aMD simulations were also performed on the norbuprenorphine- and 
buprenorphine-bound MOPr complexes in the presence of an allosteric sodium ion. 
Again, the aMD data agreed with the conventional MD, with norbuprenorphine 
adopting the shallower binding pose in the presence of sodium (Figure 4.10e). The 
W2936.48 also reverted to the “vertical” conformation in aMD simulations with an 
allosteric sodium ion bound. PCA performed on the aMD simulations of the 
norbuprenorphine- and buprenorphine-bound MOPr in the absence or presence of 
sodium again showed that in the presence of an allosteric sodium ion the 
norbuprenorphine-MOPr cluster shifted to occupy the same conformational space as 






Figure 4.10 Accelerated MD corroborates the conventional MD results 
The binding poses of a) norbuprenorphine, b) buprenorphine and c) diprenorphine are similar in 
conventional MD simulations (grey) and accelerated MD simulations (coloured). d) PCA performed on 
the aMD simulations. The norbuprenorphine-MOPr complex is in green, the buprenorphine-MOPr 
complex in blue, the diprenorphine-MOPr complex in yellow, and the black point indicates the 
conformation of the inactive MOPr model. e) The binding pose of norbuprenorphine and the conformation 
of W2936.48 in the presence of an allosteric sodium ion is similar in the conventional MD (grey) and 
accelerated MD (green). f) PCA on the sodium-free and sodium-bound aMD simulations. The 
norbuprenorphine-bound receptor in the absence of an allosteric sodium is in green and buprenorphine-
bound receptor in the absence of sodium in blue. The norbuprenorphine-bound receptor in the presence 





In this chapter I have used MD simulations to predict the binding poses of a series of 
small molecule MOPr ligands, which although structurally similar display widely 
differing signalling profiles.  
BRET assays for Gi activation and arrestin-3 recruitment confirmed the reported 
signalling characteristics of these ligands (21); norbuprenorphine and methadone 
were both full agonists for Gi activation and robustly recruited arrestin-3, whilst 
buprenorphine and morphine were partial agonists for Gi activation and with a greatly 
reduced ability to recruit arrestin-3. Diprenorphine was an antagonist for both Gi 
activation and arrestin-3 recruitment. 
Unexpectedly, comprehensive sampling (1 µs MD simulations) of the ligand-MOPr 
complexes revealed that these small molecules adopted distinct binding poses within 
the orthosteric site. We have identified a novel binding pose for norbuprenorphine 
which may provide a molecular basis for the high efficacy of this ligand compared to 
its analogues, buprenorphine and diprenorphine. This novel binding pose is deeper 
in the orthosteric site compared to the other small molecules used in this study and 
the co-crystallised ligands in the antagonist- and agonist-bound MOPr crystal 
structures, β-FNA and BU72. This observation that structural analogues can 
nevertheless bind differently was also recently reported for the 5HT2B receptor (186). 
High resolution crystal structures of the 5HT2B receptor bound to ergotamine or LSD 
showed that although both compounds share the same ergoline moiety, they adopt 
slightly different poses in the orthosteric site, with ergotamine binding deeper in the 
pocket than LSD (186). This finding from our study of morphinan ligands (152) 
highlights the importance for using both molecular docking and molecular dynamics 
simulations to predict ligand binding poses; it cannot be assumed the molecules 
derived from the same chemical structure will interact with the receptor in exactly the 




The presence of a cyclopropylmethyl ring on morphinan compounds appears to 
confer a degree of antagonist activity (324, 337, 338), for instance naloxone is an 
opioid antagonist whereas its derivative oxymorphone, which lacks the 
cyclopropylmethyl ring on the amine, is an agonist. By performing MD simulations of 
the active state MOPr crystal structure Huang et al., showed that whilst the binding 
pose of the agonist BU72 is stable, the cyclopropylmethyl ring-containing analogue, 
BU74, is unstable when docked into the same pose. They predict that this 
hydrophobic group cannot interact with residues in the polar cavity at the base of the 
ligand binding site (22). In the present study, this shared amine substituent in 
buprenorphine and diprenorphine appeared to reduce the ability of the ligand to pivot 
about the amine-D1473.32 interaction. In contrast, without this bulky ring group 
norbuprenorphine was able to pivot about the canonical amine-D1473.32 interaction to 
access the deeper binding site. We have therefore provided further molecular 
evidence for the known activity-modulating properties of this cyclopropylmethyl group 
in opioid ligands.   
Moreover, as well as norbuprenorphine’s novel binding pose, we also observed 
different conformations of the MOPr helices with norbuprenorphine bound compared 
to the lower efficacy morphinans. We propose that the alternative binding pose of 
norbuprenorphine translates to these distinct receptor conformations and that this 
reflects the differing efficacies of the bound ligands. The mechanism is likely due to 
the distinct ligand-residue interactions caused by the slightly different binding 
positions of the ligands. Indeed, unique ligand-residue interaction fingerprints which 
correlated with ligand efficacy were also observed in MD simulations of the β2 
adrenoceptor (339). Furthermore, the recently solved crystal structure of the β2 
adrenoceptor bound to a partial agonist revealed that the partial agonist, salmeterol, 





One such important interaction defined here is with the conserved tryptophan residue, 
W2936.48, at the base of the orthosteric binding pocket. W2936.48 has been previously 
described as a rotamer toggle switch for class A GPCR activation, such as the 
cannabinoid CB1 and muscarinic M3 receptors (150, 151, 156, 334). W2936.48 also 
forms part of the allosteric sodium ion binding site in the inactive state of class A 
GPCRs (122-125). This allosteric pocket collapses upon receptor activation (see 
Chapter 3 and (138, 139)). Here, we show that this residue behaved differently 
depending on the bound ligand. When the high efficacy agonists, norbuprenorphine 
and methadone are bound, W2936.48 switched from the “vertical” position of the 
inactive MOPr model to the “horizontal” position observed in the fully active agonist-
MOPr-Gi complex (23). In contrast, with the lower efficacy ligands, morphine, 
buprenorphine or diprenorphine bound, W2936.48 favoured the inactive state “vertical” 
conformation. This may provide an explanation for the differing efficacies of this panel 
of small molecules; high efficacy agonists are able to induce the rotameric change in 
W2936.48, causing the allosteric sodium ion binding site to collapse, releasing the 
brake on receptor activation and transmitting the binding of an agonist to 
conformational changes in the MOPr helices. Lower efficacy ligands are less able to 
induce the rotameric change in W2936.48, so there is a lower probability of the MOPr 
transitioning to an active state upon ligand binding than with high efficacy agonists. 
This role of W2936.48 as a microswitch for receptor activation has been described for 
other class A GPCRs (22, 134, 150, 151, 156, 334), but there is little published data 
on this phenomenon in the MOPr, particularly in relation to the binding of different 
ligands. 
Although the behaviour of the W2936.48 microswitch correlates well with ligand efficacy 
in our study, it is unlikely to be the sole mechanism of MOPr activation. Indeed, 
comparison of inactive and active state crystal structures of multiple GPCRs points to 
diverse mechanisms for the initiation of receptor activation for different ligands and 




binding pocket converge to a common conformational change at the intracellular G 
protein coupling region (82, 166); primarily the outward movement of TM6 and 
concurrent inward movements of TMs 5 and 7. In these MD simulations, neither 
morphine nor buprenorphine induced the rotameric change in W2936.48, but both are 
MOPr agonists capable of activating the receptor, albeit with reduced responses 
compared to full agonists. This poses the question of how these lower efficacy opioids 
activate the MOPr; one possibility is morphine and buprenorphine are able to engage 
the W2936.48 toggle switch but with lower probability than norbuprenorphine and 
methadone, which we did not sample in our MD simulations. Alternatively, morphine 
and buprenorphine may activate the MOPr via a different mechanism than the 
W2936.48 rotamer. Supporting this, the principal component analysis showed that the 
buprenorphine-MOPr complex sampled conformations distinct from both the 
norbuprenorphine-bound receptor and the inactive state. This may represent a 
different intermediate state to that stabilised by norbuprenorphine. Furthermore, an 
MD study comparing the MOPr bound to morphine or the biased compound, 
oliceridine, revealed different allosteric transduction mechanisms between the ligand 
binding pocket and the G protein binding site for these two ligands (263). A similar 
principle may also apply here whereby the subtly different ligand-residue interactions 
we observed can induce MOPr activation by distinct mechanisms. Moreover, it is 
important to remember that the MOPr is endogenously a peptide receptor. The 
mechanism of activation may differ markedly between small molecule and peptide 
ligands and indeed, unlike GPCRs which evolved to respond to small molecules, the 
activation mechanisms between different non-peptide opioids may not be as well 
conserved. 
The distinct MOPr conformations captured by the PCA appear to reflect the efficacy 
of the bound ligand. Certainly, the conformation of the helices with norbuprenorphine 
bound are consistent with the receptor transitioning towards an active-like 




of TM6 begins to move outwards, along with rearrangements on the extracellular side. 
In these MD simulations of the MOPr and agonist alone a fully active state of the 
receptor was not sampled. Multiple structural studies have suggested that the binding 
of an agonist is insufficient to stabilise a fully active conformation of the GPCR; the 
binding of an intracellular G protein or mimetic is also required (83, 88, 89, 92, 166, 
177). It is therefore unsurprising that we do not achieve a fully active MOPr 
conformation here. 
If the norbuprenorphine-bound MOPr favours an active-like intermediate state, we 
would predict that the presence of the negative allosteric modulator, sodium, would 
disrupt this conformation. Indeed, we found in the presence of a sodium ion the 
binding pose of norbuprenorphine was disrupted such that it assumed the shallower 
binding position of the lower efficacy ligands. Moreover, the W2936.48 rotamer 
maintained the inactive “vertical” position, and analysis of the helix conformations by 
PCA showed the receptor remained in the inactive-like conformation stabilised by the 
lower efficacy ligands, even in the presence of this high efficacy agonist. 
Experimentally, the modulatory effect of sodium is dependent on the efficacy of the 
bound ligand (120, 121). In our MD simulations, the binding pose of the low efficacy 
ligand buprenorphine was unaffected by sodium. Through these divergent effects on 
high and low efficacy ligands we provide a molecular basis for the negative 
modulatory action of sodium on MOPr agonists.  
Accelerated MD was employed to enhance the sampling by accelerating 
conformational changes which could not be accessed by conventional MD in the 
computing timescales available. Overall the aMD corroborated the conventional MD 
data, resulting in similar binding poses of the ligands and conformations of the 
receptor helices. Whilst this provided confidence that the conclusions drawn may be 
relevant to the physiological situation, it also suggested that the sampling by the 
conventional MD was sufficient to capture these initial ligand-induced changes, 





In conclusion, in this chapter I have identified molecular differences between a series 
of small molecule opioid ligands which correlate with their different intrinsic efficacies. 
The high efficacy agonist norbuprenorphine favoured an alternative binding pose to 
its lower efficacy analogues, which allowed norbuprenorphine to engage the W2936.48 
rotamer toggle switch. Similarly, the high efficacy non-morphinan agonist methadone 
also promoted the same conformational change in W2936.48, whereas the low efficacy 
ligands did not. Importantly, these differences at the level of individual residues 
appeared to translate to divergent conformations of the MOPr helices, with the high 
efficacy agonist-bound receptor occupying a different state to when bound to the low 
efficacy ligands. These conformational changes on both a residue and domain-level 
were abolished by the binding of the negative allosteric modulator sodium. Together, 
these results suggest that small changes in ligand binding pose and residue 
interactions are extremely important in determining the global conformation of the 
MOPr and highlight the potential of using this MD technique to understand how opioid 







Chapter 5: In vitro and in silico characterisation of biased 
















There are on-going efforts to develop G protein-biased MOPr agonists, based on the 
suggestion that many opioid-induced side effects may be mediated by arrestin-
dependent signalling pathways (244-247, 252). However this topic is controversial; in 
the original studies arrestin-3 knockout mice exhibited enhanced analgesia in 
response to morphine with a reduced side effect profile (244, 245), whilst a more 
recent study of phosphorylation-deficient MOPr knock-in mice showed that many 
opioid-induced side effects were either unchanged or in some cases exacerbated 
(66). Moreover, opioid-induced respiratory depression appears to be mediated in part 
by GIRK channel activation (29), which is a G protein response. Clinical trials of one 
of the first described G protein-biased compounds, oliceridine, showed only modest 
improvement over morphine (249, 341), whilst the G protein-biased agonist PZM21 
still caused respiratory depression in mice (253). Nevertheless, the development of 
biased tool compounds would be useful in deconvoluting the role of different signalling 
pathways downstream of the MOPr in mediating various opioid-driven effects.  
The molecular mechanism of biased agonism at the MOPr, and indeed any GPCR, is 
poorly understood. The current consensus is that biased ligands are able to stabilise 
a distinct receptor state to unbiased or oppositely biased ligands (222, 224, 262, 342, 
343). However, the lack of structural data for biased compounds at the MOPr makes 
this hypothesis difficult to test. Using the same techniques described in Chapter 4, we 
have used MD simulations of the MOPr bound to biased and unbiased ligands to 
attempt to determine any molecular signatures which may underlie biased agonism 
at the MOPr. 
As the MOPr is fundamentally a peptide receptor, it is important to investigate 
structure-activity relationships for peptide ligands as well as small molecules. We 
selected three peptide MOPr agonists with different bias profiles; DAMGO, 




enkephalin, Figure 5.1a), a pentapeptide highly selective for the MOPr, was chosen 
as the reference full agonist, as it is widely used as the standard agonist that efficiently 
activates both G protein and arrestin pathways and is generally assumed to be 
unbiased. Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2, Figure 5.1b), a tetrapeptide which 
also has high selectivity for the MOPr, has been previously shown to be arrestin-
biased (21, 240), with sub-maximal efficacy for G protein signalling, but exhibiting 
robust recruitment of arrestin-3 and inducing MOPr internalisation. Recently, a novel 
G protein-biased selective MOPr agonist, bilorphin, was developed from an Australian 
estuarine isolate of Penicillium bilaii (344). Bilorphin is composed of an unusual 
alternating stereochemistry of L and D amino acids ([Dmt]-D-Val-Val-D-Phe-NH2, 
Figure 5.1c) and is the first example of a G protein-biased MOPr peptide; all other 
known MOPr peptide agonists induce arrestin recruitment and receptor internalisation 
(21, 240, 241, 243).  
In this chapter, I confirm the expected signalling characteristics of these peptides in 
BRET assays for Gi activation and arrestin-3 recruitment. I perform molecular docking 
and MD simulations of the peptide-MOPr complexes to identify any differences in the 
binding pose and receptor conformation of the bilorphin-bound receptor compared to 
that with endomorphin-2 which may reveal a molecular mechanism of biased agonism 
at the MOPr. I find that bilorphin adopts a distinct binding pose from endomorphin-2 
and DAMGO, notably without interaction with the extracellular loops, and induces the 
MOPr to sample a different cluster of conformations from the endomorphin-2-bound 
receptor. The in silico work described in this chapter was included in the paper 
reporting the discovery of bilorphin, published in the Proceedings of the National 
Academy of Sciences of the United States of America (PNAS) (DOI: 






Figure 5.1 Structures of the peptide ligands 





5.2 Materials & Methods 
5.2.1 BRET assays 
BRET assays for Gi activation and arrestin-3 recruitment were performed as 
described in Chapter 2 Section 2.2.4. For the arrestin assay, the BRET2 configuration 
was used to measure arrestin-3 recruitment in HEK 293 cells expressing human 
MOPr-RlucII and arrestin-3-GFP.  
Data analysis and curve fitting was performed in GraphPad Prism v7. For the Gi 
activation assay, BRET ratios were expressed as the percentage decrease from 
vehicle-treated control wells. For the arrestin-3 recruitment assays, data were 
expressed as the BRET ratio minus background from vehicle-treated control wells.  
Data were then fitted to log concentration – response curves with a Hill Slope of 1.0, 
and the minimum constrained to zero. The EC50 and maximum response (EMax) values 
for each peptide were compared to DAMGO using one-way ANOVA with Dunnett’s 
post-test.  
Bias calculations were performed using the Black and Leff operational model to 
estimate log τ/KA values for each agonist at each pathway (201, 314, 315), as detailed 
in Chapter 2 Section 2.2.5. DAMGO and endomorphin-2 were treated as full agonists, 
as the maximum response of these ligands were not significantly different (see 
Section 5.3.1), and bilorphin as a partial agonist in both assays. As suggested by van 
der Westhuizen et al., (315), the Emax values for each pathway were constrained to 
the maximum response of DAMGO, given in Table 5.1. DAMGO was the reference 
ligand. The resulting bias factors were compared by one-way ANOVA with Tukey’s 
post-test.  
5.2.2 Molecular modelling 
Conformer generation of these highly flexible ligands and molecular docking with 
BUDE was carried out as detailed in Chapter 2 Section 2.1.3. Endomorphin-2 can 




conformation (refer to Chapter 2 Figure 2.3). There are conflicting reports in the 
literature as to which is the bioactive conformation of endomorphin-2 (294-298, 345). 
I therefore performed molecular docking and molecular dynamics simulations with 
both isomers.  
For DAMGO and bilorphin, this process yielded a single converged pose to be taken 
forward into MD simulations. These initial docked poses for DAMGO and bilorphin are 
shown in Figure 5.2.  
For endomorphin-2, after docking to the MOPr using BUDE, 4 clusters of binding 
poses were found to be energetically favourable and meet the amine-D1473.32 
distance constraint; cis endomorphin-2 with Tyr1 orientated towards the intracellular 
side of the membrane (“Cis #1”; Figure 5.3a), cis endomorphin-2 with Tyr1 orientated 
towards the extracellular side of the membrane (“Cis #2”; Figure 5.3b), trans 
endomorphin-2 with Tyr1 orientated towards the extracellular side of the membrane 
(“Trans #1”; Figure 5.3c), and trans endomorphin-2 with Tyr1 orientated towards the 
intracellular side of the membrane (“Trans #2”; Figure 5.3d). Of these, Cis #1 and 
Trans #1 were the most populated clusters; representing 90 % and 88 % of each 
isomer’s 50 lowest energy poses, respectively. A 125 ns simulation of the MOPr 
bound to endomorphin-2 in each of these 4 poses was run and the final binding poses 
analysed to decide which endomorphin-2 conformation and binding pose to use in 
further simulations (Figure 5.3). All four conformers maintained the salt bridge with 
D1473.32. However, only Cis #1 (Figure 5.3a) and Trans #2 (Figure 5.3d) were 
orientated such that the phenol group could interact with another important opioid 
binding residue, H2976.52. RMSD calculations performed on the ligand showed that 
Cis #1 switched between two binding positions due to flexibility in Phe4 (inset, Figure 
5.3a). Aside from this Phe4 flexibility, Cis#1, Cis #2 (Figure 5.3b) and Trans #2 (Figure 
5.3d) were relatively stable in their binding positions, whereas Trans #1 deviated from 
its docked position markedly and failed to become stable during the 125 ns simulation 




further MD simulations, as it showed the most favourable ligand-residue interactions 
(over Cis #2 and Trans #1), had the lowest energy binding pose which was stable 
over the 125 ns simulation, and the most populated cluster from the BUDE docking 
procedure (over Trans #2). 
After selecting the best docked poses for DAMGO, bilorphin and endomorphin-2, 1 
µs MD simulations of all 3 membrane-embedded peptide-MOPr complexes were 





Figure 5.2 Initial docked poses of bilorphin and DAMGO 
10,000 conformers of each peptide were docked using BUDE as outlined in Chapter 2 Section 2.1.3. The 






Figure 5.3 Final binding poses of the endomorphin-2 isomers after 125 ns MD simulations  
10,000 conformers of a, b) cis-endomorphin-2 and c, d) trans-endomorphin-2 were docked using BUDE 
as outlined in Chapter 2 Section 2.1.3. Two poses of each isomer were selected for short 125 ns MD 
simulations to assess stability of the binding pose. For each pose, RMSD calculations were performed 
on the heavy atoms of the ligand compared to the atom positions in the first frame of the simulation, 







5.3.1 Ligand-induced G protein activation and arrestin recruitment 
BRET assays for Gi activation and arrestin-3 recruitment were performed with 
endomorphin-2 and bilorphin, with DAMGO as the reference ligand, to determine the 
signalling characteristics of these agonists and whether any bias could be detected. 
Figure 5.4a shows concentration-response curves for each ligand in activating the Gi 
G protein. The maximum response for endomorphin-2 was not significantly different 
from DAMGO, making both peptides full agonists in this assay. In contrast, bilorphin 
was a partial agonist, reaching an Emax 79 % of the DAMGO response (Table 5.1). 
DAMGO had an EC50 of 0.4 ± 0.2 µM, whilst both the endomorphin-2 and bilorphin 
curves were right-shifted compared to DAMGO, with an EC50 of 0.8 ± 0.2 µM and 1.6 
± 0.6 µM, respectively (Table 5.1). 
In the arrestin-3 recruitment assay (Figure 5.4b), both DAMGO and endomorphin-2 
were full agonists, with similar micromolar EC50s (Table 5.1). Bilorphin produced a 
much lower response in the arrestin-3 assay, with an Emax only 24 % of that elicited 
by DAMGO (Table 5.1). Compared to the G protein assay, DAMGO was 
approximately 12-fold less potent at recruiting arrestin-3 than activating Gi. Bilorphin 
was approximately 4-fold less potent in the arrestin assay, though this was 
accompanied with a lower maximum response. On the other hand, endomorphin-2 
was only 2-fold less potent in the arrestin-3 assay, with a maximum response equal 
to that of DAMGO.   
5.3.2 Bias calculations 
Comparison of transduction ratios, as a quantification of the efficiency of an agonist 
to activate a particular signalling pathway, is a widely accepted method to characterise 
biased agonism from concentration-response data (201, 258, 346). Accordingly, the 
baseline-corrected concentration-response data in Figures 5.4a and 5.4b were fit to 




(log τ/KA) for each ligand in the Gi activation assay and the arrestin-3 recruitment 
assay (Table 5.2) (201, 314, 315). To remove any influence of system or observational 
bias, Δ log τ/KA values for endomorphin-2 and bilorphin were calculated for each 
assay by subtracting the corresponding DAMGO value. Ligand bias was expressed 
as the difference in these DAMGO-subtracted transduction ratios at the Gi activation 
versus arrestin-3 pathways. The resulting bias factors are plotted in Figure 5.4c. As 
the reference balanced agonist, DAMGO by definition has a bias factor of zero, 
ligands biased towards Gi activation would have a bias factor greater than zero, whilst 
ligands biased towards arrestin-3 recruitment would have a bias factor less than zero.  
Endomorphin-2 showed bias towards arrestin-3 recruitment over activation of Gi, a 
finding which is consistent with the previously reported bias profile of this peptide 
(240). In contrast, bilorphin displayed bias towards Gi activation over arrestin-3 
recruitment, as reported by Dekan et al., (344). The calculated bias factors for 
endomorphin-2 and bilorphin were significantly different between these oppositely 
biased peptides (p < 0.05, one-way ANOVA, Tukey’s post-test). 
Although neither of the bias factors for endomorphin-2 nor bilorphin were statistically 
different from the reference agonist DAMGO, looking at the concentration-response 
curves in Figures 5.4a and 5.4b, for endomorphin-2 there is a clear change in the 
order of potency between the Gi activation assay and the arrestin-3 recruitment assay. 
Endomorphin-2 is right shifted compared to DAMGO for Gi activation, but the curves 
overlie for arrestin-3 recruitment. In general, MOPr agonists activate Gi with greater 
potency than they recruit arrestin-3 (21, 243, 258). This lower fold change in 
endomorphin-2’s potency for Gi versus arrestin pathways, along with the calculated 
bias factor trending towards arrestin recruitment, indicates that endomorphin-2 is 
arrestin-biased.  
The relatively large error in estimating EC50 values for low efficacy ligands, such as 




when quantifying ligand bias, makes determining accurate bias factors for partial 
agonists difficult (258). The low response of bilorphin in the arrestin-3 recruitment 
assay therefore makes determining whether bilorphin is truly G protein-biased, or in 
fact a low efficacy partial agonist, challenging. However, experiments performed by 






Figure 5.4 Ligand-induced G protein activation and arrestin recruitment 
a) In HEK 293 cells expressing HA-MOPr, Gαi-RLucII and Gγ-GFP, DAMGO (black circles), 
endomorphin-2 (orange squares) and bilorphin (purple triangles) induced concentration-dependent 
activation of Gi, measured as a decrease in the BRET signal. b) In HEK 293 cells expressing MOPr-
RLucII and arrestin-3-GFP, DAMGO (black circles) and endomorphin-2 (orange squares) induced 
concentration-dependent recruitment of arrestin-3 to the MOPr, measured as an increase in the BRET 
signal. Bilorphin (purple triangles) induced a much lower response. c) Calculated bias factors for 
endomorphin-2 (orange) and bilorphin (purple), using DAMGO as the reference balanced ligand. * p < 








Table 5.1 EC50 and maximum response values for DAMGO, endomorphin-2 and bilorphin in the 
Gi activation and arrestin-3 recruitment assays 
Data are expressed as mean ± SEM, of 5 independent experiments. * p < 0.05, significantly different 






Table 5.2 Bias calculations for endomorphin-2 and bilorphin 





5.3.3 Peptide binding poses and residue interactions 
After docking and selection of the best initial binding poses, 1 µs of MD data was 
collected for each peptide-MOPr complex. RMSD calculations (Figure 5.5) for the 
ligand and the MOPr helices were performed to determine how far each peptide 
deviated from its initial docked position, how stable the final binding pose was, and 
the deviation of the receptor helices from the inactive crystal structure.  
For all peptide-MOPr complexes, the RMSD plots performed on the MOPr 
transmembrane domains quickly reached a plateau at approximately 1 Å. All 3 
peptides remained bound to the orthosteric site during the simulation time, with only 
small deviations from the initial docked poses. Both bilorphin (Figure 5.5a) and 
DAMGO (Figure 5.5c) were stable in their binding poses, only shifting from the initial 
docked positions by approximately 2 Å. In contrast, the binding pose of endomorphin-
2 appeared less stable (Figure 5.5b). However, the fluctuation in the RMSD plot can 
be attributed to the flexibility of the final C terminal Phe4, as was also observed in the 
initial short simulations (see Section 5.2.2). The aromatic group of Phe4 switched 






Figure 5.5 RMSD plots for the peptide ligand-MOPr complexes 
a) RMSD calculations performed on the heavy atoms of bilorphin compared to the initial docked position 
(purple) or the final binding pose (light blue). b) RMSD calculations performed on the heavy atoms of 
endomorphin-2 compared to the initial docked position (orange) or the final binding pose (light blue). c) 
RMSD calculations performed on the heavy atoms of DAMGO compared to the initial docked position 
(turquoise) or the final binding pose (light blue).  
RMSD calculations were also performed on the alpha carbons of the MOPr transmembrane domains, 
compared to the first frame of the MD simulation (light grey in each plot).  
Inset in b): fluctuations of Phe4 in endomorphin-2 during the MD simulation showing 3 different positions 
of Phe4. 





The final binding poses of each peptide are shown in Figure 5.6, and the ligand-
residue interaction plots in Figure 5.7.  
As these compounds are peptides, and therefore larger than the small molecule 
opioids studied in Chapter 4, they interacted with an extended binding site, contacting 
residues in the morphinan binding pocket as well as residues closer to the 
extracellular side of the receptor. In the morphinan binding site, all three peptides 
maintained interactions with residues on TM3 and TM6, including D1473.32, Y1483.33, 
N1503.35, M1513.36, W2936.48, I2966.51, H2976.52 and V3006.55, similar to the small 
molecule morphinan ligands (see Chapter 4 Section 4.3.2). Whilst all three peptides 
interacted with the essential opioid binding residue H2976.52 via the N terminal phenol 
group, bilorphin was the only ligand to alternate between a direct interaction with this 
residue and hydrogen bonding via a bridging water molecule. The canonical amine-
D1473.32 salt bridge was strongly conserved for all three peptides throughout the 
simulation.  
The ligand-residue interactions within this morphinan binding pocket were very similar 
for DAMGO, endomorphin-2 and bilorphin. However, these peptides differed in their 
interactions with the extended binding site. Both endomorphin-2 (Figure 5.6b) and 
DAMGO (Figure 5.6c) bound with the Tyr1 orientated to stack with His2976.52 and the 
rest of the peptide backbone extending out towards the extracellular loops, contacting 
W133ECL1 in ECL1 and C217ECL2, T218ECL2 and L219ECL2 in ECL2 (Figures 5.7b and 
5.7c). In contrast, the tetrapeptide backbone of bilorphin extended towards the other 
side of the MOPr binding pocket, accessing an alternative binding site near TM1 and 
interacting with Y751.39. Strikingly, the interactions with the extracellular loops 
observed for DAMGO and endomorphin-2 were absent for this G protein-biased 
peptide. These differences in the orientation of the peptides is clearer when viewing 
the binding pocket from the extracellular side of the membrane (Figure 5.6d). The C 
terminal residues of DAMGO and endomorphin-2 are positioned to the left of the 




Moreover, the conformation of the microswitch, W2936.48, differed between these 
peptides. The conformation of W2936.48 is plotted as the χ2 dihedral in Figure 5.8. For 
the high efficacy agonist DAMGO, W2936.48 adopted the “horizontal” conformation 
(Figure 5.8c), consistent with the other high efficacy ligands, norbuprenorphine and 
methadone, studied in Chapter 4. Endomorphin-2 and bilorphin both exhibit lower 
potency for G protein signalling than DAMGO (Section 5.3.1). With these lower 
efficacy peptides bound, the W2936.48 rotamer favours the “vertical” conformation 
(Figures 5.8a and 5.8b) with the endomorphin-2-MOPr complex only engaging the 






Figure 5.6 Final binding poses for the peptides 
Final binding poses of the peptide ligands in the MOPr orthosteric site after 1 µs MD simulations. The 
MOPr helices are shown in light grey, with residues forming the ligand binding site as sticks. a) bilorphin 
is depicted in purple, b) endomorphin-2 depicted in orange, and c) DAMGO depicted in turquoise. d) 
Overlaid view of the three peptides in the orthosteric pocket, viewed from the extracellular side of the 
membrane. The peptides bind on opposite sides of the black dotted line; DAMGO (turquoise) and 






Figure 5.7 Ligand-residue interactions for the peptide ligand-MOPr complexes 
a) Bilorphin, b) endomorphin-2, and c) DAMGO. Ligand-residue interactions are expressed as the 
percentage of simulation time each residue is within 4.5 Å of the ligand, with points radiating outwards 






Figure 5.8 W2936.48 rotamer toggle switch 
The behaviour of the W2936.48 rotamer toggle switch plotted as the χ2 dihedral angle over during 1 μs 
MD simulations of the MOPr bound to a) bilorphin, b) endomorphin-2, and c) DAMGO. Insets show how 
the dihedral angle relates to the conformation of the indole ring. Data expressed as raw values (faded 





5.3.4 Biased peptides stabilise distinct conformations of the MOPr 
The conformational changes in the receptor transmembrane helices induced by the 
arrestin-biased peptide, endomorphin-2, or the G protein-biased peptide, bilorphin, 
were examined by principal component analysis. As described in Chapter 2 Section 
2.1.7, after fitting to remove global rotation and translation of the system, the 
covariance matrix was generated using the alpha carbons of the receptor helices. The 
conformation of the MOPr at each time point was projected onto principal components 
(PC) 1 and 2 and plotted in Figure 5.9a. PC1 and PC2 accounted for 28.9 % and 10.9 
% of the variance, respectively. PC2 described helix conformations common between 
the peptide-MOPr complexes, but in terms of PC1 the bilorphin-bound receptor 
clustered differently to the endomorphin-2-bound receptor. A pseudo-trajectory of 
PC1 was extracted to visualise these differences. As depicted in Figure 5.9b, PC1 
primarily described alternative conformations in the extracellular region of the receptor 
close to the orthosteric binding site, and to a lesser extent differences in the 
intracellular portions of the helices. With bilorphin bound, there was a bulging of the 
middle portion of TM1 and a shift outward from the helix bundle, relative to the 
endomorphin-2-bound receptor. This movement of TM1 allowed bilorphin to occupy 
the alternative extended binding site (Section 5.3.3). There were also substantial 
movements of the extracellular ends of TMs 2, 6 and 7, and a kink formed in TM4 
allowed the extracellular part of this helix to move towards TM3 with endomorphin-2 
bound. A smaller movement of TM3 towards TM2 in the endomorphin-2-bound 
receptor, whereby M1513.36 shifted ~1.7 Å from its initial position, is in agreement with 
the active conformation of TM3 observed in the agonist-bound crystal structure (22). 
On the intracellular side of the MOPr, PC1 described inward movements of TMs 5, 6 






Figure 5.9 Principal component analysis reveals distinct MOPr conformations 
a) Principal component analysis was performed on the alpha carbons of the receptor transmembrane 
domains, before projecting the receptor conformations at each simulation time point onto PC1 and PC2. 
The bilorphin-MOPr complex is in purple, the endomorphin-2-MOPr complex in orange, and the black 
point indicates the conformation of the inactive MOPr model.  
b) Extracted structures representing the extremes of PC1 demonstrate the conformational differences 
between the bilorphin-MOPr complex (purple) and the endomorphin-2-MOPr complex (orange). Loops 
have been removed from the image to depict only the part of the receptor the principal component 
analysis was performed on. White arrows indicate conformational changes in the helices moving from 





5.3.5 Molecular modelling of the DAMGO-MOPr complex agrees with the cryo-
electron microscopy resolved structure 
The molecular modelling data presented in this chapter was performed prior to the 
release of the cryo-electron microscopy structure of the MOPr-Gi complex bound to 
DAMGO (23). We used Chimera (293) to superimpose our final structure of the 
DAMGO-MOPr complex after 1 µs MD simulation onto the cryo-electron microscopy 
resolved receptor. Using all 281 Cα atoms in common, the RMSD between our MD 
model and the structure resolved by Koehl et al., was 3.30 Å. This was largely due to 
the outward movement of TM6 in the cryo-electron structure which we did not capture 
in our MD simulations in the absence of a G protein, as with this helix removed from 
the analysis, the RMSD between the resolved structure and our model decreased to 
2.1 Å.  
The position of DAMGO itself was very similar in the resolved structure (Figure 5.10a) 
and our model (Figure 5.10b). Koehl et al., reported poor resolution of the C terminal 
portion of DAMGO and high flexibility of this region in an MD simulation. With this 
flexible C terminal ethanolamine omitted, the RMSD between all heavy atoms of 
DAMGO in the cryo-electron microscopy structure and in our final pose after 1 μs MD 
was 2.83 Å. Due to the high degree of similarity between our predicted binding pose 
for DAMGO and that resolved by cryo-electron microscopy, the ligand-residue 
interactions in the resolved structure and in our model are near identical (Figure 
5.10c). This includes interactions with residues in TM3, TM6, TM7 and the 
extracellular loops. 
Additionally, the conformation of W2936.48 in the newly resolved structure showed the 
indole ring in the “horizontal” position, predicted by our MD simulations (Figures 5.10a 
and 5.10b). 
Overall, this provides excellent validation of our docking and MD strategy for not only 
DAMGO, but also the other peptides studied in this chapter, with the ligand-residue 





Figure 5.10 Comparison of the DAMGO-MOPr cryo-electron microscopy resolved structure with 
our DAMGO-MOPr model 
a) The binding pose of DAMGO in the cryo-electron microscopy structure of the DAMGO-MOPr-Gi 
complex. b) The final binding pose of DAMGO after docking and 1 µs MD simulations. Extracellular loop 
2 (ECL2) and the conformation of the W2936.48 rotamer toggle switch are highlighted in both structures. 
c) The ligand-residue interactions in our modelled structure and the cryoEM structure are near identical; 
ligand-residue contacts identified in the MD simulation are shown in the turquoise radial plot (refer to 
Figure 5.7c) and those within the same distance cut-off in the cryo-electron microscopy structure are 






In BRET assays for Gi activation and arrestin-3 recruitment, using DAMGO as the 
reference ligand, endomorphin-2 and bilorphin exhibited signalling properties in line 
with previous reports (21, 240, 344). Endomorphin-2 was a full agonist in both assays 
and biased towards arrestin-3 recruitment. In contrast, bilorphin was a partial agonist 
in both assays, with a markedly reduced ability to recruit arrestin-3, compared to 
endomorphin-2 and DAMGO. Whilst it is difficult to accurately determine bias factors 
for partial agonists using the transduction ratio method employed here, the bias 
factors calculated for bilorphin and endomorphin-2 are significantly different, 
indicating these peptides are oppositely biased. Moreover, Dekan et al., used an 
alternative method to quantify bias by comparing Emax values in a system where all 
ligands behaved as partial agonists by inactivating a portion of available receptors. 
Under these conditions, bilorphin was biased towards G protein-mediated signalling 
over that initiated by arrestin recruitment (344).  
MD simulations of the peptide-MOPr complexes revealed notable differences in how 
these peptides interact with the MOPr orthosteric site. Specifically, DAMGO and 
endomorphin-2 engaged an extended binding site, contacting residues in ECL1 and 
ECL2, whereas the C terminal residues of bilorphin occupied the opposite side of the 
MOPr pocket and did not interact with the extracellular loops. Interaction with a 
conserved hydrophobic residue in ECL2 (L219ECL2 in the MOPr) has been proposed 
to dictate arrestin coupling and ligand residence time in 5HT receptors and other 
aminergic GPCRs (186, 187). ECL2 has been proposed to act as a “lid” in adenosine 
and muscarinic receptors, whereby upon ligand binding ECL2 closes over the 
orthosteric pocket (181, 182), which may stabilise the ligand in the binding site and 
hence increase residence time. Moreover, ligand residence time appears to correlate 
with efficacy in arrestin-mediated signalling for MOPr agonists (347). In the same 
study, bilorphin was found to have a fast dissociation rate relative to endomorphin-2 




towards G protein signalling with a reduced ability to recruit arrestin-3 because it lacks 
this interaction with L219ECL2 and other residues in the extracellular loops, resulting in 
an enhanced off-rate compared to other opioid peptides. A larger test panel of biased 
compounds would be required to test these hypotheses.  
Moreover, how these ligand-residue interactions with ECL2 translate to an allosteric 
effect on the conformation of the intracellular portion of the MOPr is yet to be 
elucidated. A computational study by Schneider et al., used mutual information 
analysis to determine allosteric coupling between residues near the ligand binding 
site and the intracellular domains of the MOPr (263). They found that the residues 
most strongly correlated between these two regions were different between 
simulations with the MOPr bound to the G protein-biased compound oliceridine versus 
morphine. With oliceridine bound, residues in TMs 1, 3 and 7 contributed to this 
allosteric coupling, whereas with morphine bound there was a greater contribution of 
residues in TMs 2 and 6 (263). Similarly, in our MD simulations bilorphin binds on the 
opposite side of the extended binding pocket to endomorphin-2 and DAMGO, closer 
to TMs 1 and 7. As we have not modelled the binding pathway of these peptides, 
there may also be important differences in the initial interactions between the ligands 
and the MOPr which allosterically alter the resulting receptor conformation.  
Principal component analysis revealed ligand-dependent differences primarily in the 
conformation of the extracellular side of the MOPr, likely due to the alternative 
extended binding pockets accessed by endomorphin-2 and bilorphin. In the absence 
of many high resolution structures of the MOPr bound to different intracellular 
signalling partners, it is challenging to associate these different ligand-induced 
receptor conformations with the subsequent preferential coupling to G proteins or 
arrestins (177, 348). However, we speculate that the differences captured in the 
present study may represent the initial changes induced by these oppositely biased 
peptides which eventually lead to alternative conformations on the intracellular 




that released by Koehl et al., showed high similarity in both the binding position of 
DAMGO and the conformation of residues in the orthosteric site (23) (Section 5.3.5), 
but our MD did not capture the conformational changes observed on the intracellular 
side of the MOPr-Gi complex. This suggests that our molecular modelling protocol is 
able to sample the initial drug-induced changes around the binding site, prior to the 
receptor interacting with a specific intracellular protein. Although we did not capture 
the large conformational changes associated with receptor activation, the helix 
movements described by the principal component analysis showed the intracellular 
ends of the transmembrane domains adopting a more closed conformation, in 
towards the helix bundle, with endomorphin-2 bound compared to the bilorphin-MOPr 
complex. This closed conformation of the intracellular region is reminiscent of the 
“occluded state” stabilised by arrestin-biased ligands at the angiotensin II type I 
receptor (224), and may be the mechanism by which endomorphin-2 can recruit 
arrestin-3 more potently than other MOPr ligands.  
As discussed in Chapter 4, the conformation of the conserved microswitch W2936.48 
appears to be dependent on the intrinsic efficacy of the bound ligand. The data 
described in the present chapter agrees with this previous hypothesis; DAMGO was 
a more potent agonist in the Gi activation assay than both endomorphin-2 and 
bilorphin (Section 5.3.1) and strongly induced the conformational change in W2936.48, 
relative to the inactive MOPr model, whereas the lower potency peptides, 
endomorphin-2 and bilorphin, did not. Furthermore, the conformation of the W2936.48 
indole ring predicted by our MD simulations was also captured in the recently released 







In conclusion, in this chapter I have described the signalling characteristics of three 
MOPr-selective peptides; the balanced agonist DAMGO, the arrestin-biased agonist 
endomorphin-2, and the novel G protein-biased agonist bilorphin. MD simulations of 
the peptide-MOPr complexes revealed distinct interactions with the MOPr extended 
binding pocket which may confer the differing bias profiles of these compounds. 
DAMGO and endomorphin-2, which recruited arrestin-3, interacted with the 
extracellular loops, notably with the conserved hydrophobic residues on ECL2 
suggested to be important for arrestin-bias and ligand kinetics (186, 187). Importantly, 
bilorphin did not engage these residues and instead interacted with a different 
extended binding site closer to TM1. Moreover, the MOPr sampled different 
conformational states in the presence of bilorphin versus endomorphin-2. These data 
add to the body of literature suggesting biased ligands can stabilise alternative GPCR 
conformations (222, 224, 262, 342, 343), and that these conformational changes are 
induced by unique ligand-residue interaction fingerprints. To our knowledge, this is 
the first study to identify structural differences between the binding of oppositely 







Chapter 6: The effect of single point mutations on ligand-















6.1 Introduction  
The real power of any in silico study is when hypotheses based on MD simulation 
data can be tested and validated in vitro, or even in vivo. By analysing the full panel 
of ligand-MOPr simulation data described in Chapters 4 and 5, I identified residues of 
interest which may be important in encoding opioid ligand efficacy and bias. The 
positions of the two residues discussed in this chapter, W2936.48 and L219ECL2, are 
shown in Figure 6.1.   
Firstly, the rotamer toggle switch W2936.48, located at the base of the orthosteric 
pocket (Figure 6.1a), adopted distinct conformations depending on the bound ligand 
(152). In simulations with high efficacy agonists, such as DAMGO (Chapter 5 Section 
5.3.3), norbuprenorphine or methadone (Chapter 4 Section 4.3.3), the indole ring of 
W2936.48 favoured the “horizontal” conformation, whilst in the presence of the lower 
efficacy ligands, bilorphin (Chapter 5 Section 5.3.3), morphine, buprenorphine or 
diprenorphine (Chapter 4 Section 4.3.3) it favoured the “vertical” conformation. A 
tryptophan, or other aromatic residue, in position 6.48 (Ballesteros-Weinstein 
numbering (81)) is highly conserved across Class A GPCRs. Table 6.1 lists the 
residues at position 6.48 in all the currently crystallised Class A GPCRs (78). Out of 
these analysed sequences, 78 % contain a tryptophan and 96 % have an aromatic 
residue. W6.48 has been suggested to act as a microswitch for receptor activation 
(149, 349, 350) and mutations at this position drastically alter ligand binding and 
signalling across a range of GPCRs including cannabinoid, serotonin, ghrelin, 
adenosine and neuropeptide Y2 receptors (150, 151, 158-160). Moreover, by 
comparison of the available crystal structures of the MOPr, the conformation of 
W2936.48 was highlighted as a key change between the inactive and active state 
receptor (22). However, to our knowledge, the effect of mutating W2936.48 on ligand-




Secondly, comparison of the oppositely biased peptides endomorphin-2 and bilorphin, 
and the reference agonist DAMGO (generally considered to be unbiased), highlighted 
differences in interactions with the extracellular loops. Peptides that robustly recruit 
arrestin interacted with W133ECL1, C217ECL2, T218ECL2 and L219ECL2, but the G protein-
biased peptide bilorphin did not (Chapter 5 Section 5.3.3). There is increasing interest 
in the role of the extracellular loops, particularly ECL2, in GPCR activation and bias 
(186, 187, 351). Notably, the presence of a hydrophobic residue at position 45.52 
(numbering follows the nomenclature for loops described in (237)) in ECL2 (L219ECL2 
in the MOPr, Figure 6.1) is reasonably conserved in Class A GPCRs; Table 6.1 shows 
that 54 % of the sequences analysed contain a hydrophobic residue at position 45.52 
(78). From our MD simulations of the peptide-MOPr complexes, we hypothesised that 
ligand interaction with the extracellular loops, including L219ECL2, may be important 
for arrestin recruitment to the MOPr (Chapter 5). Indeed, in the 5HT2B receptor 
mutation of this leucine residue to an alanine selectively reduced arrestin recruitment 
but did not alter G protein-mediated signalling (186). Furthermore, ligand interaction 
with the equivalent ECL2 residue (isoleucine) successfully predicted arrestin bias at 
the dopamine D2 receptor (187). Based on this previous literature, along with 
observations from our MD simulations in Chapter 5, I sought to investigate the effect 
of the L219ECL2A point mutation in MD simulations and in cell signalling assays.  
In this chapter, I first perform MD simulations of the W2936.48A and L219ECL2A MOPr 
variants to determine the effect of these mutations on ligand binding poses and MOPr 
conformation. I then use site-directed mutagenesis by PCR to generate the single 
point mutations in the HA-rat MOPr construct to investigate if the effect predicted by 
the MD simulations translates to altered ligand-induced signal transduction in HEK 
293 cells expressing the MOPr variants. I find that the W2936.48A mutation causes the 
MOPr to favour an overall inactive conformation in silico, which did not respond to 
opioid agonists in vitro, whilst the L219ECL2A mutation differentially modulates MOPr 





Figure 6.1 Position of the single point mutations characterised in this chapter 
a) The residues are shown as dark grey sticks on the inactive MOPr model (ribbons). L219ECL2 is 
positioned in extracellular loop 2. W2936.48 sits at the base of the orthosteric ligand binding site, on TM6. 






Table 6.1 Amino acids at positions 45.52 in ECL2 and 6.48 in TM6 are conserved across Class A 
GPCRs 
Sequences of all crystallised Class A GPCRs were analysed using the GPCRdb (78). Amino acids are 
colour-coded by side chain property; green = aromatic, yellow = hydrophobic, purple = polar, red = acidic, 





6.2 Materials & Methods  
6.2.1 In silico mutagenesis 
Point mutations of the inactive MOPr model were generated by converting the residue 
of interest (W2936.48 or L219ECL2) to an alanine in Chimera (293). As alanine contains 
only a methyl group side chain, it was not necessary to optimise the rotamer position 
of the new residue. 250 ns MD simulations were performed of each membrane-
embedded MOPr mutant bound to the ligands of interest. The initial pose of the bound 
ligand in each mutant was identical to that in the original wildtype simulations (see 
Chapter 4 Section 4.2.2 and Chapter 5 Section 5.2.2). For the W2936.48A receptor, in 
order to determine the effect of the substitution on the ability of an agonist to induce 
an active-like state, simulations were performed with either the high efficacy agonist, 
norbuprenorphine, or the antagonist, diprenorphine, in the binding pocket. For the 
L219ECL2A receptor, simulations were performed with the receptor bound to either the 
G protein-biased peptide, bilorphin, or the arrestin-biased peptide, endomorphin-2, as 
this substitution in the endomorphin-2 binding pocket was predicted to have a greater 
effect on endomorphin-2 than bilorphin.  
MD simulations and subsequent analysis were performed as described in Chapter 2 
Sections 2.1.5 and 2.1.7.  
6.2.2 In vitro mutagenesis  
To determine the effect of the W2936.48A and L219ECL2A point mutations on ligand-
induced signalling, single point mutations were introduced to the MOPr constructs 
using mutagenic PCR, as described in Chapter 2 Section 2.2.6.  
For each desired mutation, the aim was to introduce the variant into both the pcDNA3-
HA-rMOPr and the pQCXIN-Myc-hMOPR-RlucII plasmids (see Chapter 2 Section 
2.2.6), to use in the G protein and arrestin-3 BRET assays, respectively.  
After the PCR reactions, the products were visualised by gel electrophoresis on 1 % 




where both the W2936.48A and L219ECL2A reactions resulted in a band at the expected 
product size of 7 kb. E.Coli were transformed with these PCR products and the DNA 
extracted and purified as described in Chapter 2 Section 2.2.6. Figure 6.3 shows the 
DNA sequence of the mutagenized portion of the plasmid compared to the wildtype 
template plasmid for the W2936.48A (Figure 6.3a) and L219ECL2A (Figure 6.3b) 
reactions. Both mutations were successfully incorporated, with no other mis-matched 
bases elsewhere in the insert sequence. The full insert sequences are presented in 
the Appendix I and II.  
Figure 6.2b shows a representative gel from the pQCXIN-Myc-hMOPR-RlucII 
reactions. Despite attempts to alter the PCR conditions for this larger plasmid, none 
of the reactions performed resulted in a detectable band at the expected size. E.Coli 
transformed with the PCR products failed to grow on ampicillin-containing agar, 
suggesting that the mutagenized plasmid had not formed correctly.  
Cell signalling experiments were therefore performed with the pcDNA3-HA-rMOPr 
constructs. In the absence of successful mutation of the pQCXIN-Myc-hMOPR-RlucII 
plasmid, which contains the Renilla Luciferase essential for the arrestin-3 BRET 
assay, ligand-induced receptor internalisation measured by ELISA was used as a 






Figure 6.2 Gel electrophoresis of PCR products 
PCR products, including the pWhitescript control reaction, were run on 1 % agarose gels to check bands 
were the correct size, and to check for any contaminants or primer-dimer formation. a) PCR products for 
the control reaction, W2936.48A and L219ECL2A reactions with the HA-rat MOPr construct. All reactions 
produced bands of the correct size, with no detectable contaminating bands. b) PCR products for the 
control reaction, W2936.48A and L219ECL2A reactions with the Myc-human MOPr-RLucII construct. The 
control reaction produced a band at the correct size, but neither the W2936.48A nor L219ECL2A reactions 





Figure 6.3 Sequencing results for the obtained MOPr mutants 
Purified DNA obtained from the site-directed mutagenesis protocol (see Chapter 2 Section 2.2.6) was 
sequenced by Source Bioscience, and the sequences aligned to the HA-rat MOPr template sequence. 
For both the a) W2936.48A and b) the L219ECL2A reactions, only the desired mutations were incorporated 






6.2.3 Expression of the MOPr variants in HEK 293 cells 
HEK 293 cells were transfected with either the HA-rat MOPr, W293A-MOPr or L219A-
MOPr by lipofectamine transfection (see Chapter 2 Section 2.2.3). Surface expression 
of the wildtype and MOPr variants was determined 36 hours later by cell surface 
ELISA against the HA-tag, as described in Chapter 2 Section 2.2.7.  
6.2.4 BRET assays 
Using DNA ratios to produce approximately equal surface expression, as determined 
by ELISA, HEK 293 cells were transfected with either wildtype HA-rat MOPr, 
W2936.48A-MOPr or L219ECL2A-MOPr, along with Gαi-RlucII and Gγ-GFP. On the day 
of the assay, cells were counted and plated at equal cell densities for each variant, to 
allow comparison between the different plates of transfected cells.  
Ligand-induced G protein activation was measured as described in Chapter 2 Section 
2.2.4. For the single concentration experiments, all drugs were used at a 
concentration of 30 µM, except methadone which was used at 10 µM due to its off-
target effects at high concentrations (353).   
Statistical analysis was performed in GraphPad Prism version 7, comparing the ligand 
response in each MOPr variant to wildtype using two-way ANOVA with post-hoc 
Dunnett’s test.  
Full concentration-response curves were generated for DAMGO, endomorphin-2 and 
bilorphin at the wildtype HA-rat MOPr and the L219ECL2A variant, and the resulting 
EC50 and maximum response values were compared by two-way ANOVA with post-
hoc Sidak’s test, for differences between wildtype and L219ECL2A MOPr for each drug.  
6.2.5 Receptor internalisation  
Receptor internalisation in response to DAMGO, endomorphin-2 or bilorphin was 
measured by cell surface ELISA by pre-labelling receptors prior to incubation with 
drug, as described in Chapter 2 Section 2.2.8. All drugs were at added at a 




maximal receptor internalisation (21, 39, 47, 315). Data analysis was performed in 
GraphPad Prism version 7, using two-way ANOVA with post-hoc Dunnett’s test to test 






6.3.1 MD simulations of the W2936.48A MOPr variant 
The conserved tryptophan residue, W2936.48, at the base of the orthosteric binding 
pocket has been previously described as a rotamer toggle switch for GPCR activation 
(22, 150-152, 334, 354). In Chapter 4 Section 4.3.3 and Chapter 5 Section 5.3.3 the 
rotameric state of W2936.48 was assigned by measuring the χ2 dihedral; values around 
80 - 120° indicated the indole ring was in the “vertical” conformation, whilst values 
between 0 - 60° were characteristic of the “horizontal” conformation. Plotting the 
average χ2 dihedral of W2936.48 during the MD simulations of the ligand-bound 
wildtype receptor against the experimentally-derived values (21) for intrinsic efficacy 
in GTPγS binding assays (τ) showed that there was a significant strong negative 
correlation between the rotameric state of the W2936.48 side chain and the efficacy of 
the bound ligand (r = -0.85, p = 0.0165, Pearson’s correlation). Higher efficacy 
agonists induced a greater conformational change in this residue, from the “vertical” 
to “horizontal” position, than the lower efficacy ligands (Figure 6.4a). I therefore 
converted the tryptophan in position 293 to an alanine in the inactive MOPr model 
(Figure 6.4b), and 250 ns MD simulations were performed of the W2936.48A variant 
receptor bound to either norbuprenorphine or diprenorphine, as examples of a high 
efficacy small molecule and an antagonist, respectively.  
Principal component analysis comparing the wildtype and W2936.48A simulations 
showed that in simulations of the wildtype receptor, the norbuprenorphine-bound 
complex clustered differently to the diprenorphine-bound complex, adopting a 
conformation consistent with an active intermediate (152) (see Chapter 4 Section 
4.3.4). In simulations of the ligands bound to the W2936.48A mutant, the clusters for 
both complexes overlapped with the diprenorphine-bound wildtype MOPr and the 
conformation of the inactive crystal structure (Figure 6.4c). This suggests that 
mutation of W2936.48 to alanine reduced the probability of the receptor transitioning to 




Extracting structures representing extremes of PC1 showed that these differences 
between the norbuprenorphine-MOPr structure and the norbuprenorphine- W2936.48A 
receptor were mainly in the positions of the extracellular ends of the transmembrane 
domains (Figure 6.4d). In simulations of the W2936.48A variant, TMs 2, 5 and 6 moved 
outwards away from the helix bundle, whilst TM3 and TM7 shifted inwards, compared 
to the norbuprenorphine-bound wildtype MOPr. These principal motions were very 
similar to those describing the differences between the high and low efficacy agonist-
bound MOPr in Chapter 4, again suggesting that the W2936.48A variant favours an 
inactive state.  
As illustrated in Figure 6.4e, the binding pose of diprenorphine in the W2936.48A 
mutant MOPr (yellow) essentially did not differ from its pose in simulations with the 
wildtype MOPr (grey). However, for norbuprenorphine, the conversion of W2936.48 to 
alanine allowed the ligand to shift deeper into the receptor pore (green in Figure 6.4f) 
to adopt a binding pose which would clash with the indole ring of W2936.48 in the 
wildtype receptor (grey in Figure 6.4f). In these simulations, the W2936.48A mutation 
therefore altered the binding position of the high efficacy agonist norbuprenorphine, 
but not that of the antagonist diprenorphine.  
These simulations of the W2936.48A MOPr build on evidence that W2936.48 is an 
important microswitch for GPCR activation and provides a strong rationale for 






Figure 6.4 W2936.48A in silico mutagenesis 
a) The χ2 dihedral of W2936.48 from the MD simulations correlates with experimental values of ligand 
efficacy for GTPγS binding (21) (Pearson’s correlation). b) W2936.48 was converted to alanine and 250 
ns MD simulations were performed with the W2936.48A-MOPr bound to norbuprenorphine or 
diprenorphine. c) Principal component analysis performed on the alpha carbons of the receptor 
transmembrane domains. Clusters for the 1 μs simulations of the wildtype MOPr bound to 
norbuprenorphine or diprenorphine are in dark grey or light grey, respectively. Data from the 250 ns 
simulations of the W2936.48A MOPr mutant bound to either norbuprenorphine or diprenorphine are in 
green and yellow, respectively. The black point indicates the conformation of the inactive crystal 





shows helix conformational changes primarily on the extracellular side of the MOPr. Loops have been 
removed from the image to just depict the part of the receptor on which the PCA was performed. White 
arrows indicate conformational changes in the helices moving from norbuprenorphine-bound wildtype 
MOPr (grey) to norbuprenorphine-bound W2936.48A-MOPr (green). Final binding poses of e) 
diprenorphine (yellow) and f) norbuprenorphine (green) after MD simulation of the W2936.48A receptor, 





6.3.2 MD simulations of the L219ECL2A MOPr variant 
In Chapter 5, we observed differences in ligand interaction with residues in ECL2 
through MD simulations of peptide-MOPr complexes. Endomorphin-2 and DAMGO 
both transiently interacted with residues in this extracellular loop, whereas the G 
protein-biased peptide bilorphin did not. A conserved hydrophobic residue in ECL2, 
L219ECL2 in the MOPr, has been suggested to play a role in arrestin-bias in Class A 
GPCRs (186, 187). Therefore, I mutated L219ECL2 to alanine in silico (Figure 6.5a) and 
performed 250 ns MD simulations of the L219ECL2A receptor bound to either the 
arrestin-biased peptide endomorphin-2 or the G protein-biased peptide bilorphin. 
A previous study of this conserved hydrophobic residue in the 5HT2B receptor showed 
that the leucine to alanine mutation resulted in greater flexibility of ECL2 (186). Figure 
6.5b and 6.5c show the root mean square fluctuations (RMSF) of the alpha carbons 
of residues in ECL2 in simulations of the wildtype or L219ECL2A MOPr bound to 
endomorphin-2 or bilorphin. In agreement with the study by Wacker et al., in the 
L219ECL2A variant the RMSF values for the ECL2 residues were generally higher than 
in simulations of the wildtype MOPr, suggesting that the L219ECL2A mutation made 
this loop more flexible.  
Figure 6.5d shows the results of the principal component analysis performed on the 
wildtype and L219ECL2A simulations with the MOPr bound to bilorphin or endomorphin-
2. Projecting the receptor conformations onto PC1 and PC2 showed that with either 
bilorphin or endomorphin-2 bound, the L219ECL2A receptor adopted a conformation 
distinct from that stabilised by either peptide in the wildtype receptor. As both 
extracellular and intracellular loops were excluded from the analysis (see Chapter 2 
Section 2.1.7), these alternative conformations must reflect a change in the positions 
of the transmembrane domains between the wildtype and L219ECL2A simulations, 
which may have been induced by the mutation in ECL2. If so, this suggests that 




Unexpectedly, in simulations of endomorphin-2 bound to the L219ECL2A mutant there 
was a change in the rotameric state of W2936.48 consistent with the active 
conformation of the MOPr (Figure 6.5e). This may be due to the slight change in the 
binding pose of endomorphin-2 in the L219ECL2A receptor compared to the wildtype 
model, such that the N-terminal tyrosine of endomorphin-2 moved deeper into the 
receptor pore, engaging the W2936.48 activation switch (Figure 6.5f, orange). In 
contrast, the binding pose of bilorphin shifted slightly away from W2936.48 in the 
L219ECL2A receptor (Figure 6.5g, purple) and the N-terminal dimethyl tyrosine 
maintained a favourable stacking interaction with the indole ring of W2936.48, so the 
side chain remained in the “vertical”, inactive position (Figure 6.5e).  
This effect on the behaviour of a microswitch spatially distant from the L219ECL2A 
mutation suggests that L219ECL2 may play an important role in signal transduction for 
endomorphin-2. Together with the increasing literature on the role of extracellular 
loops in GPCR activation (181, 182, 186, 187, 191, 351), the impact of mutating this 







Figure 6.5 L219ECL2A in silico mutagenesis 




a) L219ECL2 was converted to alanine and 250 ns MD simulations were performed with the L219ECL2A-
MOPr bound to bilorphin or endomorphin-2. RMSF calculations performed on the alpha carbons of ECL2 
residues in simulations with the L219ECL2A variant bound to b) endomorphin-2 and c) bilorphin, compared 
to the wildtype MOPr (grey). d) Principal component analysis performed on the alpha carbons of the 
receptor transmembrane domains. Clusters for the 1 μs simulations of the wildtype MOPr bound to 
bilorphin or endomorphin-2 are in dark grey or light grey, respectively. Data from the 250 ns simulations 
of the L219ECL2A MOPr mutant bound to either bilorphin or endomorphin-2 are in purple and orange, 
respectively. The black point indicates the conformation of the inactive crystal structure. e) The rotamer 
angle of W2936.48 with bilorphin (purple) or endomorphin-2 (orange) bound in the wildtype receptor, and 
in the L219ECL2A mutant. Data expressed as raw values (faded line) and moving average over 100 frames 
(10 ns) (bold line). Final binding poses of f) endomorphin-2 (orange) and g) bilorphin (purple) after MD 





6.3.3 Surface expression of the MOPr variants in HEK 293 cells 
To investigate the effect of these MOPr variants on ligand-induced MOPr signalling in 
vitro, the W2936.48A and L219ECL2A point mutations were introduced to the HA-rat 
MOPr construct by PCR site-directed mutagenesis (see Section 6.2.2).  
Cell surface ELISAs were performed to confirm whether the MOPr variants reached 
the plasma membrane. Initially, separate dishes of HEK 293 cells were transfected 
with equal (5 µg) amounts of either wildtype HA-rat MOPr, W2936.48A MOPr or 
L219ECL2A MOPr DNA, and ELISA against the HA-tag performed 36 hours post-
transfection (Section 6.2.5). With this 1:1:1 ratio of WT:W293A:L219A DNA, although 
there was no significant difference in the level of receptor at the surface, by eye there 
appeared to be more of the wildtype HA-rat MOPr on the cell surface than the two 
variants (Figure 6.6a). For the subsequent cell signalling experiments it was important 
to have the MOPr variants expressed at equal levels to the wildtype construct so that 
any differences in ligand response could be attributed to the single point mutation and 
not different expression of the receptors which could lead to changes in observed 
agonist potency. Cells were therefore transfected with different amounts of DNA (2.5 
µg of wildtype HA-rat MOPr, 5 µg of W2936.48A MOPr, or 10 µg of L219ECL2A MOPr), 
which resulted in approximately equal, if not higher, levels of surface expression of 
each MOPr variant compared to wildtype (Figure 6.6b). This 1:2:4 ratio of 






Figure 6.6 Surface expression of the MOPr mutants 
Surface expression of the W2936.48A and L219ECL2A HA-rat MOPr constructs was measured by ELISA 
and compared to the wildtype HA-rat MOPr construct. a) Surface expression of HA-tagged receptors in 
HEK 293 cells transfected with 5 μg of receptor DNA (1:1:1 ratio). b) Surface expression of HA-tagged 
receptors in HEK 293 cells transfected with 2.5 μg of HA-rat MOPr, 5 μg of W2936.48A mutant or 10 μg 
of L219ECL2A mutant (1:2:4 ratio of WT:W293A:L219A). Data expressed as mean ± SEM of 3 
independent experiments. Surface expression of the MOPr mutants was not significantly different from 





6.3.4 Ligand-induced G protein activation  
To determine the effect of the W2936.48A and L219ECL2A point mutations on MOPr 
signalling, ligand-induced Gi activation was measured in cells expressing the wildtype 
HA-rat MOPr or the MOPr variants (Figure 6.7). The BRET signal in response to a 
single high concentration of opioid agonist (30 µM for all drugs, except methadone 10 
µM) was compared in cells expressing the wildtype HA-rat receptor, or the W2936.48A 
variant (Figure 6.7a), or the L219ECL2A variant (Figure 6.7b). Strikingly, the W2936.48A 
mutation clearly abolished Gi activation in response to all opioid ligands tested (Figure 
6.7a), even at these maximal concentrations. In contrast, the L219ECL2A mutation had 
no significant effect on the G protein BRET signal in response to a single high 
concentration of agonist (Figure 6.7b).  
Next, full concentration-response curves for the peptide opioid agonists were 
performed in cells expressing either the wildtype or L219ECL2A MOPr in order to 
determine if the mutation had an effect on the agonist potency (Figures 6.7c-e). The 
maximum response and EC50 values calculated for each peptide at the wildtype and 
L219ECL2A receptors are given in Table 6.2. As suggested by the initial single 
concentration experiments, the maximum response was not significantly changed for 
any of the peptide agonists between wildtype and L219ECL2A. DAMGO exhibited a 
small rightward shift of the curve for the L219ECL2A variant (Figure 6.7c), although the 
EC50 values were not significantly different between wildtype (0.8 ± 0.2 µM) and 
L219ECL2A (1.4 ± 0.5 µM) expressing cells (Table 6.2). The curve for endomorphin-2 
at the L219ECL2A MOPr was significantly right-shifted compared to wildtype (Figure 
6.7d), resulting in endomorphin-2 displaying over 3-fold lower potency at activating Gi 
through the L219ECL2A variant compared to wildtype, with an EC50 of 3.3 ± 0.7 µM and 
1.0 ± 0.1 µM, respectively (Table 6.2). Bilorphin had almost identical potency in 






Figure 6.7 Ligand-induced Gi activation in the MOPr mutants 
Ligand-induced Gi activation was measured by BRET assay in HEK 293 cells expressing Gαi-RLucII, 
Gγ-GFP, and either HA-rat MOPr (grey bars), HA-W2936.48A (red bars) or HA-L219ECL2A (blue bars). All 
drugs at 30 µM, except methadone 10 µM. a) The W2936.48A mutation abolished Gi activation in response 
to opioid agonist. b) For the L219ECL2A variant there was no significant effect on the level of Gi activation 
in response to a single high concentration of opioid agonist, compared to the wildtype receptor. Data 
expressed as mean ± SEM, of 3 independent experiments. * p < 0.05, two-way ANOVA, post-hoc 
Dunnett’s test for differences in ligand response between the MOPr variant and wildtype. Concentration 
response curves for c) DAMGO, d) endomorphin-2 and e) bilorphin in cells expressing Gαi-RLucII, Gγ-









Table 6.2 Maximum response and EC50 values for peptide agonists in the Gi activation assay in 
HEK 293 cells expressing wildtype HA-rMOPR or L219ECL2A variant receptors 
Data are expressed as mean ± SEM, of 5 independent experiments. * p < 0.05, significantly different 
from the respective WT value (two-way ANOVA, post-hoc Sidak’s test for differences in ligand response 





6.3.5 MOPr internalisation  
In the absence of MOPr-RlucII BRET constructs containing the desired mutations 
(see Section 6.2.2), MOPr internalisation in response to opioids was used as a proxy 
for arrestin recruitment. GPCR internalisation following arrestin recruitment is a well-
documented phenomenon, and the ability of MOPr agonists to induce internalisation 
generally correlates with efficacy in arrestin recruitment assays (6, 21, 355).   
HEK 293 cells expressing either the wildtype HA-rat MOPr, or the W2936.48A or 
L219ECL2A variants were prelabelled with HA-antibody and then incubated with 30 µM 
DAMGO, endomorphin-2, bilorphin or vehicle for 30 minutes. Cell surface receptor 
ELISAs were then performed as described in Chapter 2 Section 2.2.8. Receptor 
internalisation was expressed as the percentage decrease in absorbance compared 
to vehicle-treated cells. As with the previous ELISAs (Section 6.3.3), in vehicle-treated 
cells the surface expression of the MOPr variants was approximately equal to wildtype 
(Figure 6.8a), suggesting that not only was the surface expression of the MOPr 
unaffected by the point mutations, but that the level of constitutive receptor 
internalisation, if any, was also not altered in the W2936.48A or L219ECL2A variants.   
In agreement with previous reports (21, 240), at the wildtype receptor DAMGO and 
endomorphin-2 both induced robust internalisation of the MOPr (grey bars, Figure 
6.8b); 30 µM DAMGO induced 47.3 ± 3.0 % loss of the MOPr from the cell surface, 
whilst the same concentration of endomorphin-2 resulted in 30.7 ± 5.6 % 
internalisation. In contrast, at the wildtype receptor bilorphin induced a very low 
internalisation response, 6-fold lower than that of DAMGO, with only an 8.0 ± 5.7 % 
loss of receptor from the plasma membrane (grey bars, Figure 6.8b). This lack of 
efficacy for bilorphin in inducing MOPr internalisation agrees with the report by Dekan 
et al., describing bilorphin as a non-internalising, G protein-biased agonist (344). 
There was no detectable internalisation of the W2936.48A MOPr in response to any of 




Both DAMGO and endomorphin-2 induced internalisation of the L219ECL2A receptor, 
with neither response significantly different from wildtype (blue bars, Figure 6.8b). 
Unexpectedly, the L219ECL2A mutation converted the non-internalising G protein-
biased ligand, bilorphin, into an agonist for MOPr internalisation. 30 µM bilorphin 
induced 29.7 ± 8.9 % internalisation of the L219ECL2A receptor (blue bars, Figure 
6.8b), significantly higher than the wildtype response and similar in magnitude to that 






Figure 6.8 Ligand-induced receptor internalisation in the MOPr mutants 
Ligand-induced receptor internalisation was measured by surface receptor ELISA in HEK 293 cells 
expressing either HA-rat MOPr (grey bars), HA-L219ECL2A (blue bars) or HA-W2936.48A (red bars). a) In 
cells treated with vehicle, surface expression of the L219ECL2A and W2936.48A MOPr variants was equal 
to wildtype HA-rat MOPr. b) Loss of receptor from the cell surface in response to 30 µM DAMGO, 
endomorphin-2 or bilorphin was expressed as the percentage decrease in absorbance compared to 
vehicle-treated cells. All data are expressed as mean ± SEM, of 5 independent experiments. * p < 0.05, 
two-way ANOVA, post-hoc Dunnett’s test for differences in ligand response between the MOPr variant 






Using evidence from the MD simulations of ligand-MOPr complexes from Chapters 4 
and 5, we hypothesised firstly that, as has been shown in other GPCRs, W2936.48 is 
a key residue in translating the binding of an agonist to MOPr activation. Secondly, 
MD simulations of the peptide-MOPr complexes suggested that interactions with the 
conserved hydrophobic residue L219ECL2 may be a predictor of efficacy for arrestin 
recruitment. In this chapter, I used both in silico and in vitro mutagenesis to test these 
hypotheses by molecular modelling and in cell signalling assays.  
MD simulations of the W2936.48A MOPr model suggested this mutation produces a 
receptor incapable of being activated. Whilst the binding pose and overall protein 
conformation of the antagonist- (diprenorphine) bound receptor was not significantly 
altered in the W2936.48A variant compared to wildtype, for the high efficacy agonist 
norbuprenorphine this single amino acid change was sufficient to alter both the ligand 
binding pose and the conformational state of the receptor. This finding demonstrates 
that as in other GPCRs (349, 350, 356), the activation of the MOPr is coupled to the 
behaviour of this important residue.  
This prediction of the effect of this W2936.48A mutation was reflected in the cell 
signalling results; the W2936.48A MOPr variant was expressed on the cell surface but 
did not activate the Gi G protein nor internalise in response to a high concentration of 
any opioid agonist tested. However, this is in contrast to results reported for the DOPr 
where a W6.48L mutation selectively abrogated arrestin recruitment in response to 
the peptide agonist DADLE, but only had a modest effect on G protein-mediated 
signalling (161). It is also interesting that in the MOPr the W2936.48A mutation 
completely abolished ligand-induced signalling for all opioids used in this study. In a 
study of the 5HT4 receptor although there was an almost 30-fold difference in the EC50 
values, 5HT still invoked an agonist response in a cAMP assay with the W6.48A 




mutation substantially affected agonist activity. In contrast, the data presented in this 
chapter suggests that for the MOPr the lack of signalling in the W2936.48A variant is 
independent of the opioid agonist used.   
However, it is important to note that this lack of response could be due to ligands 
having a reduced affinity for the W2936.48A variant compared to wildtype. W2936.48 is 
located in the orthosteric binding site and all 8 opioids investigated in this thesis 
interacted with W2936.48 in the MD simulations (see Chapter 4 Section 4.3.2 and 
Chapter 5 Section 5.3.3). Indeed, the equivalent mutation in the angiotensin II AT1 
receptor resulted in a 7-fold reduction in the binding of angiotensin, whilst in the 
muscarinic M3 receptor the W6.48A mutation reduced the binding affinity of all ligands 
tested by up to 24-fold (155, 156). However, in the DOPr, mutating W6.48 had variable 
effects on ligand binding, reducing the affinity of some ligands but enhancing that of 
others (157). In the only published report of a W6.48 point mutation in the MOPr, 
substituting W6.48 for a cysteine residue reduced diprenorphine binding 3-fold, but 
did not abolish binding completely (357). No functional data was reported in this study. 
To more fully characterise the W2936.48A MOPr variant described in this chapter, it 
will be important in due course to perform radioligand binding studies to determine 
the binding affinity of tritiated diprenorphine, and whether the W2936.48A mutation has 
divergent effects on the binding of agonists versus antagonists. The MD simulation 
data presented here would suggest that agonist binding may be more adversely 
affected than antagonist binding.    
The data presented in this chapter, therefore, supports the role of W2936.48 as an 
important microswitch in transducing agonist binding to the subsequent activation of 
the MOPr, as in both the MD simulations and the cell signalling studies the W2936.48A 
mutation produced an inactive receptor. 
The MD simulation data for the L219ECL2A variant were more difficult to interpret. The 




bilorphin, however it is difficult to determine whether this relatively small change was 
due to the L219ECL2A substitution or merely differences between two independent sets 
of simulations occurring by chance. Intriguingly, we also observed a change in the 
rotameric state of W2936.48 in the endomorphin-2-bound L219ECL2A receptor, which 
may indicate an important allosteric link between L219ECL2 and this microswitch.  
In HEK 293 cells, the L219ECL2A variant also reached the cell surface and responded 
to opioid agonists to both signal through G protein and internalise. However, the 
L219ECL2A variant had divergent effects on the ligand-induced signalling by different 
agonists. For the reference agonist DAMGO there was no significant difference 
between the wildtype and L219ECL2A responses in either the Gi activation assay or in 
the receptor internalisation assay. In contrast, the arrestin-biased peptide 
endomorphin-2 had a small (3-fold decrease in potency) yet significantly right-shifted 
Gi activation curve for the L219ECL2A mutant compared to wildtype, but no significant 
difference in the level of internalisation induced by a receptor-saturating concentration 
of agonist was observed. There was no difference in the ability of the G protein-biased 
agonist bilorphin to activate Gi in wildtype or L219ECL2A MOPr, but the L219ECL2A 
mutation converted bilorphin to an internalising agonist, producing a similar level of 
receptor internalisation to endomorphin-2. This result was unexpected and suggests 
an important role of L219ECL2, or more broadly ECL2, in modulating MOPr signalling. 
In the absence of full concentration-response curves in an arrestin recruitment assay 
it is difficult to comment on the effect of the L219ECL2A mutation on the bias profile of 
endomorphin-2. However, for bilorphin the ability of this G protein-biased peptide to 
induce robust MOPr internalisation at the L219ECL2A receptor suggests that this 
mutation may have abolished the bias profile of this ligand such that at the L219ECL2A 
MOPr bilorphin becomes an un-biased agonist. To test this hypothesis further it would 
be necessary to conduct full concentration-response curves in an arrestin recruitment 




discussed for the W2936.48A variant, radioligand binding studies would confirm 
whether the affinity of these ligands was affected by the L219ECL2A mutation.  
These data on the effect of the L219ECL2A mutation on arrestin-mediated signalling do 
not correspond to previous work on aminergic receptors, where the equivalent 
mutations abolished arrestin recruitment (186, 187). These divergent effects of ECL2 
point mutations suggest that the role of ECL2 in ligand binding and receptor function 
is not a universally conserved mechanism across GPCRs. As discussed in Chapter 
4, the MOPr is endogenously a peptide receptor, and therefore it may be unsurprising 
that the precise mechanisms of receptor activation and modulation of signalling 
responses do not correspond to those seen in GPCRs which are primarily activated 
by small molecules.  
However, one finding in this chapter which does agree with the study by Wacker et 
al., concerns the movement of ECL2. The behaviour of GPCR extracellular loops has 
been proposed to affect ligand kinetics (181, 186, 191, 358) and in our MD studies 
we observed enhanced flexibility of ECL2 in the L219ECL2A variant compared to 
wildtype. Similarly, both ECL2 flexibility and ligand off-rate were enhanced by the 
L209ECL2A mutation in the 5HT2B receptor (186). It would be interesting to investigate 
the binding kinetics of opioid ligands at the L219ECL2A MOPr variant to determine if 
the effect of mutating this ECL2 residue is conserved in Class A GPCRs, and 
therefore whether this points to a more general role of ECL2 in ligand binding kinetics.  
It must be noted that conclusions drawn from any mutagenesis study come with 
certain caveats. Firstly, single point mutations may change the protein structure 
beyond just the one residue of interest. For instance, mutations which substitute one 
amino acid for another with very different side chain properties may alter protein 
folding and packing between helices. However, as both MOPr variants described in 
this chapter were expressed on the cell surface, it is likely that the receptor is folded 




may not be due to the specific residue substitution itself but may alter the behaviour 
of other nearby residues due to the disruption or formation of important contacts 
between side chains. In this study, the effect of the W2936.48A mutation could be 
directly due to the loss of the tryptophan itself or removing this bulky residue may 
impact the conformation of other residues, for instance those in the nearby allosteric 
sodium ion binding site, PIF motif, or orthosteric binding pocket. Similarly, in the MD 
simulations the L219ECL2A mutation increased the mobility of residues throughout 
ECL2, and so it is difficult to delineate whether the changes we observe are due to 
the loss of the leucine or the downstream effect this point mutation has on other parts 
of the receptor. An interesting example of this are the crystal structures of two 
adenosine A2A receptor variants; D522.50N and S913.39A. Both mutations are in the 
allosteric sodium site, but the resolved structures displayed alternative conformations 
of the spatially distant NPxxY motif (137), demonstrating an allosteric link between 
the mutation sites and this motif. As our MD simulations do not capture the fully active 
state of the MOPr (as discussed in Chapter 4 Section 4.4 and Chapter 5 Section 5.4), 
I could not determine the effect of either point mutation on the conformation of 






Using both MD simulations and in vitro cell signalling assays, in this chapter I have 
shown that W2936.48 is a crucial residue for ligand-induced activation of the MOPr. 
Whether this is primarily due to an effect on ligand affinity, or the ability of an agonist 
to induce the MOPr active state once bound, is yet to be determined. Nevertheless, 
this work highlights the key role of this W2936.48 microswitch in MOPr function and 
demonstrates that hypotheses based on computational models can be validated in 
vitro.  
Furthermore, I have characterised the L219ECL2A MOPr variant both in MD simulations 
and in cell signalling assays. These data so far suggest that L219ECL2 is able to 
modulate MOPr function, possibly by affecting the behaviour of the W2936.48 
microswitch, and differentially modulates the signalling properties of oppositely biased 
MOPr agonists. Intriguingly, the G protein-biased agonist, bilorphin, exhibited 
enhanced internalisation of the L219ECL2A receptor, a finding which was unexpected 
and may point towards an important role of L219ECL2 and ECL2 in the molecular 















7.1 Research summary 
GPCRs are important drug targets and the wealth of new structural data in recent 
years has improved our understanding of how these biologically important receptors 
function. The MOPr is a GPCR of great clinical and societal importance, due to its role 
in analgesia and drug abuse. Yet, relatively little is understood about how different 
opioids interact with the MOPr binding pocket and how different ligand-receptor 
interactions lead to different signalling outcomes. This thesis sought to use MD 
simulations combined with cell signalling assays to identify molecular mechanisms of 
agonist efficacy and agonist bias at the MOPr. 
Using MD simulations, the interactions between a panel of 8 different opioid ligands 
and the MOPr orthosteric site were characterised. These compounds span the full 
spectrum of opioid activity, from antagonists to full agonists, and small molecule and 
peptide ligands. These in silico studies have modelled different MOPr conformations 
and highlighted residues which may be important in conveying opioid ligand efficacy 
and bias. In vitro cell signalling studies have characterised these same opioid ligands 
in BRET assays to detect G protein activation and arrestin recruitment. Furthermore, 
the expression of single point MOPr mutants in HEK 293 cells has translated the in 
silico findings to effects on ligand-induced MOPr signalling in vitro.  
Firstly, MD simulations of the unliganded MOPr revealed that sodium will 
spontaneously bind to the conserved allosteric site of the inactive MOPr, whereas, 
sodium did not bind to the same site in the active state MOPr, where this allosteric 
pocket is collapsed.  
Secondly, to investigate a potential molecular mechanism for opioid ligand efficacy, a 
series of small molecule opioid ligands of varying efficacy were docked to the MOPr 
and MD simulations performed. These MD simulations showed that although opioid 
ligands may share the same chemical scaffold, they can adopt distinct binding poses 




of the W2936.48 rotamer toggle switch was dependent on the bound ligand; higher 
efficacy ligands induced a greater rotameric change in this residue than the lower 
efficacy compounds. Conformational changes in the MOPr transmembrane helices 
also differentiated high and low efficacy ligands, with the norbuprenorphine-bound 
receptor occupying a different conformational cluster to the buprenorphine- or 
diprenorphine-bound receptor. The alternative ligand binding pose, W2936.48 rotamer 
and helix conformations induced by norbuprenorphine were reversed in the presence 
of an allosteric sodium ion, suggesting a molecular mechanism for the negative 
modulatory effect of sodium at opioid receptors (115, 121, 152).  
Thirdly, a structural basis for MOPr biased agonism was also investigated using the 
oppositely biased peptides, bilorphin and endomorphin-2. MD simulations predicted 
that whilst endomorphin-2 and DAMGO interacted with the MOPr ECLs, the G protein-
biased peptide bilorphin did not (344). Moreover, these oppositely biased peptides 
stabilised different conformations of the MOPr, with the endomorphin-2-bound 
receptor favouring a more occluded conformation of the intracellular domain than the 
bilorphin-bound receptor.  
Finally, these in silico findings were tested in in vitro cell signalling assays by 
producing the relevant single point mutations of the MOPr. Corroborating the MD 
simulation data, the W2936.48A receptor did not respond to opioid agonist in in vitro 
cell signalling assays. The L219ECL2A receptor subtly modulated the biased signalling 
of the MOPr peptides, such that the G protein-biased agonist bilorphin was able to 
produce greater internalisation of the L219ECL2A receptor compared to wildtype.  
This thesis therefore provides insight into several aspects of the molecular 
pharmacology of the MOPr. Namely, the allosteric modulation of the MOPr by sodium 
ions, how different small molecule and peptide MOPr ligands interact with the 
orthosteric binding pocket, the role of the W2936.48 microswitch in agonist-induced 




7.2 Sodium modulation of MOPr function 
In Chapter 3, using MD simulations of the unliganded (apo) MOPr, the binding of a 
sodium ion to the conserved allosteric sodium binding site in the inactive state 
receptor was observed. Both the binding pathway (via the extracellular vestibule and 
orthosteric site) and the residues involved in the coordination of the sodium ion in the 
allosteric site were in agreement with the position of sodium in high resolution crystal 
structures of other GPCRs (122-125) and other computational studies modelling the 
binding of sodium to Class A GPCRs (323-325, 359).  
The negative modulatory effect of sodium ions on the MOPr appears to be due to 
interplay between the allosteric and orthosteric sites, as well as modulation of the 
W2936.48 rotamer toggle switch (Figure 7.1a). The MD simulations presented in 
Chapter 4 suggest that high efficacy agonists may disrupt sodium binding, as 
norbuprenorphine favoured a deeper binding pose close to the allosteric site and high 
efficacy agonists induced a conformational change in the W2936.48 microswitch which 
would be incompatible with a bound sodium ion. On the other hand, the presence of 
a sodium ion in the allosteric site disrupted this deeper binding pose of 
norbuprenorphine and stabilised the W2936.48 indole ring in the inactive, vertical 
position. This is similar to MD simulations of the dopamine D2 receptor, where the 
entrance of a sodium ion into the helix bundle was coupled to the toggle motion of 
W6.48 (359).  
Therefore, there appears to be allosteric communication between the orthosteric 
agonist and sodium binding sites, with occupation of either site modulating the other, 
possibly via the rotameric state of W2936.48. Indeed, disruption of the sodium site may 
be a general mechanism for agonist activation of the MOPr and other GPCRs. As 
discussed in Chapter 1 Section 1.2.3.3, the positive allosteric modulation of the MOPr 
by BMS-986122 has been suggested to be due to disruption of sodium binding (135), 




for the agonist acetylcholine at muscarinic M3 and M4 receptors was identified using 
MD simulations; this new binding site is in fact the allosteric sodium site (286). 
Moreover, an inverse agonist of the leukotriene B4 receptor exerts its activity-
quenching effect by occupying the allosteric sodium site, mimicking a bound sodium 
ion, and thereby stabilising the inactive state (360). Conversely, our group has 
recently performed MD simulations of the active state MOPr bound to fentanyl, 
suggesting that the ligand’s phenethyl group binds within the second coordination 
shell of the allosteric sodium site, allowing fentanyl to exert its highly potent agonist 
effect, presumably by disrupting sodium binding (361). In their review of the 
mechanism of sodium modulation of GPCRs, Katritch et al., elegantly argue not only 
that disruption of the bound sodium may be an activation mechanism in Class A 
GPCRs, but also that the egress of sodium from the allosteric site into the cytoplasm 
may provide an energy source for GPCR signalling (138). Whilst the MD simulations 
in this thesis did not sample a sodium ion relocating to the intracellular side of the 
membrane, the data do support a mechanism for agonist disruption of sodium binding.  
The MD simulations presented in this thesis, and the other cited reports, were carried 
out in the absence of an electrochemical gradient across the bilayer. Physiologically, 
the drive for sodium ions to bind from the extracellular side of the MOPr, and 
potentially relocate to the cytoplasm, would be even greater due to the concentration 
and potential difference across the membrane. The propensity for sodium ions to bind 
to the MOPr may even be influenced by the membrane potential. Indeed, MD 
simulations of the DOPr under a membrane potential have shown voltage-sensitivity 
of sodium binding (140). The MOPr is primarily expressed on excitable tissue where 
the membrane potential changes subject to neurotransmission. Other Class A GPCRs 
have been shown to be voltage-sensitive (141-145), and some authors have argued 
that GPCR voltage sensitivity may be mediated by the movement of cations, such as 
sodium, within the transmembrane helix bundle (140). It is tempting to speculate 




role of sodium ion modulation of receptor function to fine-tune GPCR signalling. 
Perhaps, drugs acting on the allosteric sodium binding site of the MOPr may be a 
strategy for specifically targeting opioid receptors expressed on overactive neurones 
in pain states. In any case, it is important to understand how physiological 





7.3 Opioids exhibit distinct binding poses 
The main purpose of this thesis was to characterise the binding modes of a series of 
opioid ligands with the MOPr orthosteric binding pocket. A central theme throughout 
is that despite sharing similar chemical structures, opioid ligands are predicted adopt 
distinct binding poses (152).  
The work presented in this thesis highlights the importance of using both molecular 
docking and MD simulations to predict ligand binding poses. For instance, in Chapter 
4 docking alone would not have revealed the deeper binding pose of 
norbuprenorphine compared to its analogues, buprenorphine and diprenorphine. 
Using both docking and MD simulations, norbuprenorphine was found to adopt a pose 
close to the allosteric sodium ion binding site, interacting with different residues and 
causing the rotameric change in the W2936.48 microswitch (152). These differences in 
ligand binding pose may explain norbuprenorphine’s higher efficacy compared to the 
lower efficacy yet structurally similar ligands.  
Moreover, in Chapter 5, although endomorphin-2 and bilorphin are both tetrapeptides 
with an N-terminal tyrosine (or tyrosine-like) residue, they adopted different poses in 
the orthosteric site. Bilorphin, probably due to its unusual stereochemistry of 
alternating L and D amino acids, extended towards the opposite side of the MOPr 
pocket compared to endomorphin-2 and DAMGO. Bilorphin thus accessed the 
alternative extended binding pocket and contacted TM1 (344). These different binding 
poses may provide an explanation for the different bias profiles of these compounds 
and will be discussed further in Section 7.5. 
The observation that structurally similar compounds can nevertheless adopt different 
binding positions is not unique to the MOPr. For instance, comparison of the x-ray 
crystal structures of the 5HT2B receptor bound to LSD or ergotamine revealed that 
ergotamine could rotate around the amine-D3.32 salt bridge to adopt a deeper binding 




norbuprenorphine work presented in Chapter 4, where norbuprenorphine also pivoted 
around the amine-D1473.32 interaction (152). Moreover, distinct ligand-receptor 
interaction fingerprints, such as those reported in Chapters 4 and 5, have been 
successfully used in structure-based discovery efforts to find new compounds 
targeting GPCRs and to predict ligand activity (339, 362-367). 
One caveat to the MD simulation data described here is that, as detailed in Chapter 
2 Section 2.1.3.2, the molecular docking protocol used just the extracellular portion of 
the MOPr as the search space, meaning that binding poses outside of this region 
were not evaluated. Binding pose selection was then rationalised partly based on the 
presence of the canonical interaction between the opioid amine and D1473.32, as this 
residue has been highlighted as an essential residue of opioid ligand binding in 
mutagenesis studies (95, 111-113). However, the reliance on this interaction as a 
determining factor for selecting a binding pose may mean that other alternative 
binding modes may have been missed.  
However, these caveats notwithstanding, we can be reasonably confident in the 
predicted binding poses reported here, due to the similarities between our modelled 
DAMGO-MOPr complex (Chapter 5) and the subsequently reported cryoEM structure 
of DAMGO bound to the Gi-coupled MOPr (23). As DAMGO is a pentapeptide, it is 
one of the most flexible ligands studied in this thesis, and therefore potentially more 
difficult to accurately model. However, the binding position, conformation of key 
residues (such as W2936.48) and the conformation of DAMGO itself were very similar 
between our model and the cryoEM structure.  
The MOPr has a remarkably deep orthosteric binding pocket compared to other Class 
A GPCRs, and it may be this larger available volume which gives rise to the different 
binding modes observed here. As discussed in Chapter 1 Section 1.5, this could be 





7.4 The W2936.48 activation switch 
The data in this thesis supports the hypothesis that W2936.48 serves as a link 
translating agonist binding to activation-related MOPr conformational changes (Figure 
7.1a). In Chapters 4 and 6, ligand efficacy for G protein signalling correlated with 
W2936.48 conformation in the MD simulations, as agonists with higher efficacy for G 
protein signalling, such as DAMGO, norbuprenorphine and methadone, elicited 
greater rotameric changes in the W2936.48 side chain than lower efficacy ligands, such 
as diprenorphine, buprenorphine and morphine. This finding is in agreement with both 
experimental studies and other computational work. One of the first studies to identify 
the W6.48 toggle switch used NMR spectroscopy of rhodopsin to show spectral 
changes around W6.48 in the light verses dark state (368). Whilst MD simulations of 
the adenosine A3 receptor and β2 adrenoceptor have correlated the W6.48 rotameric 
state with ligand efficacy (356, 369, 370). Furthermore, in this thesis the 
conformational change in W2936.48 could be prevented by addition of an allosteric 
sodium ion, which, as discussed above, has a negative modulatory effect on MOPr 
function (Section 7.2).  
In the simplified model depicted in Figure 7.1a, in the presence of an antagonist or a 
high sodium concentration, the W2936.48 side chain is stabilised in the inactive, vertical 
state. The binding of an agonist induces the movement of the W2936.48 indole ring, 
causing sodium to relocate to the intracellular side of the membrane, and initiating 
conformational changes in the helices to promote G protein coupling.  
However, it should be noted that this correlation between the W2936.48 dihedral and 
ligand efficacy was largely influenced by DAMGO and norbuprenorphine which both 
induced the greatest change in the W2936.48 dihedral. Ligands such as endomorphin-
2 and morphine, which do have reasonable efficacy in activating Gi (21), did not 
stabilise the horizontal conformation of W2936.48. These discrepancies suggest that 




mechanisms which can also translate agonist binding to activation of the receptor. For 
instance, the PIF motif is also adjacent to the ligand binding site and has been 
implicated in receptor activation, primarily in aminergic receptors but also the MOPr 
(22, 162, 165). Alternatively, with lower efficacy ligands bound, the probability of the 
W2936.48 conformational change may be lower and therefore is not sampled within the 
simulation times achieved here.  
Moreover, the W6.48 rotamer toggle switch is likely to work in concert with other 
GPCR activation mechanisms. For example, Yuan et al., suggest that rotameric 
changes in W6.48 allow for hydration of the GPCR helix bundle (371). The influx of 
water would alter the hydrogen bond network from the orthosteric site to the 
intracellular domain and hence lead to conformational changes in the G protein 
coupling region. An NMR spectroscopy study of the adenosine A2A receptor and the 
D2.50A variant showed interplay between W6.48 and D2.50 of the allosteric sodium 
ion binding site (349). The authors suggest a model whereby agonist-induced 
conformational changes in W6.48 are transmitted to D2.50 which then causes 
conformational changes in the GPCR intracellular domain.  
In Chapter 6, mutagenesis of W2936.48 to alanine both in the molecular modelling and 
in in vitro experiments supported the hypothesis that W2936.48 is a critical residue for 
MOPr activation. In the MD simulations, with either norbuprenorphine or 
diprenorphine bound, the W2936.48A receptor did not sample the alternative active-
like conformation observed in the norbuprenorphine-bound wildtype receptor. This 
suggested that W2936.48 is required for the conformational changes in the MOPr 
helices associated with receptor activation, and therefore the W2936.48A mutation 
produces a receptor incapable of being activated. This was reflected in the cell 
signalling studies, where the W2936.48A mutant did not signal through the Gi G protein 
or internalise in response to opioid agonist. Clearly, W2936.48 is required for agonist-
induced MOPr signalling, either as an “efficacy switch” between the orthosteric site 




of effects on both ligand affinity and efficacy. Similarly, in the adenosine A3 receptor, 
mutation of W6.48 resulted in a receptor which still bound ligand but did not signal 
(372), whereas, at the neuropeptide Y2 receptor, a W6.48 mutation only reduced 
agonist potency and interestingly, this effect could be rescued using agonists 
containing a bulky aromatic group to mimic the indole ring of W6.48 (159). Adding 
further complexity, Stoddart et al., showed that a W6.48F mutation of the adenosine 
A3 receptor impaired G protein signalling of both agonists tested, but had differential, 
ligand-dependent effects on receptor internalisation (158). Together, these studies 
and the data in this thesis suggest an important role for W6.48 in GPCR activation, 
but that the precise nature of how W6.48 modulates receptor function is dependent 
on the receptor and the ligand in question. For the MOPr, the data in this thesis 
suggests that mutation of W6.48 appears to abolish either the binding or ligand-
induced signalling of any opioid agonist, indiscriminately.  
To our knowledge, this is the first study which has reported functional data for a 
W2936.48 mutation in the MOPr, which alongside the computational data, contributes 
to our understanding of how agonists promote GPCR activation via the W2936.48 
microswitch. This study also serves as another example of how MD simulations can 
successfully model and predict the behaviour of biological molecules (see Chapter 1 
Section 1.4.3). Furthermore, the observation that the position of the W2936.48 indole 
ring in the MD simulations corresponded to agonist efficacy in an experimental system 
has potentially useful implications for future in silico screening efforts for the discovery 
of new MOPr compounds. Lower efficacy MOPr agonists, notably buprenorphine and 
oliceridine, have been reported to be safer yet still therapeutically efficacious 
analgesics (261, 373, 374), whilst new MOPr antagonists which can reverse opioid 
overdose may be required to combat the rising fentanyl epidemic (375). With these 
applications in mind, monitoring the conformation of W2936.48 could serve as a 







Figure 7.1 Proposed model for agonist efficacy and bias at the MOPr 
a) In the inactive state, a sodium ion (purple) is bound in the allosteric site, maintaining W2936.48 (blue) 
in the vertical conformation. In this conformation, agonist binding is unfavourable. Upon agonist binding 
(green), W2936.48 switches to the horizontal conformation, disrupting sodium binding so that the ion 
moves into the cytoplasm. W2936.48 is coupled to conformational changes in the MOPr helices, allowing 
binding of a G protein (yellow) to the intracellular cavity. 
b) An arrestin-biased agonist (orange) contacts or modulates residues in the extracellular loops, which 
translates to conformational changes on the intracellular side so that the MOPr adopts the “occluded” 
conformation capable of binding arrestin (blue). A G protein-biased agonist (purple) contacts or 
modulates residues in TM1, translating to the more “open” conformation of the intracellular cavity so that 






7.5 Molecular mechanisms of MOPr ligand bias 
To investigate a molecular mechanism for biased agonism at the MOPr, in Chapter 5 
two oppositely biased agonists, endomorphin-2 and bilorphin, along with the 
reference agonist DAMGO were docked to the MOPr and MD simulations performed. 
Analysis of the MD simulation data revealed that these peptides adopted different 
binding poses with respect to their interactions with the extended binding pocket 
(Figure 7.1b). As depicted in the model in Figure 7.1b, the peptides which recruit 
arrestin, endomorphin-2 and DAMGO, interacted with the ECLs, whereas the G 
protein-biased agonist, bilorphin, did not. Instead bilorphin, uniquely amongst the 
ligands studied in this thesis, contacted residues in TM1.  
Similarly, an in silico study modelling agonist binding and allosteric communication 
between the orthosteric site and the G protein binding cavity found that the weakly G 
protein-biased MOPr agonist, oliceridine, utilised residues in TM1 to transfer 
information to the intracellular domain (263). Interestingly, another computational 
study attempting to identify regions of allosteric communication between the binding 
site and intracellular region also identified the extracellular end of TM1 as important 
for allosteric communication when the DOPr was bound to a G protein-biased agonist 
(376). Furthermore, the cryoEM-resolved structure of the G protein-biased peptide, 
ExP5, bound to the GLP-1 receptor revealed interactions between the ligand and TM1 
(108). Together, these studies and the data presented in this thesis suggest that TM1 
may be an important hub for G protein bias.  
The current well-accepted model for the molecular mechanism of agonist bias is the 
stabilisation of distinct GPCR conformations which have different affinities for 
intracellular signalling partners (221, 377). The data presented in Chapter 5 support 
this hypothesis, as principal component analysis of the ligand-MOPr simulations 
showed that the biased peptides stabilised different conformations of the MOPr 




conformation of the intracellular domain, compared to the bilorphin-bound MOPr. This 
is perhaps similar to the “occluded” arrestin-biased conformations of the angiotensin 
II type I receptor and the MOPr reported in DEER and NMR spectroscopy studies 
(224, 262).   
However, the question of exactly how the presence or absence of ligand contact with 
the ECLs or TM1 translates to different conformations of the MOPr intracellular 
domain is yet to be determined. GPCRs are allosteric machines, evolved to transduce 
the signal of a ligand binding to the extracellular portion of the protein through to a 
conformational change of the intracellular domain, nearly 30 Å away from the 
orthosteric site. It is perhaps unsurprising therefore, that the primary differences 
between biased and unbiased agonists which have been captured so far are in the 
interactions and movements of the ECLs and extracellular ends of the 
transmembrane helices. How these changes are translated to the intracellular cavity 
may eventually be resolved with more structures of GPCR-effector complexes bound 
to different biased agonists.     
As L219ECL2 was one of the residues contacted by endomorphin-2 and DAMGO, but 
not bilorphin, and has been previously identified as important for encoding bias and 
ligand residence time in aminergic receptors (186, 187), in Chapter 6 I produced a 
single point mutation of this residue to determine the effect on MOPr signalling. Unlike 
the W2936.48A mutation, the L219ECL2A mutant had a subtle effect on ligand-induced 
MOPr signalling. In the G protein BRET assay, DAMGO and endomorphin-2 exhibited 
a small decrease in potency compared to the wildtype receptor, whilst in the receptor 
internalisation assay, the L219ECL2A mutation converted bilorphin to an internalising 
agonist. Hence, it could conceivably be hypothesised that L219ECL2 can modulate bias 
between G protein and arrestin pathways, as at the L219ECL2A mutant bilorphin is 




However, these results should be interpreted with caution, as without full 
concentration-response curves in an arrestin assay it cannot be definitively concluded 
whether the bias profile of bilorphin had been altered by the L219ECL2A mutation. 
Moreover, based on a MD simulation data a greater effect of the L219ECL2A 
substitution may have been expected, particularly on the potency of endomorphin-2. 
In the MD simulations of the L219ECL2A receptor, endomorphin-2 induced greater 
rotameric changes in the W2936.48 rotamer toggle switch than at the wildtype MOPr, 
but this did not translate to increased potency of endomorphin-2 in the G protein BRET 
assay. In fact, the opposite was evident. Other residues in the alternative extended 
binding pockets may have a more profound effect on the signalling profiles of these 
peptides. For example, W133ECL1, T218ECL2 and Y751.39.  
Another mechanism of biased agonism has been proposed whereby ligand residence 
time is linked with arrestin recruitment, as in general, MOPr agonists with a slower off-
rate show greater efficacy for arrestin recruitment (347). Similarly, in the 5HT2B 
receptor, interactions between LSD and ECL2 controlled both ligand dissociation rate 
and arrestin recruitment (186). Whilst conventional MD simulations cannot determine 
ligand binding kinetics, it is possible that the lack of interaction between bilorphin and 
the ECLs results in the faster off-rate and minimal arrestin recruitment stimulated by 
this biased ligand (344, 347).  
Overall, the data presented here add to the body of literature proposing that agonist 
bias is due to the stabilisation of different receptor conformations (162, 221, 222, 224, 
262, 343, 377). Moreover, for the two biased compounds studied, differential 
interactions with the ECLs and TM1 may be the mechanism by which these alternative 





7.6 Future directions 
To more fully test the hypotheses presented in this thesis, it would be necessary to 
use a greater panel of opioid ligands to determine if for instance, changes in the 
W2936.48 rotamer are conserved across different opioid agonists, or whether 
interaction with the ECLs is a common differentiator between opioids of opposing bias 
profiles. Furthermore, with a much larger test set of ligands, machine learning 
approaches (378-380) could be utilised to analyse the MD simulation data to identify 
conserved ligand-residue interactions, pharmacophores and conformational 
signatures associated with different signalling outcomes.  
To establish whether the lack of agonist-induced signalling at the W2936.48A mutant 
is due to an effect on agonist binding or agonist efficacy, radioligand binding studies 
need to be conducted to measure the binding of the MOPr antagonist 3H-
diprenorphine and its displacement by opioid agonists. If agonist binding is 
unimpaired at this MOPr variant, it would be interesting to determine whether the lack 
of the W2936.48 activation switch prevents formation of the agonist-bound and G 
protein-coupled high affinity state (381, 382). The MD simulations presented in 
Chapter 6 predict that the W2936.48A mutation would cause the MOPr to adopt an 
inactive conformation, and therefore would not exhibit a G protein-coupled high affinity 
state. 
Building on the work using the L219ECL2A MOPr variant, it would be interesting to 
examine the trafficking of this mutant. When stimulated with DAMGO or endomorphin-
2 the L219ECL2A receptor was internalised, presumably via the canonical arrestin-
dependent mechanism (383). When stimulated with bilorphin, unlike the wildtype 
MOPr, the L219ECL2A mutant was internalised. This may be arrestin-mediated or via 
an arrestin-independent mechanism. Similarly, the naturally occurring single 
nucleotide polymorphism (SNP), L831.47I, unlike the wildtype MOPr, internalises in 




internalisation (317). Cooke et al., found morphine-induced internalisation of this SNP 
to be GRK2-dependent, but with no change in the levels of S375 phosphorylation or 
arrestin recruitment, concluding that the enhanced internalisation in response to 
morphine may be via a novel endocytic process (317). It would be interesting to 
conduct the same kind of study with the L219ECL2A mutant to determine if there are 
any parallels in the agonist-induced trafficking of these MOPr variants.  
The MD simulation data presented in this thesis also identifies other residues which 
may be important for encoding ligand efficacy or bias at the MOPr. For instance, 
residues in the ECLs other than L219ECL2 were contacted by DAMGO and 
endomorphin-2 but not bilorphin, notably W133ECL1, whereas Y751.39 formed part of 
the extended binding pocket for bilorphin. As well as W2936.48, other residues in the 
allosteric sodium site are likely to affect ligand efficacy, for instance D1142.50 and 
N1503.35. Further research could also be conducted to determine the effect of a single 
point mutation of one or more of these residues, and others, on ligand binding and 
ligand-induced MOPr signalling. 
Although the molecular modelling approach used here provides insight into the 
binding position of the opioid ligands within the orthosteric site, it does not capture the 
means of access or egress of the ligand between the extracellular milieu and the 
MOPr helix bundle. The use of advanced MD approaches, such as coarse grained or 
steered MD, could be employed to model the binding pathway of a ligand, as this may 
reveal further ligand-receptor interactions which can modulate MOPr conformation. In 
particular, the unusually slow dissociation rate of buprenorphine (333) may be 
explained by identification of another metastable binding site along the dissociation 
pathway. Moreover, in the sphingosine-1-phosphate, cannabinoid CB2 and PAR1 
receptors, lipophilic ligands have been predicted to bind through the lipid bilayer via a 
channel in the receptor transmembrane domains (284, 285, 384). The fentanyls are 
highly potent and lipophilic MOPr agonists (385), and it is tempting to speculate that 




7.7 Conclusion  
The MD simulations presented in this thesis predict that opioid ligands adopt distinct 
binding poses in the MOPr orthosteric site. These ligands therefore interact with 
different subsets of residues, and these distinct ligand-residue interactions appear to 
translate to different conformations of the MOPr and hence different signalling 
outcomes. Through these simulations I also propose a mechanism for sodium ion 
negative modulation of MOPr function, via destabilisation of agonist binding and 
prevention of the conformational changes in the W2936.48 microswitch and the MOPr 
helices. Using both MD simulations and expression of the W2936.48A mutant in HEK 
293 cells, the data in this thesis has shown that, like other Class A GPCRs, W2936.48 
is important for ligand-induced MOPr activation. Moreover, using the same 
techniques, I have characterised the binding modes of the MOPr biased agonists, 
endomorphin-2 and bilorphin. These MD simulation data, alongside expression of the 
L219ECL2A MOPr variant, have demonstrated that for these peptides, interaction with 
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W2936.48A MOPr  
Sequence alignment between the wildtype template HA-rat MOPr plasmid and the 
W2936.48A mutant. Base changes are highlighted in yellow. 
W293A 1    TACCCATACGATGTGCCCGACTATGCTCTGGTGCCGCGGGACAGCAGCACCGGCCCAGGG  60 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1    TACCCATACGATGTGCCCGACTATGCTCTGGTGCCGCGGGACAGCAGCACCGGCCCAGGG  60 
 
W293A 61   AACACCAGCGACTGCTCAGACCCCTTAGCTCAGGCAAGTTGCTCCCCAGCACCTGGCTCC  120 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 61   AACACCAGCGACTGCTCAGACCCCTTAGCTCAGGCAAGTTGCTCCCCAGCACCTGGCTCC  120 
 
W293A 121  TGGCTCAACTTGTCCCACGTTGATGGCAACCAGTCCGATCCATGCGGTCTGAACCGCACC  180 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 121  TGGCTCAACTTGTCCCACGTTGATGGCAACCAGTCCGATCCATGCGGTCTGAACCGCACC  180 
 
W293A 181  GGGCTTGGCGGGAACGACAGCCTGTGCCCTCAGACCGGCAGCCCTTCCATGGTCACAGCC  240 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 181  GGGCTTGGCGGGAACGACAGCCTGTGCCCTCAGACCGGCAGCCCTTCCATGGTCACAGCC  240 
 
W293A 241  ATTACCATCATGGCCCTCTACTCTATCGTGTGTGTAGTGGGCCTCTTCGGAAACTTCCTG  300 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 241  ATTACCATCATGGCCCTCTACTCTATCGTGTGTGTAGTGGGCCTCTTCGGAAACTTCCTG  300 
 
W293A 301  GTCATGTATGTGATTGTAAGATACACCAAAATGAAGACTGCCACCAACATCTACATTTTC  360 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 301  GTCATGTATGTGATTGTAAGATACACCAAAATGAAGACTGCCACCAACATCTACATTTTC  360 
 
W293A 361  AACCTTGCTCTGGCAGACGCCTTAGCGACCAGTACACTGCCCTTTCAGAGTGTCAACTAC  420 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 361  AACCTTGCTCTGGCAGACGCCTTAGCGACCAGTACACTGCCCTTTCAGAGTGTCAACTAC  420 
 
W293A 421  CTGATGGGAACATGGCCCTTCGGAACCATCCTCTGCAAGATCGTGATCTCAATAGATTAC  480 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 421  CTGATGGGAACATGGCCCTTCGGAACCATCCTCTGCAAGATCGTGATCTCAATAGATTAC  480 
 
W293A 481  TACAACATGTTCACCAGCATATTCACCCTCTGCACCATGAGCGTGGACCGCTACATTGCT  540 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 








W293A 541  GTCTGCCACCCAGTCAAAGCCCTGGATTTCCGTACCCCCCGAAATGCCAAAATCGTCAAC  600 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 541  GTCTGCCACCCAGTCAAAGCCCTGGATTTCCGTACCCCCCGAAATGCCAAAATCGTCAAC  600 
 
W293A 601  GTCTGCAACTGGATCCTCTCTTCTGCCATCGGTCTGCCTGTAATGTTCATGGCAACCACA  660 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 601  GTCTGCAACTGGATCCTCTCTTCTGCCATCGGTCTGCCTGTAATGTTCATGGCAACCACA  660 
 
W293A 661  AAATACAGGCAGGGGTCCATAGATTGCACCCTCACGTTCTCCCACCCAACCTGGTACTGG  720 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 661  AAATACAGGCAGGGGTCCATAGATTGCACCCTCACGTTCTCCCACCCAACCTGGTACTGG  720 
 
W293A 721  GAGAACCTGCTCAAAATCTGTGTCTTTATCTTCGCTTTCATCATGCCGATCCTCATCATC  780 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 721  GAGAACCTGCTCAAAATCTGTGTCTTTATCTTCGCTTTCATCATGCCGATCCTCATCATC  780 
 
W293A 781  ACTGTGTGTTACGGCCTGATGATCTTACGACTCAAGAGCGTTCGCATGCTATCGGGCTCC  840 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 781  ACTGTGTGTTACGGCCTGATGATCTTACGACTCAAGAGCGTTCGCATGCTATCGGGCTCC  840 
 
W293A 841  AAAGAAAAGGACAGGAATCTGCGCAGGATCACCCGGATGGTGCTGGTGGTCGTGGCTGTA  900 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 841  AAAGAAAAGGACAGGAATCTGCGCAGGATCACCCGGATGGTGCTGGTGGTCGTGGCTGTA  900 
 
W293A 901  TTTATCGTCTGCGCCACCCCCATCCACATCTACGTCATCATCAAAGCGCTGATCACGATT  960 
           ||||||||||||   ||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 901  TTTATCGTCTGCTGGACCCCCATCCACATCTACGTCATCATCAAAGCGCTGATCACGATT  960 
 
W293A 961  CCAGAAACCACATTTCAGACCGTTTCCTGGCACTTCTGCATTGCTTTGGGTTACACGAAC 1020 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 961  CCAGAAACCACATTTCAGACCGTTTCCTGGCACTTCTGCATTGCTTTGGGTTACACGAAC 1020 
 
W293A 1021 AGCTGCCTGAATCCAGTTCTTTACGCCTTCCTGGATGAAAACTTCAAGCGATGCTTCAGA 1080 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1021 AGCTGCCTGAATCCAGTTCTTTACGCCTTCCTGGATGAAAACTTCAAGCGATGCTTCAGA 1080 
 
W293A 1081 GAGTTCTGCATCCCAACCTCGTCCACGATCGAACAGCAAAACTCCACTCGAGTCCGTCAG 1140 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1081 GAGTTCTGCATCCCAACCTCGTCCACGATCGAACAGCAAAACTCCACTCGAGTCCGTCAG 1140 
 
W293A 1141 AACACTAGGGAACATCCCTCCACGGCTAATACAGTGGATCGAACTAACCACCAGCTAGAA 1200 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






W293A 1201 AATCTGGAGGCAGAAACTGCTCCATTGCCCTAA  1233 
           ||||||||||||||||||||||||||||||||| 






L219ECL2A MOPr  
Sequence alignment between the wildtype template HA-rat MOPr plasmid and the 
L219ECL2A mutant. Base changes are highlighted in yellow. 
L219A 1    TACCCATACGATGTGCCCGACTATGCTCTGGTGCCGCGGGACAGCAGCACCGGCCCAGGG  60 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1    TACCCATACGATGTGCCCGACTATGCTCTGGTGCCGCGGGACAGCAGCACCGGCCCAGGG  60 
 
L219A 61   AACACCAGCGACTGCTCAGACCCCTTAGCTCAGGCAAGTTGCTCCCCAGCACCTGGCTCC  120 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 61   AACACCAGCGACTGCTCAGACCCCTTAGCTCAGGCAAGTTGCTCCCCAGCACCTGGCTCC  120 
 
L219A 121  TGGCTCAACTTGTCCCACGTTGATGGCAACCAGTCCGATCCATGCGGTCTGAACCGCACC  180 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 121  TGGCTCAACTTGTCCCACGTTGATGGCAACCAGTCCGATCCATGCGGTCTGAACCGCACC  180 
 
L219A 181  GGGCTTGGCGGGAACGACAGCCTGTGCCCTCAGACCGGCAGCCCTTCCATGGTCACAGCC  240 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 181  GGGCTTGGCGGGAACGACAGCCTGTGCCCTCAGACCGGCAGCCCTTCCATGGTCACAGCC  240 
 
L219A 241  ATTACCATCATGGCCCTCTACTCTATCGTGTGTGTAGTGGGCCTCTTCGGAAACTTCCTG  300 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 241  ATTACCATCATGGCCCTCTACTCTATCGTGTGTGTAGTGGGCCTCTTCGGAAACTTCCTG  300 
 
L219A 301  GTCATGTATGTGATTGTAAGATACACCAAAATGAAGACTGCCACCAACATCTACATTTTC  360 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 301  GTCATGTATGTGATTGTAAGATACACCAAAATGAAGACTGCCACCAACATCTACATTTTC  360 
 
L219A 361  AACCTTGCTCTGGCAGACGCCTTAGCGACCAGTACACTGCCCTTTCAGAGTGTCAACTAC  420 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 361  AACCTTGCTCTGGCAGACGCCTTAGCGACCAGTACACTGCCCTTTCAGAGTGTCAACTAC  420 
 
L219A 421  CTGATGGGAACATGGCCCTTCGGAACCATCCTCTGCAAGATCGTGATCTCAATAGATTAC  480 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 421  CTGATGGGAACATGGCCCTTCGGAACCATCCTCTGCAAGATCGTGATCTCAATAGATTAC  480 
 
L219A 481  TACAACATGTTCACCAGCATATTCACCCTCTGCACCATGAGCGTGGACCGCTACATTGCT  540 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 








L219A 541  GTCTGCCACCCAGTCAAAGCCCTGGATTTCCGTACCCCCCGAAATGCCAAAATCGTCAAC  600 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 541  GTCTGCCACCCAGTCAAAGCCCTGGATTTCCGTACCCCCCGAAATGCCAAAATCGTCAAC  600 
 
L219A 601  GTCTGCAACTGGATCCTCTCTTCTGCCATCGGTCTGCCTGTAATGTTCATGGCAACCACA  660 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 601  GTCTGCAACTGGATCCTCTCTTCTGCCATCGGTCTGCCTGTAATGTTCATGGCAACCACA  660 
 
L219A 661  AAATACAGGCAGGGGTCCATAGATTGCACCGCCACGTTCTCCCACCCAACCTGGTACTGG  720 
           ||||||||||||||||||||||||||||||  |||||||||||||||||||||||||||| 
RMOPR 661  AAATACAGGCAGGGGTCCATAGATTGCACCCTCACGTTCTCCCACCCAACCTGGTACTGG  720 
 
L219A 721  GAGAACCTGCTCAAAATCTGTGTCTTTATCTTCGCTTTCATCATGCCGATCCTCATCATC  780 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 721  GAGAACCTGCTCAAAATCTGTGTCTTTATCTTCGCTTTCATCATGCCGATCCTCATCATC  780 
 
L219A 781  ACTGTGTGTTACGGCCTGATGATCTTACGACTCAAGAGCGTTCGCATGCTATCGGGCTCC  840 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 781  ACTGTGTGTTACGGCCTGATGATCTTACGACTCAAGAGCGTTCGCATGCTATCGGGCTCC  840 
 
L219A 841  AAAGAAAAGGACAGGAATCTGCGCAGGATCACCCGGATGGTGCTGGTGGTCGTGGCTGTA  900 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 841  AAAGAAAAGGACAGGAATCTGCGCAGGATCACCCGGATGGTGCTGGTGGTCGTGGCTGTA  900 
 
L219A 901  TTTATCGTCTGCTGGACCCCCATCCACATCTACGTCATCATCAAAGCGCTGATCACGATT  960 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 901  TTTATCGTCTGCTGGACCCCCATCCACATCTACGTCATCATCAAAGCGCTGATCACGATT  960 
 
L219A 961  CCAGAAACCACATTTCAGACCGTTTCCTGGCACTTCTGCATTGCTTTGGGTTACACGAAC 1020 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 961  CCAGAAACCACATTTCAGACCGTTTCCTGGCACTTCTGCATTGCTTTGGGTTACACGAAC 1020 
 
L219A 1021 AGCTGCCTGAATCCAGTTCTTTACGCCTTCCTGGATGAAAACTTCAAGCGATGCTTCAGA 1080 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1021 AGCTGCCTGAATCCAGTTCTTTACGCCTTCCTGGATGAAAACTTCAAGCGATGCTTCAGA 1080 
 
L219A 1081 GAGTTCTGCATCCCAACCTCGTCCACGATCGAACAGCAAAACTCCACTCGAGTCCGTCAG 1140 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
RMOPR 1081 GAGTTCTGCATCCCAACCTCGTCCACGATCGAACAGCAAAACTCCACTCGAGTCCGTCAG 1140 
 
L219A 1141 AACACTAGGGAACATCCCTCCACGGCTAATACAGTGGATCGAACTAACCACCAGCTAGAA 1200 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






L219A 1201 AATCTGGAGGCAGAAACTGCTCCATTGCCCTAA  1233 
           ||||||||||||||||||||||||||||||||| 
RMOPR 1201 AATCTGGAGGCAGAAACTGCTCCATTGCCCTAA  1233 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
